WO2021055013A1 - Processes and agents for glaucoma - Google Patents

Processes and agents for glaucoma Download PDF

Info

Publication number
WO2021055013A1
WO2021055013A1 PCT/US2020/024592 US2020024592W WO2021055013A1 WO 2021055013 A1 WO2021055013 A1 WO 2021055013A1 US 2020024592 W US2020024592 W US 2020024592W WO 2021055013 A1 WO2021055013 A1 WO 2021055013A1
Authority
WO
WIPO (PCT)
Prior art keywords
glaucoma
evs
administration
composition
complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/024592
Other languages
French (fr)
Inventor
John T. G. PENA
James Murray MITCHELL
Harmon Lawrence REMMEL
Melissa A. MORGAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aufbau Medical Innovations Ltd
Cornell University
Original Assignee
Aufbau Medical Innovations Ltd
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aufbau Medical Innovations Ltd, Cornell University filed Critical Aufbau Medical Innovations Ltd
Priority to AU2020348176A priority Critical patent/AU2020348176A1/en
Priority to CA3151625A priority patent/CA3151625A1/en
Priority to EP20864492.2A priority patent/EP4031244A4/en
Priority to JP2022517878A priority patent/JP7617085B2/en
Priority to CN202080080832.2A priority patent/CN114929340B/en
Publication of WO2021055013A1 publication Critical patent/WO2021055013A1/en
Priority to US17/696,625 priority patent/US20220211800A1/en
Anticipated expiration legal-status Critical
Priority to JP2025001749A priority patent/JP2025069138A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502746—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by the means for controlling flow resistance, e.g. flow controllers, baffles or throttle valves
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0809—Geometry, shape and general structure rectangular shaped
    • B01L2300/0816—Cards, e.g. flat sample carriers usually with flow in two horizontal directions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/08—Regulating or influencing the flow resistance
    • B01L2400/084—Passive control of flow resistance
    • B01L2400/086—Passive control of flow resistance using baffles or other fixed flow obstructions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2525/00—Culture process characterised by gravity, e.g. microgravity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2527/00—Culture process characterised by the use of mechanical forces, e.g. strain, vibration
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/168—Glaucoma

Definitions

  • This invention relates to methods and compositions for detecting, identifying and treating glaucoma diseases. More particularly, this invention discloses compositions and methods for affecting intraocular pressure and increasing ocular outflows in glaucoma.
  • Glaucoma diseases are a world-wide leading cause of vision loss and affect an estimated 70 million people. Glaucoma is a permanently blinding disease that is asymptomatic until patients experience advanced vision loss. Diagnosis of glaucoma is often delayed.
  • POAG Primary open-angle glaucoma
  • IOP intraocular pressure
  • Risk factors for POAG include elevated IOP, advancing age, family history, African ancestry, myopia, and associations with diabetes or hypertension.
  • the pathophysiology responsible for glaucoma is related to increased resistance to aqueous outflow, but the direct mediator of this process remains unknown.
  • the etiology of glaucoma is poorly understood and the factors contributing to its progression have not been identified.
  • Signs and symptoms of glaucoma include damage to the optic nerve, with degeneration of retinal ganglion cells, changes to the optic nerve head, and corresponding visual field loss. Elevation of IOP is related to retinal ganglion cell (RGC) death and ultimately visual field (VF) loss. IOP-related optic nerve damage is important in the pathogenesis of POAG. Patients with POAG and ocular hypertension (OHT) have elevated IOP. Raised IOP is a significant risk factor for the progression from OHT to POAG. Raised IOP is the only common clinical finding in a wide variety of secondary glaucomas. Reduction of IOP was shown to lower the risk of progression in NTG. In animal models, raised IOP precedes glaucomatous nerve damage.
  • the etiology of elevated IOP may be due to reduced aqueous outflow.
  • Pharmaceutical treatment of glaucoma is directed to lowering IOP which may slow disease progression in some patients.
  • Drawbacks of current treatments include lack of efficacy and side effects of medications.
  • This invention provides methods, compositions, devices, kits and reagents for detecting, identifying and treating glaucoma diseases.
  • this invention provides methods and compositions for reducing intraocular pressure and increasing ocular outflows in glaucoma subjects. Aspects of this invention can reduce formation and presence of aggregational features and structures in ocular humor.
  • this disclosure provides therapeutic compositions for glaucoma.
  • Embodiments of this invention provide devices for measuring and characterizing glaucoma aggregational features, as well as intraocular pressure and ocular outflows.
  • Additional aspects of this disclosure include diagnostic and screening modalities for glaucoma. Further embodiments include kits and reagents for carrying out the foregoing.
  • Embodiments of this invention include the following:
  • An aqueous pharmaceutical composition for ophthalmic use comprising an active agent selected from cetylpyridinium chloride, polymyxin B sulfate, a mycin, and heparin sodium.
  • the mycin can be selected from neomycin, salinomycin, azithromycin, rapamycin, gentamycin, erythromycin, adriamycin, bleomycin, dactinomycin, mitomycin, plicamycin, dihydrostreptomycin, kanamycin, natamycin, rifamycin, and tobramycin.
  • the active agent may comprise 0.01-2% w/v of the composition.
  • the active agent can comprise 0.01-0.2% w/v of the composition.
  • the composition can have a pH of about 7.3.
  • composition above may reduce intraocular pressure when administered to the eye.
  • composition above may reduce ocular extracellular vesicle complexes when administered to the eye.
  • composition above can be effective for treating a glaucoma disease when administered to the eye.
  • the composition above can further comprise one or more of a solubilizer, a surfactant, a tonicifier, and a preservative.
  • the solubilizer may be selected from a phosphate, a citric acid monohydrate, a trisodium citrate, and combinations thereof.
  • the surfactant can be selected from a phospholipid, a polyglycerol ester, a propylene glycol ester, a polyethylene glycol ester, a copolymer ester, a polyoxyethylene sorbitan ester, a cyclodextrin, a polyvinyl alcohol, povidone, a hydroxypropyl methyl cellulose, a poloxamer, a carboxymethyl cellulose, a hydroxyethyl cellulose, a polyacrylate, and combinations thereof.
  • the tonicifier may be selected from sodium chloride, trehalose, mannitol, sorbitol, dextrose, potassium chloride, and combinations thereof.
  • the preservative can be selected from benzalkonium chloride, polyquaternium-1, benzododecinium bromide, sorbic acid, methyl paraben, propyl paraben, chlorobutanol, benzylic alcohol, phenylethyl alcohol, an oxychloro complex, thimerosal, sodium perborate, disodium edetate, and combinations thereof.
  • a composition above may be used in medical therapy, in the treatment of the human or animal body, in reducing intraocular pressure in the human or animal body, in reducing ocular extracellular vesicle complexes in the human or animal body, or in preparing or manufacturing a medicament for preventing, ameliorating, or treating a disease or condition associated with glaucoma in a subject in need.
  • Embodiments of this invention further contemplate methods for treating a glaucoma disease, reducing intraocular pressure, or reducing ocular extracellular vesicle complexes in a subject in need thereof, the method comprising administering a composition above to the eye of the subject.
  • the administration may be by injection.
  • the ocular extracellular vesicle complexes can be aggregates of extracellular vesicles having a diameter greater than about 300 nanometers.
  • FIG. 1 shows an illustration of normal eye (left) anatomy compared to glaucomatous eye (right).
  • FIG. 2 shows an electron micrograph of a sample of trabecular meshwork (left), and an illustration of aqueous humor flow in eye trabecular meshwork (right).
  • FIG. 3 shows a diagram of an embodiment of a device for detecting flow and pressure of a fluid composition in a channel.
  • the channel may contain a meshwork having properties like a trabecular meshwork of the eye.
  • the channel meshwork may have a uveal meshwork portion, a corneoscleral meshwork portion, and a justacanalicular meshwork portion.
  • the channel can be a microfluidic channel.
  • FIG. 4 shows an embodiment of a series of test channels for detecting the effect or various compounds, compositions and substances on the flow and pressure of a fluid composition in a channel.
  • FIG. 5 shows an embodiment of a device and system for detecting flow and pressure of a fluid composition in a channel.
  • a channel may contain a meshwork having properties like a trabecular meshwork of the eye.
  • the device may utilize a reservoir for a test sample of a fluid composition.
  • the channel can be a microfluidic channel.
  • FIG. 6 shows imaging of extracellular vesicles with conventional fixation techniques result in inefficient EV imaging due to failure of EVs to adhere. Imaging is surprisingly improved using a non-reversible crosslinking reagent (a) Representative photomicrographs of isolated bovine vitreous EVs, 4 million loaded, fixed to the copper grid with glutaraldehyde and subsequent UA and lead citrate solution, show few negatively stained EVs (arrowhead) at low (left) magnification, and in other photographs no EVs are visualized (middle and right).
  • Negatively stained EVs are shown with signal (black) surrounding the perimeter of the EV and lower signal (white or grey) in the center (b) Schematic diagram shows that EVs in solution that were applied to the electron microscopy grid surface fail to attach. The EVs are present in the discarded solution (black box) and we quantitated the size and number of EVs using nanoparticle tracking analysis (NT A) (c) NTA shows the size and concentration of EVs applied to the TEM grid surface (d) NTA shows the size and concentration of EVs that were present in the discarded solution.
  • NT A nanoparticle tracking analysis
  • This number represents the size and number of EVs that fail to adhere to the TEM grid surface
  • FIG. 7 shows healthy human aqueous humor, control, Patient #1, shows a diffuse distribution of non-aggregated EVs.
  • a-c Representative photomicrographs of diluted human healthy control aqueous humor EVs (EVs were NOT isolated with ultracentrifugation, only diluted with buffered saline), fixed to the copper grid with EDC, glutaraldehyde and subsequently stained with UA solution. Photographs were captured with transmission electron microscopy and recorded. The images show many negatively stained EVs of various sizes, and the majority of EVs exist in the fluid independent without aggregation. One EV-aggregate was observed and was in the minority of samples imaged. Scale bars are marked on the photographs.
  • FIG. 8 shows healthy human aqueous humor, control, Patient #2, shows a diffuse distribution of non-aggregated EVs.
  • a-d Representative photomicrographs of diluted human healthy control aqueous humor EVs (EVs were NOT isolated with ultracentrifugation, only diluted with buffered saline), fixed to the copper grid with EDC, glutaraldehyde and subsequently stained with UA solution. Photographs were captured with transmission electron microscopy and recorded. The images show many negatively stained EVs of various sizes. No EV-aggregates larger than 2 pm were observed, nor were large clumps of EVs visualized. Scale bars are marked on the photographs. [0030] FIG.
  • FIG. 10 shows POAG aqueous humor and shows large glaucoma-associated-EV- aggregates in Patient #2.
  • (a-c) Representative transmission electron microscopy photographs from a second POAG sample (EVs were NOT isolated with ultracentrifugation, only diluted with buffered saline), fixed to the copper grid with EDC, glutaraldehyde and subsequently stained with UA solution. Photographs were captured with transmission electron microscopy and recorded. The second POAG aqueous humor specimens show evidence of sizeable glaucoma-associated-EV- aggregates and larger free EVs. Scale bars are marked on the photographs.
  • FIG. 11 shows a known glaucoma treatment, bimatoprost, reduces the size of POAG- associated EV complexes in the aqueous humor of a patient with glaucoma, when compared to untreated glaucoma samples (a-b)
  • Representative transmission electron microscopy photographs show human aqueous humor collected from a patient with POAG and no treatment (placebo, control, buffered saline) shows evidence of extracellular matrix and glaucoma associated-EV-complexes in the aqueous humor.
  • FIG. 12 shows treatment of a glaucoma patient’s aqueous humor with buffered saline has no effect on PO AG-associated EV complexes of a second subject diagnosed with glaucoma.
  • FIG. 12 Representative transmission electron microscopy photographs show human aqueous humor collected from a patient with POAG and no treatment (placebo, control, buffered saline) shows evidence of glaucoma associated-EV-complexes. Images show large electron dense glaucoma associated-EV-complexes in all panels. The placebo treatment had no effect the glaucoma associated-EV-complexes. Scale bars are marked on the figures.
  • FIG. 13 shows bimatoprost reduces the size of PO AG-associated EV complexes in the aqueous humor of a second subject diagnosed with glaucoma, when compared to control -treated glaucoma samples.
  • FIG. 13 Representative photographs show POAG aqueous humor from Subject #2 samples treated with bimatoprost show a disruption of the large electron dense glaucoma- associated-EV-aggregates. The glaucoma-associated-EV-aggregates were smaller in size, when compared to the controls (shown in FIG. 12). On high power imaging, we do not observe many aggregated EVs. Scale bars are marked on the figures.
  • FIG. 14 shows glaucoma patients’ aqueous humor contains larger electron dense structures in the aqueous humor that are not present in healthy controls.
  • Graphical representation that depicts the size and number of an unidentified material that we termed, “glaucoma-associated- EV-aggregates” in healthy controls or POAG specimens.
  • the data shows that most EVs did not have glaucoma-associated-EV- aggregates.
  • the data show that three subjects with a diagnosis of POAG had numerous glaucoma- associated-EV-aggregates that are several micrometers in size. Theses aggregates were not observed in healthy controls.
  • the graph shows a substantial difference in the size of the glaucoma-associated- EV-aggregates in POAG, when compared to healthy controls.
  • FIG. 15 shows glaucoma patients' aqueous humor contains EVs that aggregate and contact each other, when compared to healthy controls that have fewer EVs touching each other.
  • Graphical representation that depicts the number of EVs that are in contact with each other (X-axis) and the count frequency (percent of total).
  • the data shows that two subjects with a diagnosis of POAG have aqueous humor that contains EVs that contact a large number of other EVs.
  • the graph shows a substantial difference between the number of EVs contacting each other in POAG, when compared to healthy controls.
  • FIG. 16 shows a curvilinear chart of the data in FIG. 15.
  • Glaucoma patients' aqueous humor contains EVs that aggregate and contact each other, when compared to healthy controls that have fewer EVs touching each other.
  • FIG. 17 shows extracellular vesicles are present in human aqueous humor obtained from healthy control patients and have a dominant population of EVs between 100 to 200 nm.
  • Graphical representation that depicts the EV population in human aqueous humor obtained from a single healthy control patient. The EV count frequency is shown as a function of size.
  • We fixed healthy control human aqueous humor after measuring EVs diameter after fixing human aqueous humor from a healthy control that was fixed with EDC fixation and imaged with transmission electron microscopy.
  • the data shows that healthy control human aqueous humor contains EVs. The majority of EVs between 100-200 nm in diameter for this patient. All EVs that were visualized were free from contact with other EVs (not aggregated).
  • FIG. 18 shows extracellular vesicles in the aqueous humor of subject #1 with the diagnosis of POAG are located within the “glaucoma-associated-EV-aggregates,” shows all EVs located within the glaucoma-associated-EV-aggregate.
  • the data show the number and size of individual EVs present within the glaucoma-associated-EV-aggregate (gray bar) as a function of the total number EVs counted.
  • a substantial number of EVs are between 36 nm and 300 nm with a high number of EVs 100 - 200 nm in size.
  • Subject #l aqueous humor, we did not observe free EVs (EVs that do not contact each other).
  • FIG. 19 shows extracellular vesicles in aqueous humor obtained from human subjects with the diagnosis of primary open angle glaucoma (POAG) are contacting each other to create an aggregate or the EVs were present as free EVs (non-aggregated).
  • POAG primary open angle glaucoma
  • FIG. 19 Graphical representation of the EV population in human aqueous humor obtained from a single subject with the diagnosis of POAG. We fixed the aqueous humor with EDC fixation and imaged with transmission electron microscopy. The photographs were analyzed and EV size and number were quantitated. We observed EVs that were present within an aggregate (defined as EVs that contact each other) or a free EVs (EVs that do not contact each other). The data shows that a population of EVs that are free from contact with each other (non-aggregated EVs). There was a substantial number of EVs between 100-500 nm, and some that are larger in size.
  • FIG. 20 shows a graph representing the size and frequency of EVs that are contacting other EVs and were located within a “glaucoma-associated-EV-aggregate” for the patient of FIG. 19.
  • a substantial amount of the EVs were between 36 nm and 300 nm, with a few larger free EVs observed.
  • FIG. 21 shows extracellular vesicles in the aqueous humor of a single subject with the diagnosis of POAG are located within the “glaucoma-associated-EV-aggregates,” with a substantial population of EVs present within the glaucoma-associated-EV-aggregate.
  • the data show the number and size of individual EVs present within the glaucoma-associated-EV-aggregate (black bar) or the number and size of EVs that are not aggregated (free EVs, black and white stripe bar), as a function of the total number EVs counted.
  • a substantial number of EVs were located within the glaucoma- associated-EV-aggregate.
  • a substantial number of EVs within the aggregate show a diameter from 100-300 nm in size. The larger EVs had higher populations show a substantial number of free EVs (non-aggregate EVs) in the larger size range.
  • FIG. 22 shows extracellular vesicles in two separate glaucoma patient shows similar sizes and number of EVs that are located within the “glaucoma-associated-EV-aggregate.”
  • FIG. 23 shows extracellular vesicles in the aqueous humor of human subjects with the diagnosis of POAG differ in size and frequency, when compared to aqueous humor of healthy control subjects
  • FIG. 24 shows extracellular vesicles POAG aggregates are similar in size and frequency to healthy human subjects
  • a Graphical representation of the EV population from human subject’s aqueous humor obtained from healthy controls (free EVs) or POAG subjects (aggregated EVs).
  • free EVs non-aggregate, defined as EVs that do not contact each other
  • the data show the size and number of free EVs from healthy controls (white bar), aggregate-EVs from POAG Subject #1 (grey bar), aggregate-EVs from POAG Subject #2 (stripe bar).
  • FIG. 25 shows that agent cetylpridinium chloride reduced intraocular pressure (IOP) in a glaucoma model as compared to control.
  • the agent was tested by controlling flow and measuring relative IOP using in a microfluidic device.
  • the agent was compared against placebo (buffered saline) by preparing each in bovine vitreous humor (BVH) and pre-incubating at 37°C for 24 hours.
  • the timepoint of injection into the device is denoted by an arrow and the letter “a.”
  • the IOP for placebo (dashed line) increased greatly after injection of the placebo sample.
  • FIG. 26 shows that agent polymyxin B reduced intraocular pressure (IOP) in a glaucoma model as compared to control.
  • the agent was tested by controlling flow and measuring relative IOP using in a microfluidic device.
  • the agent was compared against placebo (buffered saline) by preparing each in bovine vitreous humor (BVH) and pre-incubating at 37°C for 24 hours.
  • the timepoint of injection into the device is denoted by an arrow and the letter “a.”
  • the IOP for placebo (dashed line) increased greatly after injection of the placebo sample.
  • the IOP rose steadily to a maximum pressure of about 250 mmHg.
  • the IOP after injection of the agent polymyxin B solid line
  • FIG. 27 shows that agent neomycin reduced intraocular pressure (IOP) in a glaucoma model as compared to control.
  • the agent was tested by controlling flow and measuring relative IOP using in a microfluidic device.
  • the agent was compared against placebo (buffered saline) by preparing each in bovine vitreous humor (BVH) and pre-incubating at 37°C for 24 hours.
  • the timepoint of injection into the device is denoted by an arrow and the letter “a.”
  • the IOP for placebo (dashed line) increased greatly after injection of the placebo sample.
  • the IOP rose steadily to a maximum pressure of about 64 mmHg.
  • the IOP after injection of the agent neomycin solid line
  • FIG. 28 shows that agent heparin sodium reduced intraocular pressure (IOP) in a glaucoma model as compared to control.
  • the agent was tested by controlling flow and measuring relative IOP using in a microfluidic device.
  • the agent was compared against placebo (buffered saline) by preparing each in bovine vitreous humor (BVH) and pre-incubating at 37°C for 24 hours.
  • the timepoint of injection into the device is denoted by an arrow and the letter “a.”
  • the IOP for placebo (dashed line) increased greatly after injection of the placebo sample.
  • the IOP rose steadily to a maximum pressure of about 67 mmHg.
  • the IOP after injection of the agent heparin sodium solid line was 32% lower than for placebo, and the difference was sustained. This result showed that the agent heparin sodium was surprisingly effective to reduce IOP in the glaucoma model.
  • FIG. 29 shows that compound sodium dodecyl sulfate was a negative control for intraocular pressure (IOP) in a glaucoma model.
  • the compound was tested by controlling flow and measuring relative IOP using in a microfluidic device microfluidic.
  • the compound was compared against placebo (buffered saline) by preparing each in bovine vitreous humor (BVH) and pre- incubating at 37°C for 24 hours.
  • the timepoint of injection into the device is denoted by an arrow and the letter “a.”
  • the IOP for placebo (dashed line) increased greatly after injection of the placebo sample.
  • the IOP rose steadily to a maximum pressure of about 60 mmHg.
  • This invention provides methods, compositions, devices, kits and reagents for detecting, identifying and treating glaucoma disease.
  • Embodiments of this invention utilize ultrastructural features of ocular aqueous humor as guides and markers for glaucoma therapeutic modalities.
  • this invention provides methods and compositions for reducing intraocular pressure and increasing ocular outflows in glaucoma subjects. Aspects of this invention can reduce formation and presence of aggregational features and structures in ocular humor.
  • this disclosure provides therapeutic compositions for glaucoma.
  • Embodiments of this invention provide devices for measuring and characterizing glaucoma aggregational features, as well as intraocular pressure and ocular outflows.
  • Additional aspects of this disclosure include diagnostic and screening modalities for glaucoma. Further embodiments include kits and reagents for carrying out the foregoing.
  • Embodiments of this invention can provide glaucoma diagnosis based on a unique and reliable ultrastructural biomarker herein identified.
  • the ultrastructural component can block the trabecular meshwork, increasing IOP and, over time, ocular aqueous outflow resistance increases leading to elevated intraocular pressure, and eventual vision loss.
  • the ultrastructural component in the humor fluid of a patient with POAG can be reflected in EV aggregates formed together in large EV-complexes.
  • the EV-complexes can be multiple microns in size and are glaucoma-associated-EV-complexes.
  • the EV- complexes may be present in glaucoma patient samples and sizeable enough to block the trabecular meshwork.
  • Embodiments of this invention can provide compositions and methods for purifying and/or synthesizing EV-complexes of this ultrastructural component for use in therapeutic and biological methods.
  • Embodiments of this invention can provide compositions and methods for therapeutics and treatment of POAG and testing POAG aqueous humor specimens.
  • compositions and methods of this invention can reduce intraocular pressure and/or increase ocular outflows.
  • Embodiments of this invention further contemplate methods for treating glaucoma.
  • a glaucoma disease may be treated by administering a surface active agent for affecting EV-complexes.
  • a surface active agent may be used for ameliorating, alleviating, inhibiting, lessening, delaying, and/or preventing at least one symptom or condition of a glaucoma disorder.
  • IOP can be determined by the rate of aqueous humor formation and the rate fluid exit.
  • FIG. 1, right In general, reduced aqueous outflow in glaucoma can be related to raised IOP. Aqueous humor outflow can be related to elevated IOP and glaucomatous visual damage. Aqueous humor exits the eye via two pathways: the trabecular meshwork and to a lesser extent the uveolscleral outflow. (FIG. 2)
  • TM trabecular meshwork
  • the TM is a filter-like tissue composed of a series of fenestrated striations that allow aqueous humor to flow and exit the anterior chamber via Schlemm's canal.
  • the primary function of the TM is to allow aqueous humor to exit the eye and establish IOP.
  • JCT juxtacanalicular tissue
  • ECM extracellular matrix
  • Abnormal regulation of aqueous flow through the TM may be associated with elevated IOP.
  • the ECM of the TM can be a barrier that may isolate the ocular fluid outflow.
  • Ultrastructural features or compositions in the aqueous humor can include structures based on extracellular vesicles (EV). EVs are transport nano-vesicles related to inter-cellular communication via transfer of biomolecules such as proteins, lipids, and nucleic acids from one cell to another.
  • EVs extracellular vesicles
  • various cell types secrete EVs into fluids like blood, cerebrospinal fluid, and urine.
  • examples include exomeres approximately 35 nm, exosomes about 40 100 nm, larger micro-vesicles about 100-1000 nm, and apoptotic bodies about 1-5 pm.
  • EVs can be associated with pathophysiology of disease.
  • ultrastructural features and compositions based on EVs are utilized in characterizing ocular fluids.
  • ultrastructural features and compositions based on EVs can be utilized in devices for determining IOP.
  • Ultrastructural features and compositions based on EVs can be monitored for determining therapeutic effects in reducing IOP.
  • Ultrastructural features and compositions based on EVs can be monitored as biomarkers for determining therapeutic effects in reducing IOP.
  • ultrastructural features and compositions based on EVs can be utilized in devices for measuring ocular outflows. Ultrastructural features and compositions based on EVs can be monitored for determining therapeutic effects in increasing ocular outflows. Ultrastructural features and compositions based on EVs can be monitored as biomarkers for determining therapeutic effects in increasing ocular outflows. [0073] In further embodiments, ultrastructural features and compositions based on EVs are utilized in reducing formation and presence of aggregational features, structures and particles in ocular humor.
  • ultrastructural features and compositions based on EVs are utilized in devices for detecting ocular conditions and parameters.
  • ultrastructural features and compositions based on EVs are utilized in identifying glaucoma in a subject.
  • ultrastructural features and compositions based on EVs are utilized in methods, kits and reagents for glaucoma.
  • ultrastructural features and compositions based on EVs in glaucoma may have larger structures that block the TM and/or other outflows.
  • Glaucoma disorders that can be treated with the methods and compositions as described herein include, but are not limited to, preglaucoma open angle with borderline findings, open angle, low risk, anatomical narrow angle primary angle closure suspect, steroid responder, ocular hypertension, primary angle closure without glaucoma damage (PAS or high IOP with no optic nerve or visual field loss), unspecified open-angle glaucoma, primary open-angle glaucoma, chronic simple glaucoma, low-tension glaucoma, pigmentary glaucoma, capsular glaucoma with pseudo exfoliation of lens, residual stage of open-angle glaucoma, unspecified primary angle- closure glaucoma, acute angle-closure glaucoma attack, chronic angle-closure glaucoma, intermittent angle-closure glaucoma, residual stage of angle-closure glaucoma, glaucoma secondary to eye trauma,
  • glaucoma secondary to drugs glaucoma with increased episcleral venous pressure, hypersecretion glaucoma, aqueous misdirection malignant glaucoma, glaucoma in diseases classified elsewhere, congenital glaucoma, axenfeld’s anomaly, buphthalmos, glaucoma of childhood, glaucoma of newborn, hydrophthalmos, keratoglobus, congenital glaucoma macrocornea with glaucoma, macrophthalmos in congenital glaucoma, megalocornea with glaucoma, absolute glaucoma.
  • a composition of this disclosure can be administered systemically.
  • Systemic administration can be achieved via intravenous administration, oral administration, intraarterial administration, inhalation, intranasal administration, intra- peritoneal administration, intra-abdominal administration, subcutaneous administration, intra-articular administration, intrathecal administration, transdural administration, transdermal administration, submucosal administration, sublingual administration, enteral administration, parenteral administration, percutaneous administration, periarticular administration, or intraventricular administration.
  • a composition of this disclosure can be administered locally.
  • a composition may be administered locally to ocular tissue.
  • ocular tissue refers to the eye, including tissues within the sclera, e.g., the retina, and outside the sclera, e.g., ocular muscles within the orbit.
  • Ocular tissue also includes tissues neurologically connected to, but distinct from the eye, such as the optic nerve, the geniculate nucleus and the visual cortex.
  • Local administration to ocular tissue can be achieved via intraocular administration.
  • Intraocular administration can be carried out via intracameral administration, intravitreal administration, or subretinal administration.
  • local administration to ocular tissue can be achieved via periocular administration.
  • Periocular administration can be carried out via sub conjunctival injection, sub-Tenon’s injection, direct periocular injection, or depot periocular injection.
  • a subject may be administered a therapeutically effective amount of the composition.
  • a therapeutically effective amount can be an amount effective to ameliorate, alleviate, inhibit, lessen, delay, and/or prevent at least one symptom or condition of the condition being treated.
  • a therapeutically effective amount can be the amount effective to ameliorate the ocular condition being treated.
  • the dose may be determined according to various parameters, especially according to the severity of the condition, age, and weight of the patient to be treated; the route of administration; and the required regimen. A physician will be able to determine the required route of administration and dosage for any particular patient. Dosages may vary depending on the relative potency of the composition being administered, and can generally be estimated based on the half maximal effective concentration (EC50) found to be effective in in vitro and in vivo models.
  • EC50 half maximal effective concentration
  • Embodiments of this invention provide methods for detecting EVs in biological fluids.
  • a cross-linking agent can be used to provide robust imaging of EV ultrastructures with, for example, electron microscopy.
  • a glutaraldehyde-alternative cross-linker can be used.
  • Additional embodiments of this invention contemplate detecting and characterizing EV-complexes in glaucoma.
  • EV-complexes in glaucoma can block the TM or JCT and inhibit ocular aqueous outflow pathways.
  • EVs in glaucoma can be aggregated together in EV- complexes.
  • Glaucoma-associated EV-complexes may be up to multiple microns in size or diameter.
  • EV-complexes can be an ultrastructural feature of the disease. This ultrastructural feature can be a target for characterizing glaucoma. EV-complexes can be used for detecting therapeutic parameters and modalities for glaucoma. In some embodiments, EV-complexes can be used for diagnosis, prognostication, and/or screening of glaucoma compositions. EV-complexes can also be used in devices for determining therapeutic compositions, doses and regimens.
  • diameter refers to the longest linear dimension of an irregularly- shaped particle such as an extracellular vesicle complex.
  • the term diameter has its usual meaning as the line segment passing through the center with endpoints on the sphere.
  • this disclosure provides compositions of purified EV-complexes from glaucoma.
  • Purified EV-complexes from glaucoma can be used in a device for assaying and detecting changes in EV ultrastructural components which can be related to intraocular pressure and ocular outflows.
  • This invention provides devices containing purified EV-complexes which can be used for characterizing and measuring ocular blockage and ocular outflows.
  • Purified EV-complexes from glaucoma can be used in a device for screening effects of therapeutic agents on ocular EV ultrastructural components.
  • this disclosure provides compositions of synthetic EV- complexes for characterizing glaucoma.
  • Synthetic EV-complexes for characterizing glaucoma can be used in a device for assaying and detecting changes in EV ultrastructural components which can be related to intraocular pressure and ocular outflows.
  • This invention provides devices containing synthetic EV-complexes which can be used for characterizing and measuring ocular blockage and ocular outflows.
  • Synthetic EV- complexes from glaucoma can be used in a device for screening effects of therapeutic agents on ocular EV ultrastructural components.
  • EV ultrastructural components such as EV-complexes can be composed of complexes or aggregates of extracellular vesicles.
  • extracellular vesicles include exomeres, exosomes, multivesicular bodies, intraluminal vesicles (ILVs), multivesicular endosomes (MVEs), oncosomes, micro-vesicles, apoptotic bodies, and vesicles originating from endosome or plasma membranes.
  • Complexes or aggregates of extracellular vesicles can be protein-EV structures having micrometer diameters, or diameters greater than about 1 micrometer.
  • Extracellular vesicle aggregates can have a size of from about 360 to about 21,000 nanometers (nm).
  • exomeres can be about 35 nm in diameter
  • exosomes can be about 40-100 nm in diameter
  • micro-vesicles can be about 100-1000 nm in diameter
  • apoptotic bodies can be about 1-5 micrometers in diameter.
  • Complexes or aggregates of extracellular vesicles may contain 10, 20, 30, 40, 50, 100, 200, 500 or more extracellular vesicles.
  • a healthy subject may have free EVs, which are non-aggregated EVs, about 100-200 nm in diameter, which are mainly exosomes, along with some micrometer sized vesicles.
  • a healthy subject may not have EV-aggregates or EV ultrastructural features larger than 0.4-20 micrometers in diameter in aqueous humor.
  • a subject in glaucoma, may have EV-aggregates larger than 0.4-20 micrometers in diameter.
  • a healthy subject may have small EV aggregates of about 36-300 nm, which are mainly exomeres, along with some micro-vesicles.
  • a glaucoma subject may have reduced amounts of free EVs, or very few remaining free EVs.
  • Free EVs in glaucoma may be of larger sizes than free EVs in a healthy subject.
  • EV aggregates in glaucoma may be composed of any of exomeres, exosomes, micro-vesicles, and/or apoptotic bodies, as well as other kinds of vesicles or bodies.
  • a device of this invention can be used to characterize the activity of a biologically active agent toward glaucoma.
  • a device of this invention can be used to detect or characterize ocular conditions or parameters in a model system or patient pathology.
  • An active agent may be capable of providing a therapeutic benefit, especially in glaucoma.
  • an active agent may be a known drug effective for treating a disease of the eye.
  • a fluid composition in a device of this invention can be analyzed by various techniques.
  • a fluid composition can be analyzed by an imaging technique.
  • imaging techniques include electron microscopy, stereoscopic microscopy, wide-field microscopy, polarizing microscopy, phase contrast microscopy, multiphoton microscopy, differential interference contrast microscopy, fluorescence microscopy, laser scanning confocal microscopy, multiphoton excitation microscopy, ray microscopy, and ultrasonic microscopy.
  • imaging techniques include positron emission tomography, computerized tomography, and magnetic resonance imaging.
  • Examples of assay techniques include colorimetric assay, chemiluminescence assay, spectrophotometry, and light scattering.
  • this invention can provide a device for measuring pressure and flow rate of a fluid composition.
  • the device may have a channel having an inlet at a first end and an outlet at a second end, wherein the inlet and outlet are in fluid communication.
  • the device can have a meshwork composition lodged in the channel for providing resistance to flow.
  • the meshwork composition may have any one or more, or all of the following portions.
  • a meshwork composition can be composed of glass beads, micro beads, magnetic beads, gel particles, dextran particles, or polymer particles.
  • a meshwork composition may also be composed of glass fibers, polymeric fibers, inorganic fibers, organic fibers, or metal fibers.
  • a uveal meshwork may have fenestrations of about 25 micrometers.
  • a corneoscleral meshwork may have fenestrations of about 2-15 micrometers.
  • a juxtacanalicular meshwork may have fenestrations of about 1 to 4 micrometers or less.
  • a device may further include a fluid reservoir for holding the fluid composition, so that the fluid reservoir is in fluid communication with the inlet of the channel for introducing the fluid composition into the inlet of the channel.
  • a device of this disclosure can have a pressure source for applying pressure to the fluid composition in the fluid reservoir for introducing the fluid composition into the inlet of the channel.
  • a device of this invention can have a flow sensor in fluid communication with the fluid composition for measuring the flow rate and pressure of the fluid composition at the inlet of the channel and transmitting the flow rate and pressure to a processor.
  • Signals and data from the device can be received by a processor.
  • the processor can display the flow rate and pressure.
  • Memory or media can store instructions or files, such as a machine-readable storage medium.
  • a machine-readable storage medium can be non-transitory.
  • a processor of this disclosure can be a general purpose or special purpose computer.
  • a processor can execute instructions stored in a machine readable storage device or medium.
  • a processor can include an integrated circuit chip, a microprocessor, a controller, a digital signal processor, any of which can be used to receive and/or transmit data and execute stored instructions.
  • a processor can also transform data, and/or store data in memory, media or a file.
  • a processor may receive and execute instructions which may include performing one or more steps of a method of this invention.
  • a device of this invention can include one or more non-transitory machine-readable storage media, one or more processors, one or more memory devices, and/or one or more user interfaces.
  • a processor my have an integral display for displaying data or transformed data.
  • a device may have a microfluidic channel.
  • One or more channels can also be arranged in a microfluidic chip.
  • a device of this disclosure can include one or more detectors for analyzing the fluid composition within the channel or at the inlet or exiting the outlet of the channel.
  • a device of this invention may include a meshwork composition which contains extracellular vesicles or extracellular vesicle complexes.
  • An EV-complex for use in a meshwork composition may be purified from glaucoma ocular humor, aqueous humor, or vitreous humor.
  • the ocular humor may be from animal or clinical sources.
  • An EV- complex for use in a meshwork composition may be composed of extracellular vesicles, and may have a diameter from about 360 to about 21,000 nanometers.
  • an EV-complex for use in a meshwork composition may include a fixative, a stabilizing component, or a cross linking component which can transform the structure to a stable, uniform composition.
  • stabilizing components include fixatives as described herein, cross linking compounds as described herein, organic solvents, polypeptides, and pharmaceutically-acceptable organic salts.
  • salts include ammonium salts, alkali metal salts including sodium, lithium, and potassium salts, alkaline earth metal salts including calcium and magnesium salts, salts with organic bases, for example, organic amines, such as benzathines, dicyclohexylamines, hydrabamines formed with N,N-bis(dehydroabietyl)ethylenediamine), N-methyl-D-glucamines, N-methyl-D-glucamides, t-butyl amines, and salts with amino acids including arginine and lysine.
  • organic bases for example, organic amines, such as benzathines, dicyclohexylamines, hydrabamines formed with N,N-bis(dehydroabietyl)ethylenediamine), N-methyl-D-glucamines, N-methyl-D-glucamides, t-butyl amines, and salts with amino acids including arginine and lysine.
  • salts include acetates, adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, hydrochlorides, hydrobromides, hydroiodides, 2-hydroxyethanesulfonates, lactates, maleates, methanesulfonates, 2- napthalenesulfonates, nicotinates, nitrates, oxalates, pectinates, persulfates, digluconates, dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, 3-phenylpropionates, phosphates,
  • Extracellular vesicle complexes that are cross linked can be reversibly cross linked, or non-reversibly cross linked.
  • Extracellular vesicles that are cross linked can be reversibly cross linked, or non- reversibly cross linked.
  • a device of this invention may contain an EV-complex meshwork composition that can be used for identifying or screening active agents for effects in reducing IOP and/or increasing ocular outflows.
  • An EV-complex for use in a meshwork composition may include a drug delivery excipient.
  • An EV-complex meshwork composition for a device may be a synthetic EV-complex or a purified EV-complex.
  • FIG. 4 An embodiment of an arrangement of channels of this invention is illustrated in FIG. 4.
  • FIG. 5 An embodiment of a device of this invention is illustrated in FIG. 5.
  • a device of this invention may be used for measuring the quantity or level of an EV-complex in a test sample. Measuring the quantity or level of an EV-complex in a test sample can provide a diagnostic marker level for the test sample.
  • a device of this invention can be used to identify glaucoma or pre-glaucoma in a subject.
  • a device of this invention may be used for measuring a pressure which can be related to a quantity or level of an EV-complex in a test sample.
  • a pressure value in a channel can be related directly to a quantity or level of an EV-complex in a test sample.
  • a device of this invention may be used for measuring an assay value which can be related to a quantity or level of an EV-complex in a test sample.
  • An assay value of a composition in a channel can be related directly to a quantity or level of an EV-complex in a test sample.
  • an assay may be a colorimetric assay, a chemiluminescence assay, a spectrophotometry assay, or a light scattering assay.
  • an aqueous humor sample from a subject can be provided and analyzed for a quantity of glaucoma extracellular vesicle complexes.
  • the subject can be identified as having glaucoma or pre-glaucoma based on the quantity exceeding a reference value.
  • a reference value can be a quantity or level of glaucoma extracellular vesicle complexes in a reference population of healthy individuals.
  • the subject can be diagnosed as having glaucoma or pre-glaucoma.
  • a quantity or level of glaucoma extracellular vesicle complexes may include one or more of the number, size, density, morphology, and spatial distribution of the extracellular vesicle complexes.
  • a reference value can be a quantity or level of glaucoma extracellular vesicle complexes in a reference population of healthy individuals.
  • the reference value can be the average value in samples from the reference population.
  • Glaucoma may be found in a subject where a test sample from the subject contains a quantity or level of glaucoma extracellular vesicle complexes exceeding a glaucoma reference value.
  • a glaucoma reference value can be that the number of extracellular vesicle complexes which contain 10 or more aggregated extracellular vesicles is zero per sample. In certain embodiments, a glaucoma reference value can be that the number of extracellular vesicle complexes which contain 10 or more aggregated extracellular vesicles is 10 per sample. In certain embodiments, a glaucoma reference value can be that the number of extracellular vesicle complexes which contain 10 or more aggregated extracellular vesicles is 50 per sample. In certain embodiments, a glaucoma reference value can be that the number of extracellular vesicle complexes which contain 10 or more aggregated extracellular vesicles is 100 per sample.
  • a glaucoma reference value can be that the number of extracellular vesicle complexes which contain 10 or more aggregated extracellular vesicles, wherein the complexes are larger than 360 nm, is zero per sample. In certain embodiments, a glaucoma reference value can be that the number of extracellular vesicle complexes which contain 10 or more aggregated extracellular vesicles, wherein the complexes are larger than 360 nm, is 10 per sample.
  • a glaucoma reference value can be that the number of extracellular vesicle complexes which contain 10 or more aggregated extracellular vesicles, wherein the complexes are larger than 360 nm, is 50 per sample. In certain embodiments, a glaucoma reference value can be that the number of extracellular vesicle complexes which contain 10 or more aggregated extracellular vesicles, wherein the complexes are larger than 360 nm, is 100 per sample.
  • a glaucoma reference value can be the number of extracellular vesicle complexes larger than 360 nm is 10 per sample. In certain embodiments, a glaucoma reference value can be the number of extracellular vesicle complexes larger than 360 nm is 50 per sample. In certain embodiments, a glaucoma reference value can be the number of extracellular vesicle complexes larger than 360 nm is 100 per sample. In certain embodiments, a glaucoma reference value can be the number of extracellular vesicle complexes larger than 360 nm is 200 per sample.
  • a meshwork composition in a device of this invention can be an anterior half or portion of an animal eye with lens, wherein the TM of the eye is oriented in between the inlet and the outlet of the channel.
  • Extracellular vesicles in the aqueous humor in patients with POAG may be compared to a population of healthy controls.
  • EV complex ultrastructure in the aqueous humor in subjects with ocular pathology such as glaucoma can be compared to healthy controls such as subjects with no ocular pathology aside from cataracts.
  • the level of EV complexes in the aqueous humor in glaucoma subjects can exceed the level in healthy subjects.
  • the kind of EVs in glaucoma aqueous humor can be larger than in healthy subjects.
  • the level of larger EV structures can be reduced to un-block the aqueous humor meshwork and increase humor outflows.
  • the EV complexes in glaucoma aqueous humor can be larger than any EV in a healthy subject.
  • the level of EV complexes can be reduced to un-block the aqueous humor meshwork and increase humor outflows.
  • EVs in healthy human aqueous humor can be diffusely and evenly distributed without aggregation.
  • Healthy control aqueous humor may contain EVs that are non-aggregated and have diffuse distribution.
  • Glaucoma EV-complexes can be larger than EVs observed in healthy controls and may block the trabecular meshwork.
  • purified EV-complexes can be obtained from aqueous humor in POAG.
  • the purified EV-complexes may be several microns in size.
  • the glaucoma EV-complex can be larger than the opening of the JCT (1 to 4 pm, or up to 2 to 20 pm), which may be large enough to block the juxtacanalicular tissue.
  • the EV-complexes in POAG may be used to block the trabecular meshwork and reduce aqueous outflow.
  • the level of EV- complexes can be reduced to un-block the trabecular meshwork and increase aqueous outflow.
  • EV complexes can be contacted with a composition containing an active agent such as bimatoprost.
  • an active agent such as bimatoprost.
  • the level of EV-complexes can be reduced to un block a trabecular meshwork and increase aqueous outflow.
  • the level or quantity of glaucoma EV-complexes can be reduced in a POAG subject by administering an active agent such as bimatoprost.
  • purified EV-complexes can have a size from about 360 nm to 21,000 nm.
  • a purified EV-complex can be substantially larger than any particle found in healthy aqueous humor.
  • a purified EV-complex can have a size from about 360 nm to about 21,000 nm, or 360 nm to about 10,000 nm, or 360 nm to about 5,000 nm, or 360 nm to about 3,000 nm, or 360 nm to about 2,000 nm, or 360 nm to about 1,000 nm.
  • the number of EVs contacting each other can be from about 5 to about 300, or from 10 to 300, or from 10 to 200, or from 10 to 100, or from 10 to 50, or from 10 to 40, or from 10 to 20.
  • the number of EVs contacting each other can be from 20 to 300, or from 30 to 300, or from 40 to 300, or from 50 to 300.
  • the number of EVs contacting each other can be from 20 to 200, or from 20 to 100, or from 30 to 200, or from 30 to 100, or from 40 to 200, or from 40 to 100, or from 50 to 200, or from 50 to 100.
  • purified EV-complexes can provide particles of a size for a uveal meshwork.
  • Purified EV-complexes for a uveal meshwork can be about 10,000 nm to about 25,000 nm, or 15,000 nm to 25,000 nm, or 20,000 nm to 25,000 nm.
  • purified EV-complexes can provide particles of a size for a corneoscleral meshwork.
  • Purified EV-complexes for a corneoscleral meshwork can be about 1,000 nm to about 15,000 nm, or 2,000 nm to 10,000 nm, or 2,000 nm to 5,000 nm.
  • purified EV-complexes can provide particles of a size for a juxtacanalicular meshwork.
  • Purified EV-complexes for a juxtacanalicular meshwork can be about 360 nm to about 1,000 nm, or 360 nm to 2,000 nm, or 260 nm to 3,000 nm, or 1,000 nm to 3,000 nm.
  • EV complexes can be synthesized by contacting EVs with reagents to form larger structures.
  • Reagents can include fixatives, cross linkers, and buffer suspensions. Synthesized EV complexes may be composed of many EVs contacting each other to form aggregates.
  • the number of EVs contacting each other can be from about 5 to about 300, or from 10 to 300, or from 10 to 200, or from 10 to 100, or from 10 to 50, or from 10 to 40, or from 10 to 20.
  • the number of EVs contacting each other can be from 20 to 300, or from 30 to 300, or from 40 to 300, or from 50 to 300.
  • the number of EVs contacting each other can be from 20 to 200, or from 20 to 100, or from 30 to 200, or from 30 to 100, or from 40 to 200, or from 40 to 100, or from 50 to 200, or from 50 to 100.
  • a synthesized EV-complex can have a size from about 360 nm to about 25,000 nm, or 360 nm to 21,000 nm, or 360 nm to about 10,000 nm, or 360 nm to about 5,000 nm, or 360 nm to about 3,000 nm, or 360 nm to about 2,000 nm, or 360 nm to about 1,000 nm.
  • synthesized EV-complexes can provide particles of a size for a uveal meshwork. Synthesized EV-complexes for a uveal meshwork can be about 10,000 nm to about 25,000 nm, or 15,000 nm to 25,000 nm, or 20,000 nm to 25,000 nm.
  • synthesized EV-complexes can provide particles of a size for a corneoscleral meshwork.
  • Synthesized EV-complexes for a corneoscleral meshwork can be about 1,000 nm to about 15,000 nm, or 2,000 nm to 10,000 nm, or 2,000 nm to 5,000 nm.
  • synthesized EV-complexes can provide particles of a size for a juxtacanalicular meshwork.
  • Synthesized EV-complexes for a juxtacanalicular meshwork can be about 360 nm to about 1,000 nm, or 360 nm to 2,000 nm, or 260 nm to 3,000 nm, or 1,000 nm to 3,000 nm.
  • extracellular vesicles and EV-complexes can be synthesized, isolated, and/or purified by size exclusion chromatography or gel filtration chromatography.
  • extracellular vesicles including exosomes and EV- complexes can be synthesized, isolated, and/or purified by centrifugation, differential centrifugation, density gradient centrifugation, or ultracentrifugation.
  • extracellular vesicles including exosomes and EV- complexes can be synthesized, isolated, and/or purified using precipitation reagents, for example polymeric precipitation reagents, protamine, sodium acetate, or organic solvents.
  • extracellular vesicles including exosomes and EV- complexes can be synthesized, isolated, and/or purified using immunoaffmity capture techniques.
  • extracellular vesicles including exosomes and EV- complexes can be synthesized, isolated, and/or purified using microfluidic devices, acoustic fluidic devices, and microfluidic chips.
  • extracellular vesicles including exosomes and EV- complexes can be synthesized, isolated, and/or purified using sequential filtration techniques.
  • extracellular vesicles including exosomes can be detected by resistive pulse sensing using a tunable pore sensor, or tunable resistive pulse sensing.
  • extracellular vesicles including exosomes can be detected by electron microscopy, light microscopy and flow cytometry.
  • extracellular vesicles including exosomes can be detected by dynamic light scattering and/or mass spectrometry.
  • extracellular vesicles including exosomes and EV-complexes can be synthesized, isolated, and/or purified by first isolating the vesicles from cell culture.
  • extracellular vesicles including exosomes and EV-complexes can be synthesized, isolated, and/or purified by first isolating the vesicles from bodily fluids, such as ocular humor.
  • the isolated vesicles can be diluted, filtered and protected with protease inhibitors.
  • steps for purification of extracellular vesicles including exosomes and EV-complexes include contacting with a fixative.
  • extracellular vesicles including exosomes can be synthesized by controlled biogenesis and release from in vitro grown cell lines. Active agents
  • active agents include small molecule drugs, proteins, nucleic acids, polysaccharides, biologies, and combinations thereof.
  • active agents include cytokines, growth factors, proteins, peptides, anti-metabolites, signaling modulators, antibiotics, antibodies, chemotherapeutic compounds, and combinations thereof.
  • active agents include antiinfective agents, anesthetic agents, anti- VEGF agents, anti-inflammatory agents, an intraocular pressure reducing agent, and combinations thereof.
  • Examples of active agents include anesthetics, analgesics, and combinations thereof.
  • active agents include cell transport or mobility impending agents such as colchicine, vincristine, cytochalasin B, and combinations thereof.
  • active agents include antiglaucoma drugs.
  • active agents include beta-blockers such as timolol, betaxolol, atenolol, prostaglandins, and combinations thereof.
  • active agents include lipid-receptor agonists or prostaglandin analogues such as bimatoprost, travoprost, tafluprost, latanoprost, unoprostone, and combinations thereof.
  • active agents include alpha-adrenergic agonists including brimonidine, dipivefrine, and combinations thereof.
  • Examples of active agents include carbonic anhydrase inhibitors such as acetazolamide, methazolamide, dichlorphenamide, diamox, and combinations thereof.
  • Examples of active agents include and neuroprotectants such as nimodipine.
  • Examples of active agents include agents for dry AMD such as rapamycin, glatiramer acetate, complement C5aR blocker, ciliary neurotrophic factor, fenretinide, rheopheresis, and combinations thereof.
  • active agents include agents for wet AMD such as mecamylamine; VEGF trap eye, complement inhibitor POT-4.
  • active agents include kinase inhibitors such as bevacizumab, BIBW 2992, cetuximab, imatinib, trastuzumab, gefitinib, ranibizumab, pegaptanib, sorafenib, dasatinib, sunitinib, erlotinib, nilotinib, lapatinib, panitumumab, vandetanib, E7080, and combinations thereof.
  • kinase inhibitors such as bevacizumab, BIBW 2992, cetuximab, imatinib, trastuzumab, gefitinib, ranibizumab, pegaptanib, sorafenib, dasatinib, sunitinib, erlotinib, nilotinib, lapatinib, panitumumab, vandetanib, E7080, and combinations thereof.
  • active agents include antibiotics such as tetracycline, chlortetracycline, bacitracin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, gentamycin, and erythromycin.
  • antibiotics such as tetracycline, chlortetracycline, bacitracin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, gentamycin, and erythromycin.
  • active agents include antibacterials such as sulfonamides, sulfacetamide, sulfamethizole and sulfisoxazole.
  • active agents include anti-fungal agents such as fluconazole, nitrofurazone, amphotericin B, and ketoconazole.
  • active agents include anti-viral agents such as trifluorothymidine, acyclovir, ganciclovir, DDI, AZT, foscamet, vidarabine, trifluorouridine, idoxuridine, ribavirin, protease inhibitors, and anti-cytomegalovirus agents.
  • anti-viral agents such as trifluorothymidine, acyclovir, ganciclovir, DDI, AZT, foscamet, vidarabine, trifluorouridine, idoxuridine, ribavirin, protease inhibitors, and anti-cytomegalovirus agents.
  • active agents include antiallergenics such as methapyriline; chlorpheniramine, pyrilamine and prophenpyridamine.
  • active agents include anti-inflammatories such as hydrocortisone, dexamethasone, fluocinolone, prednisone, prednisolone, methylprednisolone, fluorometholone, betamethasone and triamcinolone.
  • anti-inflammatories such as hydrocortisone, dexamethasone, fluocinolone, prednisone, prednisolone, methylprednisolone, fluorometholone, betamethasone and triamcinolone.
  • active agents include decongestants such as phenylephrine, naphazoline, and tetrahydrazoline; miotics, and muscarinics.
  • Examples of active agents include anti-cholinesterases such as pilocarpine, carbachol, di-isopropyl fluorophosphate, phospholine iodine, and demecarium bromide.
  • Examples of active agents include mydriatics such as atropine sulfate, cyclopentolate, homatropine, scopolamine, tropicamide, eucatropine.
  • Examples of active agents include sympathomimetics such as epinephrine.
  • Examples of active agents include ranibizumab, bevacizamab, and triamcinolone.
  • Examples of active agents include antiinflammatories, such as non-steroidal anti inflammatories (NSAID) including acetylsalicylic acid, ibuprofen, indomethacin; and COX-2 inhibitors.
  • NSAID non-steroidal anti inflammatories
  • active agents include immunosuppressive agents including sirolimus.
  • active agents include matrix metalloproteinase (MMP) inhibitors such as tetracycline.
  • MMP matrix metalloproteinase
  • active agents include anticlotting agents such as heparin, antifibrinogen, fibrinolysin, and anti-clotting activase.
  • active agents include antidiabetic agents including acetohexamide, chlorpropamide, glipizide, glyburide, tolazamide, tolbutamide, insulin, and aldose reductase inhibitors.
  • active agents include amines such as Thonzonium.
  • active agents include detergents such as Taurocholic acid, Glycocholic acid, Glycochenodeoxycholic Acid, Benzalkonium, Cetylpyridinium, Taurochenodeoxycholic acid, Polidocanol, and Tyloxapol.
  • detergents such as Taurocholic acid, Glycocholic acid, Glycochenodeoxycholic Acid, Benzalkonium, Cetylpyridinium, Taurochenodeoxycholic acid, Polidocanol, and Tyloxapol.
  • Examples of active agents include lipids such as Sodium lauryl sulfate.
  • active agents include antibacterials such as Polymyxin B.
  • active agents include amines such as Thonzonium and related compounds Thonzylamine, mepyramine and Piribedil.
  • active agents include Ophthalmics such as Aceclidine, Acetazolamide, Acetylcysteine, Acyclovir, Aflibercept, Alcaftadine, Alclometasone, Alteplase, Ampicillin, Anecortave, Ascorbic acid, Atropine, Azelastine, Azithromycin, Befunolol, Bendazac, Benzylpenicillin, Besifloxacin, Betamethasone, Betaxolol, Bibrocathol, Bimatoprost, Brimonidine, Brinzolamide, Bromfenac, Carbamoylcholine, Carteolol, Cefuroxime, Cenegermin, Chloramphenicol, Chlorhexidine, Chlortetracycline, Chymotrypsin, Cinchocaine, Ciprofloxacin, Clobetasone, Clonidine, Cocaine, Cortisone, Cromoglicic acid, Cy
  • active agents include anti-cancer agents such as 5-fluorouracil, adriamycin, asparaginase, azacitidine, azathioprine, bleomycin, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, cyclosporine, cytarabine, dacarbazine, dactinomycin, daunorubicin, doxorubicin, estramustine, etoposide, etretinate, filgrastin, floxuridine, fludarabine, fluorouracil, fluoxymesterone, flutamide, goserelin, hydroxyurea, ifosfamide, leuprolide, levamisole, lomustine, nitrogen mustard, melphalan, mercaptopurine, methotrexate, mitomycin, mitotane, pentostatin, pipobroman, plic
  • active agents include hormones, peptides, steroids, nucleic acids, saccharides, lipids, glycolipids, and glycoproteins.
  • active agents include endocrine hormones such as pituitary, insulin, insulin-related growth factor, thyroid, and growth hormones.
  • active agents include heat shock proteins.
  • active agents include immunological response modifiers such as muramyl dipeptide, cyclosporins, interferons, interleukin-2, cytokines, tacrolimus, tumor necrosis factor, pentostatin, thymopentin, transforming factor beta2, and erythropoietin.
  • active agents include brain nerve growth factor (BNGF), ciliary nerve growth factor (CNGF), and vascular endothelial growth factor (VEGF).
  • active agents include anti-coagulants, anti-proliferatives, quinoxalines, and potassium channel blockers.
  • active agents include guanylate cyclase inhibitor, such as methylene blue, butylated hydroxyanisole, N-methylhydroxylamine, 2-(4-methylaminobutoxy) diphenylmethane, and apraclonidine.
  • guanylate cyclase inhibitor such as methylene blue, butylated hydroxyanisole, N-methylhydroxylamine, 2-(4-methylaminobutoxy) diphenylmethane, and apraclonidine.
  • active agents include prostaglandins such as metabolite derivatives of arachidonic acid.
  • active agents include sugars, such as trehalose.
  • active ingredients include viscoelastic agents including hyaluronic acid, dimethicone, and Hypromellose.
  • active ingredients include ophthalmic viscosurgical devices, sodium hyaluronate, chondroitin sulfate, hydroxypropyl methycellulose, hydroxy-propyl- methylcellulose, hyaluronic acid, dimethicone, and hypromellose.
  • Examples of active agents include detergents, purifying or cleansing agents, for example salts of long-chain aliphatic bases or acids, which can have cleansing, oil dissolving, and/or antimicrobial effects.
  • Examples of active agents include Glycochenodeoxycholic Acid, Glycocholic acid, Peanut oil, Benzalkonium, Cetylpyridinium, Taurochenodeoxycholic acid, Polidocanol, Tyloxapol, Taurocholic acid, and N-Dodecyl-N,N-Dimethyl-3-Ammonio-l-Propanesulfonate.
  • Embodiments of this invention further contemplate use of active agents for treating glaucoma disorders.
  • a glaucoma disorder may be treated by administering a surface active agent for affecting EV-complexes.
  • An effective amount a surface active agent can be administered for ameliorating, alleviating, inhibiting, lessening, delaying, and/or preventing at least one symptom or condition of a glaucoma disorder.
  • the term surface active agent refers broadly to surfactants, detergents, purifying or cleansing agents, soaps, and modified variations thereof.
  • active agents include surfactants including Lucinactant, Calfactant, Beractant, Tyloxapol, Sodium lauryl sulfoacetate, Thonzonium, Nonoxynol-9 Cetalkonium, Dimethicone, Polyethylene glycol 400, Sinapultide, Palmitoyloleoyl-phosphatidylglycerol, Lapyrium, Sodium Lauryl Sulfate (SLS), Polyethylene glycol 300, Trolamine, Polysorbate 80, Poloxamer 407, Sodium tetradecyl sulfate, Polysorbate 20, Docusate, Poractant alfa, Colfosceril palmitate, Castor oil, Benzalkonium, N-alkyl ethylbenzyl dimethyl ammonium (cl2-cl4), Quaternium-15, Ambroxol, Pumactant, Ethanolamine, Lecithin, soybean, and Cocamidopropyl betaine.
  • surfactants including Lucinactant,
  • active agents include agents as described herein can be modified for delivery or metabolic acceptability, or can be PEGylated with a polyethylene glycol chain, or have a polypropylene glycol chain attached.
  • This disclosure includes the agents described above as modified active agents, or PEGylated, or with other chain modifications.
  • active agents include antibodies, antibody fragments, VEGF inhibitors, small molecules, corticosteroids, and combinations thereof.
  • active agents include tyrosine kinase inhibitors, monoclonal antibodies, and combinations thereof.
  • Examples of active agents include antibodies and antibody fragments.
  • the term "antibody” as referred to herein includes whole antibodies, e.g., two heavy chains and two light chains, antibody binding fragments thereof, e.g., single chain antibodies (scFv), single domain antibodies, e.g., nanobodies or Fv, Fab, Fab’, F(ab’)2, and, variants thereof, e.g., tandem scFv, Fd fragments, diabodies, triabodies.
  • Antibody fragments may be obtained using conventional techniques known to those of skill in the art, and the fragments may be used in the same manner as intact antibodies.
  • Antibody and antibody fragments as disclosed herein can be mono-valent, bi valent, or tri-valent with regard to binding domains, and the binding domains may be mono-specific, bi-specific, or tri-specific in binding specificity by design.
  • Suitable antibodies include monoclonal antibodies or a polyclonal antibody mixture.
  • the antibody may be a chimeric antibody, a CDR-grafted antibody, a humanized antibody or an antigen binding portion of any of the foregoing thereof.
  • Therapeutic antibodies may be derived from a variety of species, including, without limitation, mouse, human, camel, llama, goat, rabbit, bovine, and cartilaginous fish.
  • an antibody or antigen binding fragment thereof can be used for the treatment of an ocular disease or condition.
  • antibodies or antigen binding fragments include those that bind to and preferentially block or reduce the activity of integrins associated with disease, such as an anti-avP3 integrin antibody and an anti- a4b1 integrin antibody, anti-epidermal growth factor receptor antibody, anti-vascular endothelial growth factor (VEGF) receptor antibody, anti-VEGF antibodies, e.g., bevacizumab, ranibizumab, anti-TNFa antibodies, e.g., infliximab and adalimumab, an anti-fibroblast growth factor antibody, an anti-epidermal growth factor antibody, an anti- CD20 antibody, an anti-CD52 antibody, an anti-CDl la antibody, and anti-IL-2 antibody.
  • integrins associated with disease such as an anti-avP3 integrin antibody and an anti- a4b1 integrin antibody, anti-epid
  • a therapeutic protein can be an antibody mimetic.
  • antibody mimetic encompasses any organic compound, e.g., a peptide or polypeptide, that can specifically bind an antigen like an antibody and is about 3-20 kDa.
  • An antibody mimetic may comprise a scaffold which binds its target antigen via amino acids in exposed loops similar to the CDR loops of an antibody.
  • Antibody mimetics include adnectins, lipocalins, Kunitz domain-based binders, avimers, knottins, fynomers, atrimers, and cytotoxic T-lymphocyte associated protein-4 (CTLA4)-based binders.
  • Examples of active agents include agents used for Parkinson’s such as Benzatropine, Ropinirole, Tolcapone, Trihexyphenidyl, Procyclidine, Pramipexole, Entacapone, Biperiden, Amantadine, Selegiline, Bromocriptine, Levodopa, Dexetimide, Piribedil, Budipine, Melevodopa, Profenamine, Cabergoline, Lisuride, Progabide, Gabapentin, Memantine, Orphenadrine, 3,5-Dinitrocatechol, Pimavanserin, Ifenprodil, Opicapone, Benserazide, Metixene, Apomorphine, Pergolide, Rasagiline, Rotigotine, Etilevodopam, Tropatepine, Dihydroergocryptine, Phenglutarimide, Mazaticol, Etybenzatropine, Bornaprine, Etanautine, Carbidopa, Sa
  • Epoprostenol Dinoprost, Carboprost tromethamine, Dinoprost tromethamine, Dinoprostone, Prostaglandin D2, Prostalene, Reidispongiolide C, Unoprostone, Gemeprost, Limaprost, Iloprost, Latanoprost, Cloprostenol, Sepetaprost, Bimatoprost, Fenprostalene, Latanoprostene Bunod, Travoprost, Carboprost Tromethamine, Dinoprost, Tafluprost, Cabazitaxel, Cloprostenol Sodium, Bimatoprost, (-)-Corey Lactone 4- Phenylbenzoate Alcohol, Dutasteride, Isopropyl Unoprostone, Beraprost Sodium, Prostaglandin El, Cloprostenol, Remodulin, Trenbolone Cyclohexylmethylcarbonate, Pros
  • Examples of active agents include vitamins such as 1-alpha, 25-dihydroxyl-20- epi-22-oxa-24, 26 ,27-trihomovitamin D3.
  • active agents include antibotics such as Brefeldin A, Fusidic acid, Ovalicin, Narasin, and Salinomycin.
  • Examples of active agents include steroids such as Hydrocortisone cypionate, Hydrocortisone valerate, Hydrocortisone butyrate, Hydrocortisone probutate, Hydrocortisone aceponate, Prednisolone tebutate, Trilostane Hydrocortisone acetate, Cholesteryl Linoleate, Methylprednisolone aceponate, Eldecalcitol Pregnenolone acetate, Testosterone propionate Drospirenone Clascoterone Norethindrone enanthate, Prednisolone hemisuccinate, Hydroxyprogesterone caproate, Trenbolone acetate, Fluprostenol Anecortave acetate Oleandrin Cortisone acetate, Calcipotriol Gestodene Dimethyl carbate, Calcipotriol lalpha,24S-Dihydroxyvitamin D2, Ethynodiol dia
  • steroids
  • active agents include statins such as Lovastatin, atorvastatin, pravastatin, rosuvastatin, fluvastatin, and simvastatin.
  • active agents include aggregation inhibitors such as Pentoxifylline, Argatroban, and Von Willebrand Factor Human.
  • active agents include prostacyclin such as Treprostinil.
  • active agents include amyloid targeting agents such as caprospinol and similar compounds including Cholesteryl Linoleate, Pregnenolone acetate, and P- 57AS3.
  • Examples of active agents include lactones such as Reidispongiolide A and Soraphen A, and Canrenone. [00241] Examples of active agents include Benzoquinones such as Antroquinonol.
  • Examples of active agents include Oxepanes such as Triptolide PG-701.
  • Examples of active agents include Lipids such as gibberellin A4 and Fumagillin.
  • Examples of active agents include blood glucose lowering agents such as Mitiglinide.
  • active agents include central nervous system depressant such as Glutethimide.
  • active agents include benzenoids such as sildenafil, udenafil, and vardenafil.
  • active agents include carbohydrates such as Fusicoccin and treholose.
  • Examples of active agents include Cholinergic Agents such as Biperiden, Cycrimine, Procyclidine, and Trihexyphenidyl.
  • Examples of active agents include Terpenes such as Cyclohexanes.
  • the molecules, compounds and/or compositions of this disclosure may be asymmetric, having one or more chiral stereocenters.
  • a compound containing one or more chiral centers can include substances described as an "isomer,” a “diastereomer,” a “stereoisomer,” an “optical isomer,” an “enantiomer,” or as a “racemic mixture.”
  • Conventions for stereochemical nomenclature for example the stereoisomer naming rules of Cahn, Ingold and Prelog, as well as methods for the determination of stereochemistry and the separation of stereoisomers are known in the art. See, e.g., March’s Advanced Organic Chemistry (7th ed., 2013).
  • the compounds, composition and structures of this disclosure are intended to encompass all possible isomers, stereoisomers, diastereomers, enantiomers, and/or optical isomers that exist for the compound, composition and/or structure, including any mixture, racemate, or racemic or other mixtures thereof.
  • a compound can exist in un-solvated and solvated forms, or hydrated forms.
  • solvated forms with pharmaceutically acceptable solvents, such as water or ethanol, are to be taken as equivalent to the un-solvated forms.
  • Compounds and salts, or solvates thereof may also exist in tautomeric forms, which are to be taken as equivalent.
  • the molecules, compounds and/or compositions of this disclosure may be found in different crystalline forms, which are intended to be encompassed by this disclosure. Compositions and formulations
  • An active agent of this disclosure can include drugs and agents for diseases of the eye, including small molecule drugs, peptides, antibodies and protein agents.
  • a formulation of an active agent may be prepared by dissolving a composition in water to produce an aqueous solution and rendering the solution sterile.
  • a formulation of this disclosure can be in the form of a sterile injectable aqueous or oily suspension.
  • a suspension can be formulated including a dispersing or wetting agent.
  • a sterile injectable preparation can be a sterile injectable solution or suspension in a non-toxic, pharmaceutically acceptable diluent or solvent.
  • solvents examples include water, water for injection, Ringer's solution, balanced salt saline, isotonic sodium chloride solution, 1,3-butanediol, synthetic mono-or diglycerides, and fatty acids such as oleic acid.
  • a formulation of this disclosure can be in the form of eye drops for topical delivery.
  • An ophthalmic formulation can be a solution or suspension for topical administration.
  • a composition can be a viscous or semi-viscous gel, or other solid or semi solid compositions.
  • An ophthalmic formulation can be locally delivered by direct injection or by use of an infusion pump.
  • An ophthalmic formulation can include artificial tears carriers.
  • An ophthalmic formulation can include a phospholipid carrier.
  • An ophthalmic formulation can include a surfactant, a preservative, an antioxidant, a tonicity adjusting excipient, a buffer, a co-solvent, and a viscosity excipient.
  • An ophthalmic formulation may include an excipient to adjust osmolarity of the formulation.
  • An ophthalmic formulation can include a viscosity excipient such as a polysaccharide, hyaluronic acid, chondroitin sulfate, a dextran, a cellulose polymer, a vinyl polymer, and an acrylic acid polymer.
  • a viscosity excipient such as a polysaccharide, hyaluronic acid, chondroitin sulfate, a dextran, a cellulose polymer, a vinyl polymer, and an acrylic acid polymer.
  • An ophthalmic formulation may have a viscosity of from 1 to 400 centipoises, or from 1 to 100 centipoises, or from 2 to 40 cps. An ophthalmic formulation may have a viscosity of about 15, 20, 25, 30, 40, or 50 centipoises.
  • excipients or carriers for a formulation of this invention include ophthalmologically acceptable preservatives, viscosity enhancers, penetration enhancers, buffers, sodium chloride, sterile water, water for injection, and combinations thereof.
  • a dosage form of a composition of this invention can be liquid or an emulsion.
  • a dosage form of the composition of this invention can be solid, which can be reconstituted in a liquid prior to administration.
  • a composition of this disclosure can also be in the form of an oil-in-water emulsion.
  • the oily phase can be a vegetable oil or a mineral oil.
  • emulsifying agents include naturally-occurring gums, gum acacia, gum tragacanth, phosphatides, esters of fatty acids, hexitol, sorbitan monooleate, and polyoxyethylene sorbitan monooleate.
  • Embodiments of this invention can advantageously provide effective activity of an active agent at dosage levels significantly lower than conventional dosage levels.
  • An effective amount of an active agent composition of this disclosure can be an amount sufficient to ameliorate or reduce a symptom of the disease treated.
  • a composition may be administered as a single dosage or may be administered in a regimen with repeated dosing.
  • an appropriate dosage level of an active agent can be determined by a skilled artisan.
  • an active agent can be present in a composition in an amount from about 0.001% to about 40%, or from about 0.01 % to about 20%, or from about 0.1% to 10% by weight of the total formulation.
  • An active agent of this disclosure can be combined with one or more pharmaceutically acceptable carriers.
  • a carrier can be in a variety of forms including fluids, viscous solutions, gels, or solubilized particles. Examples of carriers include pharmaceutically acceptable diluents, solvents, saline, and various buffers.
  • an active agent may be delivered without a carrier for reducing extracellular vesicle complexes in glaucoma ocular humor.
  • Examples of carriers include pyrogen free water; isotonic saline, Ringer's solution, ethyl alcohol, and phosphate buffer solution.
  • a formulation of this disclosure may include a polymer such as a polyethylene glycol (PEG), polypropylene glycol, or poly(lactic-co-glycolic acid) having a molecular weight of about 0.2 to about 50 kDa.
  • PEG polyethylene glycol
  • polypropylene glycol polypropylene glycol
  • poly(lactic-co-glycolic acid) having a molecular weight of about 0.2 to about 50 kDa.
  • carrier polymers include polyvinyl acetate, polyvinyl alcohol, polyvinylpyrrolidone, chitosan, collagen, sodium alginate, gelatin, hyaluronic acid, polylactic acid, poly(lactic acid-glycolic acid) copolymer, polyhydroxybutyric acid, poly(hydroxybutyric acid-glycolic acid) copolymer, cellulose, hydroxymethylcellulose, hydroxypropylcellulose, fatty acid esters, and polyglycerins.
  • additives include saccharides, sucrose, mannitol, lactose, L- arabinose, D-erythrose, D-ribose, D-xylose, D-mannose, D-galactose, lactulose, cellobiose, gentibiose, glycerin, polyethylene glycol, N-methylpyrrolidone, oligovinyl alcohol, ethanol, ethylene glycol, and propylene glycol.
  • solubility enhancing agents include cyclodextrins.
  • a formulation can include galactose, lactose, mannitol, monosaccharide, fructose, maltose, galactose, glucose, D-mannose, sorbose, disaccharide, lactose, sucrose, trehalose, cellobiose, polysaccharide, maltodextrin, dextran, starch, mannitol, or xylitol.
  • An ophthalmic formulation may include a lipid such as dipalmitoylethylphosphocholine, dioleoyl phosphatidylethanolamine, or 3B-[N-(N',N'- Dimethylaminoethane)-carbamoyl] cholesterol.
  • a lipid such as dipalmitoylethylphosphocholine, dioleoyl phosphatidylethanolamine, or 3B-[N-(N',N'- Dimethylaminoethane)-carbamoyl] cholesterol.
  • An ophthalmic formulation may include a lipid such as 1,2-Dioleoyl-sn-Glycero- 3-[Phospho-L-Serine], l,2-Dioleoyl-sn-Glycero-3 -Phosphate.
  • An ophthalmic formulation may include a lipid such as 1,2-Dipalmitoyl-sn- Glycero-3-Phosphocholine, distearoylphosphatidylcholine, diarachidoylphosphatidylcholin, dipalmitoyl phosphatidylethanolamine.
  • An ophthalmic formulation may include a fatty acid, oleic acid, myristoleic, or aracadonic acid.
  • An ophthalmic formulation may include a phospholipid such as phosphatidylcholine, lecithin, phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, and phosphatidylethanolamine.
  • a phospholipid such as phosphatidylcholine, lecithin, phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, and phosphatidylethanolamine.
  • An ophthalmic formulation may include a polymer such as polyvinylpyrrolidone, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, hydroxyethylstarch, cyclodextrin, 2-hydroxypropyl-P-cyclodextrin, sulfobutylether-b- cyclodextrin, polyethylene glycol, pectin, poly(lactide-co-glycolide), polylactide, polyethylene imine, or poly-L-lysine.
  • a polymer such as polyvinylpyrrolidone, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, hydroxyethylstarch, cyclodextrin, 2-hydroxypropyl-P-cyclodextrin, sulfobutylether-b- cyclodextrin, polyethylene glycol, pectin, poly(lactide-co-glycolide), poly
  • an ophthalmic formulation may include one or more of a pH adjusting excipient, a buffering excipient, a tonicity excipient, a viscosity excipient, or a wetting excipient.
  • an ophthalmic formulation may include an acidifying excipient, a preservative, an antioxidant, a solubilizing excipient, a humectant, or a suspending excipient.
  • An ophthalmic formulation may include additives, diluents, delivery vehicles, or carrier materials such as a polymer, a polyethylene glycol, a dextran, a diethylaminoethyl dextran, a cyclodextrin, or a carboxymethyl cellulose.
  • excipients include sodium chloride, sodium dihydrogen phosphate monohydrate, and disodium hydrogen phosphate anhydrous.
  • formulation additives include vegetable oils, olive oil, sesame oil, coconut oil, mineral oil, and paraffin.
  • dispersing or wetting agents examples include lecithin, polyoxyethylene stearate, heptadecaethyleneoxycetanol, polyoxyethylene sorbitol monooleate, and polyethylene sorbitan monooleate.
  • antioxidants include ascorbic acid, cysteine hydrochloride, sodium bisulfite, sodium metabisulfite, sodium sulfite, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, lecithin, propyl gallate, alpha-tocopherol, citric acid, ethylenediamine tetraacetic acid, sorbitol, tartaric acid, and phosphoric acid.
  • formulation additives include a thickening agent, for example beeswax, paraffin, or cetyl alcohol.
  • formulation excipients include a suspending excipient, sodium carboxymethylcellulose, methylcellulose, hydropropyl-methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth, or gum acacia.
  • An ophthalmic formulation may include a carrier or co-solvent such as Polysorbate 20, 60 or 80, Pluronic F-68, F-84 or P-103, Tyloxapol, Cremophor, sodium dodecyl sulfate, glycerol, PEG 400, propylene glycol, cyclodextrin, and combinations thereof.
  • a carrier or co-solvent can be used in concentrations from about 0.01% to about 2% by weight.
  • An ophthalmic formulation may include a gel excipient such as gellan, xanthan gum, and combinations thereof.
  • An ophthalmic formulation may include a viscosity enhancer such as polyvinyl alcohol, methyl cellulose, hydroxy propyl carboxymethyl cellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, polyvinylpyrrolidone, and combinations thereof.
  • a viscosity enhancer can be used in concentrations from about 0.01% to about 2% by weight.
  • An ophthalmic formulation may include a preservative such as benzalkonium chloride, chlorobutanol, benzododecinium bromide, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, onamer, polyquaternium-1, hydroxybenzoate, sodium benzoate, phenol, cresol, p-chloro-m-cresol, benzyl alcohol, thimerosal, sorbic acid, benzethonium chloride, and combinations thereof.
  • a preservative can be used in concentrations from about 0.001% to about 1.0% by weight.
  • a unit dose composition can be sterile, but may not contain a preservative.
  • An ophthalmic formulation may include a pH adjusting excipient such as citric acid buffer, acetic acid buffer, succinic acid buffer, malic acid buffer, and gluconic acid buffer.
  • An ophthalmic formulation may include an additional acid such as hydrochloric acid, or and additional base, such as sodium hydroxide for pH adjustment.
  • additional acid such as hydrochloric acid
  • additional base such as sodium hydroxide for pH adjustment.
  • pH control agents include arginine, sodium hydroxide, glycine, hydrochloric acid, and citric acid.
  • An ophthalmic formulation may include a buffer such as citric acid, ascorbic acid, gluconic acid, carbonic acid, tartaric acid, succinic acid, acetic acid, phthalic acid, tris, tromethamine hydrochloride, and phosphate buffer.
  • An ophthalmic formulation may include a surfactant.
  • Examples of a surfactant include nonionic surfactants, polysorbate-80, polysorbate-20, polysorbates, sorbitan esters, a lipid, a phospholipid, lecithin, a phosphatidylcholine, a phosphatidylethanolamine, a phosphatidylglycerol, a fatty acid, a fatty ester, a cholesterol.
  • surfactants include oleic acid, sorbitan trioleate, and long chain diglycerides.
  • surfactants include beractant, poractant alfa, and calfactant.
  • An ophthalmic formulation may include a tonicifier tonicity adjusting excipient.
  • a tonicity adjusting excipient, isotonizing excipient include sodium chloride, mannitol, and sorbitol.
  • Examples of a tonicity adjusting excipient include sugars, polyols, amino acids, and organic and inorganic salts.
  • Embodiments of this invention include kits containing any of reagents, pharmaceutical excipients, active agents, and instructions for use.
  • a kit may include a container or formulation that contains one or more active agents formulated in a pharmaceutical preparation for delivery.
  • An ophthalmic formulation kit can be a multidose form.
  • a kit may include a dispenser or dropping device for topical delivery and use.
  • a kit can include one or more unit doses of a composition for delivery.
  • a unit dose can be hermetically sealed to preserve sterility.
  • the sample was transferred to an ultracentrifuge tube (Beckman) and in a swinging bucket rotor (SW-41, Beckman) and centrifuged at 100,000 g in an L7-55 ultracentrifuge (Beckman) at 4°C for 1 hour. The supernatant was transferred to a new tube. The step was repeated. Samples were resuspended in 50 m ⁇ of sterile tris buffered saline (TBS, pH 8) and placed in a siliconized tube. Samples for imaging were immediately processed, and remaining sample was frozen at -80 °C.
  • Nanoparticle tracking analysis is described.
  • the NanoSight NS300 system (Malvern) was used to perform nanoparticle tracking analysis to characterize particles from 30 - 800 nm in solution.
  • TBS tris buffered saline
  • Particles were loaded, the camera was focused, and 5 videos were captured for 60 sec each. Videos were recorded and then analyzed using NanoSight software (Version 3.0) to determine the size distribution and particle concentration of EVs.
  • Graphs were created. The Brownian motion of each particle is tracked between frames, ultimately allowing calculation of the size through application of the Stokes-Einstein equation.
  • EDC-ETT solution preparation is described. Methods for EDC solution fixation were adapted from previous reportsl7, 18.
  • 0.1 M 1-Methylimidazole buffer solution 0.1 M 1-methylimidazole, 300 mM NaCl, with an adjusted pH to 8.0 with 12 N NaOH
  • the pH was adjusted to 8.0 with 12 N NaOH.
  • EDC l-ethyl-3-(3-dimethylaminopropyl) carbodiimide
  • EDC-glutaraldehyde fixation of liquid samples on electron microscopy is described. All isolated EVs were resuspended in 20 m ⁇ of TBS (pH 8.0) and kept at 4°C. We obtained Formvar/carbon-coated EM grids (Electron Microscopy Sciences) and coated the surface with Poly-L-lysine solution (%, Sigma Aldrich). We applied approximately 15 m ⁇ of poly-L-lysine to the formvar/carbon-coated surface of the EM grid and incubated the sample in a humidified chamber for 15 min at room temperature. We removed the poly-L- lysine solution with a pipette and set aside the grid in a humidified chamber until it is ready for use.
  • the samples were removed from the incubator and the EDC-solution was removed using a pipette.
  • the samples were fixed with a secondary fixation using a glutaraldehyde-based crosslinking solution containing; 2.5% glutaraldehyde, 4% paraformaldehyde, 0.02% picric acid in 0.1M sodium cacodylate buffer and incubated for 15 min at room temperature.
  • the glutaraldehyde solution was removed by pipetting the bubble from the EM grid.
  • the grid was washed by placing 15 m ⁇ of double distilled water onto the grid and incubating for 5 minutes at room temperature. The water was removed and washed a second time.
  • the samples were negatively stained or stained for DNA, RNA and protein as described below.
  • the samples were contrasted successively in 2% uranyl acetate, pH 7, and 2% methylcellulose/0.4% uranyl acetate, pH 4.
  • the EM grids were then mounted for imaging on the electron microscope as described below.
  • Samples were post-fixed with 1% 0s04-1.5% K-ferri cyanide (aqueous) for 60 min at room temperature20. Samples were washed with buffer 3 times for 5 min each at room temperature. Samples were set en bloc and stained with 1.5% uranyl acetate for 60 min at room temperature. Samples were dehydrated through graded ethanol series and transitioned through acetonitrile. Samples were infiltrated and embedded in Embed 812 resin (Electron Microscopy Sciences). Tissue sections were cut at 60-65 nm using a Diatome diamond knife (Diatome) on Leica Ultracut T ultramicrotome (Leica Microsystems).
  • Sections were contrasted with lead citrate21 and viewed on a JEM 1400 electron microscope (JEOL, USA, Inc) operated at lOOkV. Digital images were captured on a Veleta 2K x 2K CCD camera (Olympus-SIS). Electron microscopy images were recorded and analyzed for size and frequency of EVs using ImageJ software. For TEM staining of nucleic acids, we incubated Acridine Orange stain solution (Exo-Red Exosome RNA Fluorescent Label, System Biosciences) with 5 m ⁇ of ultracentrifuge purified EVs for 30 min at 25°C.
  • EtBr ethidium bromide
  • EDC-HC1 powder should be stored at -20 °C under argon. To avoid condensation of humidity, only open bottles after they reached room temperature, i.e. take the bottle out of freezer 1 h before weighing out sample.
  • EDC/5-ETT solution should be made at most 1 h prior to use.
  • Lumigan was obtained directly from the dispensing bottle and was NOT diluted. 10 ul of POAG sample was mixed with lOul of TBS or lOul POAG sample was mixed with 10 ul of undiluted Lumigan. The tubes were then incubated in a thermocycler PCR machine and were allowed to sit for 72 hours at 37°C. The samples were then diluted (1:10). Next, we fixed with EDC on an electron microscopy grid using the following protocol.
  • EDC-HC1 powder should be stored at -20 °C under argon. To avoid condensation of humidity, only open bottles after they reached room temperature, i.e. take the bottle out of freezer 1 h before weighing out sample.
  • EDC/5-ETT solution should be made at most 1 h prior to use.
  • a method of identifying glaucoma or pre-glaucoma in a subject comprising: providing an aqueous humor sample from a subject potentially having glaucoma; analyzing the sample for glaucoma-associated-extracellular vesicle-complexes which are either: aggregates of extracellular vesicles, or individual extracellular vesicles having a diameter greater than 300 nanometers, or from 300 to 3,000 nm, or from 300 to 5,000 nm, or from 300 to 10,000 nm; and identifying, based on said analyzing, the subjects having glaucoma or pre-glaucoma.
  • the glaucoma-associated-extracellular vesicle complexes are complexes of extracellular vesicles selected from the group consisting of exomeres, exosomes, multivesicular bodies, intraluminal vesicles (ILVs), multivesicular endosomes (MVEs), oncosomes, micro-vesicles, apoptotic bodies, and vesicles originating from endosome or plasma membranes.
  • the glaucoma-associated extracellular vesicle complexes are complexes of individual extracellular vesicles, where the complexes may have a diameter of from 360 to 21,000 nanometers.
  • the glaucoma-associated extracellular vesicle complexes can be aggregates of 10, 20, 30, 40 or more extracellular vesicles.
  • the glaucoma-associated extracellular vesicle complexes can be aggregates of 50, 100 or 200 or more extracellular vesicles.
  • the method above further comprising: fixing the glaucoma-associated extracellular vesicles in the sample prior to said analyzing.
  • the fixing the glaucoma- associated extracellular vesicles comprises: contacting the sample with a non-reversible cross-linking agent; and contacting the sample with an aldehyde-containing fixative before, after, or at the same time as said contacting the sample with a non-reversible cross-linking agent to fix the glaucoma- associated-extracellular vesicle-complexes.
  • non-reversible cross-linking agent is selected from the group consisting of a water-soluble carbodiimide, cyanogen halide, and mixtures thereof.
  • non-reversible cross-linking agent is 1 -ethyl-3 - (3 - dimethylaminopropylj-carbodiimide.
  • non-reversible cross-linking agent is a cyanogen halide selected from the group consisting of cyanogen bromide, cyanogen fluoride, cyanogen chloride, and cyanogen iodide.
  • identifying comprises: providing a standard image of a clinical aqueous humor sample containing the glaucoma- associated- extracellular vesicle-complexes fixed with the non-reversible cross-linking agent and the aldehyde containing fixative, from a subject having glaucoma; comparing the image of the clinical sample of the subject to the standard image with regard to size, density, morphology, or spacial distribution of the fixed glaucoma-associated- extracellular vesicle- complexes; and determining if the subject has glaucoma or pre-glaucoma based on said comparing.
  • identifying involves monitoring progression or regression of glaucoma and comprises: providing a prior image of a clinical aqueous humor sample of the subject, containing glaucoma-associated-extracellular vesicle-complexes fixed with a non-reversible cross-linking agent and the aldehyde containing fixative; comparing the image of the clinical aqueous humor sample of said subject containing the glaucoma-associated-extracellular vesicle-complexes fixed with the non-reversible cross- linking agent and the aldehyde containing fixative to the prior image with regard to size, density, morphology, or spacial distribution of the fixed glaucoma-associated-extracellular vesicle- complexes; and determining if the glaucoma is progressing or regressing based on said comparing.
  • a method of screening compounds for their ability to treat glaucoma comprising: providing candidate agents potentially useful in treating glaucoma; providing a sample containing glaucoma-associated extracellular vesicle-complexes, wherein the extracellular vesicles are either: aggregates of extracellular vesicles, or individual extracellular vesicles, having a diameter greater than 300 nanometers; contacting the candidate agents with the glaucoma-associated extracellular vesicle- complexes; and identifying candidate compounds which are effective in reducing the size of glaucoma- associated-extracellular vesicle-complexes based on said contacting.
  • the method above further comprising: contacting a second sample containing the glaucoma-associated extracellular vesicle- complexes with a placebo and comparing size reduction of the glaucoma-associated extracellular vesicle-complexes of the samples contacted with the placebo versus that achieved with the candidate agent, to identify candidate compounds which are effective in reducing the size of glaucoma-associated- extracellular vesicle-complexes.
  • a reagent for detection of glaucoma comprising: an isolate sample comprising glaucoma-associated-extracellular vesicle-complexes which are either: aggregates of extracellular vesicles, or individual extracellular vesicles having a diameter over 300 nanometers.
  • Embodiments of this invention further contemplate compositions for ophthalmic use.
  • an aqueous pharmaceutical composition for ophthalmic use may contain an active agent selected from cetylpyridinium chloride, polymyxin B sulfate, neomycin sulfate, and heparin sodium.
  • the active agent may comprise 0.01-2% w/v of the composition. In some embodiments, the active agent can be 0.01-0.2% w/v of the composition.
  • the pH of a composition can be adjusted using, for example, sodium hydroxide and hydrochloric acid.
  • the composition may have a pH of from 6.8 to 7.9, or about 7.3.
  • the composition can reduce intraocular pressure when administered to the eye.
  • the composition can reduces ocular extracellular vesicle complexes when administered to the eye.
  • the composition may be effective for treating a glaucoma disease when administered to the eye.
  • a composition of this invention may further contain one or more of a solubilizer, a surfactant, a tonicifier, and a preservative.
  • Examples of a solubilizer include a phosphate, a citric acid monohydrate, a trisodium citrate, and combinations thereof.
  • Examples of a phosphate include monosodium dihydrogen phosphate, disodium monohydrogen phosphate, dipotassium monohydrogen phosphate, monopotassium dihydrogen phosphate, and combinations thereof.
  • Examples of a surfactant include a phospholipid, a polyglycerol ester, a propylene glycol ester, a polyethylene glycol ester, a copolymer ester, a polyoxyethylene sorbitan ester, a cyclodextrin, a polyvinyl alcohol, povidone, a hydroxypropyl methyl cellulose, a poloxamer, a carboxymethyl cellulose, a hydroxyethyl cellulose, a polyacrylate, and combinations thereof.
  • Examples of a tonicifier include sodium chloride, trehalose, mannitol, sorbitol, dextrose, potassium chloride, and combinations thereof.
  • Examples of a preservative include benzalkonium chloride, polyquatemium-1, benzododecinium bromide, sorbic acid, methyl paraben, propyl paraben, chlorobutanol, benzylic alcohol, phenylethyl alcohol, an oxychloro complex, thimerosal, sodium perborate, disodium edetate, and combinations thereof.
  • a solubilizer can also have effect as a buffer, or as a stabilizer, or as a thickener.
  • a surfactant in the context of an ophthalmic composition, can also have effect as a solubilizer.
  • a composition of this invention may consist only of an active agent and a carrier.
  • a composition may be an aqueous solution of an active agent.
  • Examples of a carrier include water, sterile water, water for injection, water for irrigation, a phosphate buffer, and combinations thereof.
  • a composition of this invention can be used in medical therapy.
  • a composition of this invention can be used in the treatment of the human or animal body. [00387] A composition of this invention can be used in reducing intraocular pressure in the human or animal body.
  • a composition of this invention can be used in reducing ocular extracellular vesicle complexes in the human or animal body.
  • a composition of this invention can be used in preparing or manufacturing a medicament for preventing, ameliorating, or treating a disease or condition associated with glaucoma in a subject in need.
  • Embodiments of this invention also contemplate methods for treating a glaucoma disease, reducing intraocular pressure, or reducing ocular extracellular vesicle complexes in a subject in need thereof, by administering a composition of this disclosure to the eye of the subject.
  • the administration may be by injection.
  • the ocular extracellular vesicle complexes can be aggregates of extracellular vesicles having a diameter greater than about 300 nanometers.
  • Example 1 Eising improved fixation to enhance imaging of extracellular vesicles in biological fluids.
  • EV ultrastructure in fluids can be detected with transmission electron microscopy (TEM) combined with negative staining.
  • TEM transmission electron microscopy
  • this technique led to inconsistent or often negative results.
  • TEM transmission electron microscopy
  • Example 2 Imaging EVs suspended in liquids with conventional methods has a low yield due to massive loss of vesicles to the discarded solution.
  • EVs isolated from the bovine vitreous humor gel-like matrix, located between the lens and the retina of the eye
  • aqueous as a model system.
  • NTA nanoparticle-tracking analysis
  • Table 2 shows extracellular vesicles poorly adhere to electron microscopy grids.
  • We isolated EVs from mouse mammary tumor cell line, 4T1 cell media using ultracentrifugation methods and measurements were conducted using nanoparticle tracking analysis (NTA), using identical settings for all variables in NTA 2.3 build 17 software. The mean size, mode size and mean concentration of EVs applied over the TEM grid surface, and EVs present in the discarded fraction are shown (n 3).
  • Example 3 Using formalin-EDC fixation retains EVs and allows for robust imaging of EVs suspended in liquids.
  • EVs were poorly bound to the TEM grid and attempted to permanently adhere EVs suspended in a liquid on the grid by adding a heat stable fixative, EDC, a carbodiimide that creates a non-reversible crosslink between positively charged amino group side chains and carboxyl groups of proteins.
  • EDC heat stable fixative
  • we combined 4 million isolated bovine vitreous EVs and EDC fixation solution applied this to the surface of a poly-l-lysine coated formvar TEM grid, and activated the EDC solution by applying heat (50°C) for 3 hr (FIG. 6, 3 rd row, middle).
  • Example 4 Comparing extracellular vesicles in the aqueous humor from healthy controls and patients with POAG.
  • the aqueous humor is a transparent, water-like biological fluid that is like plasma, but contains 98% water, along with amino acids, electrolytes, ascorbic acid, glutathione, and immunoglobulins.
  • Aqueous humor has been shown to contain EVs. In these studies, the EVs were isolated using ultracentrifugation protocols and they did not observe any glaucoma-associated-EV-aggregates.
  • Example 5 Study design; obtaining aqueous humor from healthy and glaucoma patients.
  • Control samples were those with a diagnosis of cataracts, but no other ocular comorbidity, nor another systemic comorbidity. All patients in the control cohort were undergoing elective outpatient, ambulatory cataract surgery and were generally healthy.
  • Study samples will be those who in addition to the cataract also have POAG and none of the following conditions: diabetic retinopathy, or age-related macular degeneration.
  • the pool of glaucoma patients will be chosen from patients who will have cataract extraction and lens implantation surgery.
  • Inclusion criteria include the following; outpatient cataract surgery patients, age 18 years or older, who have either no ocular co-morbidities besides cataract, or who also have a documented clinical diagnosis of POAG.
  • Exclusion criteria include ocular comorbidities, other than cataracts.
  • An Institutional Review Board approved the protocol to collect samples and complete these studies.
  • Example 6 Obtaining aqueous humor samples from patients with and without glaucoma: During cataract surgery, incisions are made to enter the anterior chamber and access the cataractous lens. The aqueous egresses from the eye during the surgery and is replaced by irrigation solution infused through the instruments. We collected a small sample the aqueous, which would normally be lost as medical waste, at the beginning of the cataract surgery. The sample was assigned a numerical study ID code to de-identify it and transferred immediately from the OR to the laboratory for TEM imaging analysis. Patients did not undergo surgery or additional interventions for the purposes of this study, but were instead those individuals who were scheduled to undergo cataract surgery for therapeutic purposes.
  • the cataract surgical schedule was reviewed to identify those patients that meet the inclusion and exclusion criteria delineated above, for control or POAG cohorts. Informed consent was obtained from each patient prior to inclusion in the study. Patients then underwent standard cataract surgery with the following exception. At the beginning of the cataract surgery a 30-gauge needle on a TB syringe was be inserted through the clear cornea to aspirate 0.05 - O.lcc of aqueous humor. The wound self-sealed. Subsequently, the corneal paracentesis incision was made as per standard cataract surgery as per the surgeon. We collected samples and transported the sample on ice to the laboratory. The study sample was identified a random study ID code to ensure it is de-identified. For all experiments, we did not isolate EVs using ultra-centrifugation methods, rather imaged the biological fluid in situ.
  • Example 7 Imaging the ultrastructure of healthy control aqueous humor in situ shows a diffuse distribution of EVs: To understand the morphology of EVs in the normal physiological state, we imaged healthy patients aqueous humor in situ. No prior glaucoma studies have used the EDC fixation to visualize EVs in aqueous humor in situ. To understand the ultrastructural content of aqueous humor, we diluted the sample 1:10 with buffered saline (note: we did not isolate EVs), fixed the sample with EDC, then glutaraldehyde, negatively stained the specimen, and imaged with TEM. The data showed that healthy human aqueous humor contains an abundant number of EVs from multiple control human subjects (FIG. 7-8).
  • Example 8 Imaging the ultrastructure of POAG aqueous humor in situ shows a sizeable glaucoma-associated-EV-complex that is larger than EVs observed in healthy controls.
  • POAG patients have a previously unidentified material present in the aqueous humor that is responsible for blocking the trabecular meshwork.
  • the glaucoma-associated-EV-complex was present is two different patient samples and measure larger than the opening of the JCT (1 to 4 pm, or up to 2 to 20 pm), which is large enough to block the juxtacanalicular tissue.
  • Example 9 Treating large EV complexes with Bimatoprost breaks up the EV-complex, when compared to controls.
  • Bimatoprost lumigan
  • bimatoprost is known to enhance the outflow of aqueous humor by remodeling the extracellular matrix, via regulation of matrix metallo-proteinases and remodeling of extracellular matrix.
  • bimatoprost we hypothesized that the glaucoma-associated-EV-complex would be reduced in size by the addition of bimatoprost.
  • a POAG patient we incubated a POAG patient’s aqueous humor with bimatoprost or buffered saline (placebo or control condition) at 37°C for 72 hours, and imaged the EV ultrastructure using EDC fixation, negative staining and transmission electron microscopy (FIG. 11-13).
  • Example 10 Glaucoma patients’ aqueous humor contains larger electron dense structures in the aqueous humor that are not present in healthy controls.
  • the electron microscopy images showed large electron dense structure in the POAG specimen aqueous humor that were not present in the healthy controls.
  • the POAG glaucoma-associated-EV- aggregates were larger in size and present in higher numbers when compared to healthy controls. Therefore, we obtained the electron microscopy photographs from healthy controls or POAG samples and measured the number and size of glaucoma-associated-EV-aggregates.
  • the data showed that POAG aqueous humor has substantially larger glaucoma-associated-EV-aggregates that measure from 361 nm to 20,214 nm (FIG. 14).
  • JCT is composed of the loosely arranged extracellular matrix (ECM) into which cells are embedded.
  • ECM of JCT has been implicated as a barrier that may isolate the ocular fluid outflow. Therefore, we hypothesize that this material (glaucoma-associated-EV-aggregate) in the aqueous humor of patients with glaucoma, that is physically larger than the diameter of the JCT outlet, may block the aqueous outflow and be related to glaucoma pathology.
  • Example 11 Glaucoma patients’ aqueous humor contains EVs that contact each other that form larger structures called, “glaucoma-associated-EV-aggregates”, that are not present in healthy control aqueous humor.
  • aqueous humor contains EVs that contact each other that form larger structures called, “glaucoma-associated-EV-aggregates”, that are not present in healthy control aqueous humor.
  • To determine the composition of the glaucoma-associated-EV- aggregates we analyzed the TEM images and found that these ultra-structures are composed of many EVs contacting each other to form larger aggregates.
  • To quantify the number of EVs found within the glaucoma-associated-EV-aggregates we counted the total number of EVs present in the image, quantified the number of EVs in each aggregate, or calculated the number of EVs that were not contacting another EV (Free EVs).
  • Example 12 Extracellular vesicles in the aqueous humor of healthy control subjects exist as “Free-EVs” and with a majority of EVs between 100 to 200 nm in size.
  • To determine the size distribution of EVs in healthy control aqueous humor we characterized the EV population in human aqueous humor obtained from a single healthy control patient (FIG. 17).
  • EDC negatively stained the sample and imaged with TEM.
  • Example 13 Extracellular vesicles in the aqueous humor of subjects with the diagnosis of POAG are located within the glaucoma-associated-EV-aggregates are similar in size to “Free- EVs” found in healthy controls.
  • Example 14 Free-EVs in the aqueous humor of human subjects with the diagnosis of POAG differ in size and frequency, when compared to aqueous humor of healthy control subjects.
  • Example 15 Extracellular vesicles from POAG aqueous humor that are present with the glaucoma-associated-EV-aggregates are similar in size and frequency too free EVs obtained from healthy human subjects.
  • the EVs present in the glaucoma-associated-EV- aggregate are similar in size and count frequency to the healthy control EVs.
  • the EVs from POAG aqueous humor located within the glaucoma-associated-EV-aggregate are similar in size and frequency to the non-aggregated EVs in healthy human subjects (FIG. 24).
  • An active agent for use in treating glaucoma can be cetylpyridinium Formula XI, which may be used in a prodrug form or in a pharmaceutically-acceptable salt form.
  • a solution of the agent compound was prepared by weighing out the compound in a microcentrifuge tube and dissolving the solid material in lx PBS buffer at pH 7.2. For a compound that was less soluble in water, a stock solution was prepared in ethanol or DMSO, and then diluted ten-fold to achieve the final concentration with a 10% ethanol or DMSO vehicle. Heat (37°C) and vortex mixing were applied to the solution of the compound to facilitate dissolution.
  • BVH bovine vitreous humor
  • PBS buffer 50 uL BVH was aliquoted into 0.5 mL PCR tubes. 50 uL of the solution of the compound was added to the BVH, bringing the BVH total concentration to 12.5%. The sample was briefly vortexed and then incubated at 37°C overnight.
  • test BVH solution was introduced into the reservoir of the device.
  • a fluidic probe was attached to the inlet of the microfluidic chip and a flow rate of 2ul/min was established with PBS as the source fluid. Once fluid began exiting from the outlet of the chip and a steady flow of 2 ul/min was achieved, the flow rate and the pressure change within the microfluidic chip were recorded. Baseline flow rate and pressure readings were recorded for 5 minutes, after which 7 ul of the test BVH solution was injected into the chip through a sample injector. Recording of the flow rate and pressure change was continued for 50 additional minutes after the sample injection. Recording was stopped after 55 minutes. The relative change in chip pressure for the entire course of the experiment was plotted on a graph.
  • FIG. 25 shows that agent cetylpridinium chloride reduced intraocular pressure (IOP) in a glaucoma model as compared to control.
  • the agent was tested by controlling flow and measuring relative IOP using in a microfluidic device.
  • the agent was compared against placebo (buffered saline) by preparing each in bovine vitreous humor (BVH) and pre-incubating at 37°C for 24 hours.
  • the timepoint of injection into the device is denoted by an arrow and the letter “a.”
  • the IOP for placebo (dashed line) increased greatly after injection of the placebo sample.
  • the IOP rose steadily to a maximum pressure of about 64 mmHg.
  • An active agent for use in treating glaucoma can be polymyxin B Formula XXI, which may be used in a prodrug form or in a pharmaceutically-acceptable salt form.
  • a solution of the agent compound was prepared by weighing out the compound in a microcentrifuge tube and dissolving the solid material in lx PBS buffer at pH 7.2. For a compound that was less soluble in water, a stock solution was prepared in ethanol or DMSO, and then diluted ten-fold to achieve the final concentration with a 10% ethanol or DMSO vehicle. Heat (37°C) and vortex mixing were applied to the solution of the compound to facilitate dissolution.
  • BVH bovine vitreous humor
  • PBS buffer 50 uL BVH was aliquoted into 0.5 mL PCR tubes. 50 uL of the solution of the compound was added to the BVH, bringing the BVH total concentration to 12.5%. The sample was briefly vortexed and then incubated at 37°C overnight.
  • test BVH solution was introduced into the reservoir of the device.
  • a fluidic probe was attached to the inlet of the microfluidic chip and a flow rate of 2ul/min was established with PBS as the source fluid. Once fluid began exiting from the outlet of the chip and a steady flow of 2 ul/min was achieved, the flow rate and the pressure change within the microfluidic chip were recorded. Baseline flow rate and pressure readings were recorded for 5 minutes, after which 7 ul of the test BVH solution was injected into the chip through a sample injector. Recording of the flow rate and pressure change was continued for 50 additional minutes after the sample injection. Recording was stopped after 55 minutes. The relative change in chip pressure for the entire course of the experiment was plotted on a graph.
  • FIG. 26 shows that agent polymyxin B reduced intraocular pressure (IOP) in a glaucoma model as compared to control.
  • the agent was tested by controlling flow and measuring relative IOP using in a microfluidic device.
  • the agent was compared against placebo (buffered saline) by preparing each in bovine vitreous humor (BVH) and pre-incubating at 37°C for 24 hours.
  • the timepoint of injection into the device is denoted by an arrow and the letter “a.”
  • the IOP for placebo (dashed line) increased greatly after injection of the placebo sample.
  • the IOP rose steadily to a maximum pressure of about 250 mmHg.
  • the IOP after injection of the agent polymyxin B solid line
  • An active agent for use in treating glaucoma can be neomycin Formula XI, which may be used in a prodrug form or in a pharmaceutically-acceptable salt form.
  • Formula XI [00430] A solution of the agent compound was prepared by weighing out the compound in a microcentrifuge tube and dissolving the solid material in lx PBS buffer at pH 7.2. For a compound that was less soluble in water, a stock solution was prepared in ethanol or DMSO, and then diluted ten-fold to achieve the final concentration with a 10% ethanol or DMSO vehicle. Heat (37°C) and vortex mixing were applied to the solution of the compound to facilitate dissolution.
  • the concentration of neomycin sulfate was 35 mg/ml.
  • BVH bovine vitreous humor
  • PBS buffer 50 uL BVH was aliquoted into 0.5 mL PCR tubes. 50 uL of the solution of the compound was added to the BVH, bringing the BVH total concentration to 12.5%. The sample was briefly vortexed and then incubated at 37°C overnight.
  • test BVH solution was introduced into the reservoir of the device.
  • a fluidic probe was attached to the inlet of the microfluidic chip and a flow rate of 2ul/min was established with PBS as the source fluid. Once fluid began exiting from the outlet of the chip and a steady flow of 2 ul/min was achieved, the flow rate and the pressure change within the microfluidic chip were recorded. Baseline flow rate and pressure readings were recorded for 5 minutes, after which 7 ul of the test BVH solution was injected into the chip through a sample injector. Recording of the flow rate and pressure change was continued for 50 additional minutes after the sample injection. Recording was stopped after 55 minutes. The relative change in chip pressure for the entire course of the experiment was plotted on a graph.
  • FIG. 27 shows that agent neomycin reduced intraocular pressure (IOP) in a glaucoma model as compared to control.
  • the agent was tested by controlling flow and measuring relative IOP using in a microfluidic device.
  • the agent was compared against placebo (buffered saline) by preparing each in bovine vitreous humor (BVH) and pre-incubating at 37°C for 24 hours.
  • the timepoint of injection into the device is denoted by an arrow and the letter “a.”
  • the IOP for placebo (dashed line) increased greatly after injection of the placebo sample.
  • the IOP rose steadily to a maximum pressure of about 64 mmHg.
  • the IOP after injection of the agent neomycin solid line was 72% lower than for placebo, and the difference was sustained. This result showed that the agent neomycin was surprisingly effective to reduce IOP in the glaucoma model.
  • An active agent for use in treating glaucoma can be heparin, which may be used in a prodrug form or in a pharmaceutically-acceptable salt form.
  • a solution of the agent compound was prepared by weighing out the compound in a microcentrifuge tube and dissolving the solid material in lx PBS buffer at pH 7.2. For a compound that was less soluble in water, a stock solution was prepared in ethanol or DMSO, and then diluted ten-fold to achieve the final concentration with a 10% ethanol or DMSO vehicle. Heat (37°C) and vortex mixing were applied to the solution of the compound to facilitate dissolution.
  • the concentration of heparin sodium was 10 mg/ml.
  • BVH bovine vitreous humor
  • PBS buffer a solution of 25% homogenized bovine vitreous humor
  • 50 uL BVH was aliquoted into 0.5 mL PCR tubes.
  • 50 uL of the solution of the compound was added to the BVH, bringing the BVH total concentration to 12.5%. The sample was briefly vortexed and then incubated at 37°C overnight.
  • test BVH solution was introduced into the reservoir of the device.
  • a fluidic probe was attached to the inlet of the microfluidic chip and a flow rate of 2ul/min was established with PBS as the source fluid. Once fluid began exiting from the outlet of the chip and a steady flow of 2 ul/min was achieved, the flow rate and the pressure change within the microfluidic chip were recorded. Baseline flow rate and pressure readings were recorded for 5 minutes, after which 7 ul of the test BVH solution was injected into the chip through a sample injector.
  • FIG. 28 shows that agent heparin sodium reduced intraocular pressure (IOP) in a glaucoma model as compared to control.
  • the agent was tested by controlling flow and measuring relative IOP using in a microfluidic device.
  • the agent was compared against placebo (buffered saline) by preparing each in bovine vitreous humor (BVH) and pre-incubating at 37°C for 24 hours.
  • the timepoint of injection into the device is denoted by an arrow and the letter “a.”
  • the IOP for placebo (dashed line) increased greatly after injection of the placebo sample.
  • the IOP rose steadily to a maximum pressure of about 67 mmHg.
  • the IOP after injection of the agent heparin sodium (solid line) was 32% lower than for placebo, and the difference was sustained. This result showed that the agent heparin sodium was surprisingly effective to reduce IOP in the glaucoma model.
  • Example 20 Sodium dodecyl sulfate was a negative control for intraocular pressure (IOP) in a glaucoma model.
  • a solution was prepared by weighing out the compound in a microcentrifuge tube and dissolving the solid material in lx PBS buffer at pH 7.2. For a compound that was less soluble in water, a stock solution was prepared in ethanol or DMSO, and then diluted ten-fold to achieve the final concentration with a 10% ethanol or DMSO vehicle. Heat (37°C) and vortex mixing were applied to the solution of the compound to facilitate dissolution.
  • the concentration of sodium dodecyl sulfate was 24 mg/ml.
  • BVH bovine vitreous humor
  • PBS buffer a solution of 25% homogenized bovine vitreous humor
  • 50 uL BVH was aliquoted into 0.5 mL PCR tubes.
  • 50 uL of the solution of the compound was added to the BVH, bringing the BVH total concentration to 12.5%. The sample was briefly vortexed and then incubated at 37°C overnight.
  • test BVH solution was introduced into the reservoir of the device.
  • a fluidic probe was attached to the inlet of the microfluidic chip and a flow rate of 2ul/min was established with PBS as the source fluid. Once fluid began exiting from the outlet of the chip and a steady flow of 2 ul/min was achieved, the flow rate and the pressure change within the microfluidic chip were recorded. Baseline flow rate and pressure readings were recorded for 5 minutes, after which 7 ul of the test BVH solution was injected into the chip through a sample injector. Recording of the flow rate and pressure change was continued for 50 additional minutes after the sample injection. Recording was stopped after 55 minutes. The relative change in chip pressure for the entire course of the experiment was plotted on a graph.
  • FIG. 29 shows that compound sodium dodecyl sulfate was a negative control for intraocular pressure (IOP) in a glaucoma model.
  • the compound was tested by controlling flow and measuring relative IOP using in a microfluidic device.
  • the compound was compared against placebo (buffered saline) by preparing each in bovine vitreous humor (BVH) and pre-incubating at 37°C for 24 hours.
  • the timepoint of injection into the device is denoted by an arrow and the letter “a.”
  • the IOP for placebo (dashed line) increased greatly after injection of the placebo sample.
  • the IOP rose steadily to a maximum pressure of about 60 mmHg.
  • intraocular administration can be carried out via intracameral administration, intravitreal administration, or subretinal administration.
  • Periocular administration can be carried out via sub -conjunctival injection, sub-Tenon’s injection, direct periocular injection, or depot periocular injection.
  • Systemic administration may be carried out via intravenous administration, oral administration, intraarterial administration, inhalation, intranasal administration, intra-peritoneal administration, intra-abdominal administration, subcutaneous administration, intra-articular administration, intrathecal administration, transdural administration, transdermal administration, submucosal administration, sublingual administration, enteral administration, parenteral administration, percutaneous administration, periarticular administration, or intraventricular administration.
  • An ophthalmic formulation can be locally delivered by an eye drop, by direct injection or by use of an infusion pump.
  • Intraocular administration can be carried out via intracameral administration, intravitreal administration, or subretinal administration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Clinical Laboratory Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

This invention relates to methods and compositions for detecting, identifying and treating glaucoma diseases. In addition, this invention discloses compositions and methods for affecting intraocular pressure and increasing ocular outflows in glaucoma. Compositions are provided for treating a glaucoma disease, reducing intraocular pressure, and/or reducing ocular extracellular vesicle complexes in a subject.

Description

PROCESSES AND AGENTS FOR GLAUCOMA
TECHNICAL FIELD
[0001] This invention relates to methods and compositions for detecting, identifying and treating glaucoma diseases. More particularly, this invention discloses compositions and methods for affecting intraocular pressure and increasing ocular outflows in glaucoma.
BACKGROUND
[0002] Glaucoma diseases are a world-wide leading cause of vision loss and affect an estimated 70 million people. Glaucoma is a permanently blinding disease that is asymptomatic until patients experience advanced vision loss. Diagnosis of glaucoma is often delayed.
[0003] Forms of glaucoma are described as open angle glaucoma or closed angle glaucoma. Primary open-angle glaucoma (POAG) is most prevalent, about 75% of cases. Narrow angle glaucoma and other less common forms account for the other 25%. In POAG, the anterior chamber angle appears healthy and open and there is elevated intraocular pressure (IOP) with no underlying disease.
[0004] Risk factors for POAG include elevated IOP, advancing age, family history, African ancestry, myopia, and associations with diabetes or hypertension. The pathophysiology responsible for glaucoma is related to increased resistance to aqueous outflow, but the direct mediator of this process remains unknown. The etiology of glaucoma is poorly understood and the factors contributing to its progression have not been identified.
[0005] Signs and symptoms of glaucoma include damage to the optic nerve, with degeneration of retinal ganglion cells, changes to the optic nerve head, and corresponding visual field loss. Elevation of IOP is related to retinal ganglion cell (RGC) death and ultimately visual field (VF) loss. IOP-related optic nerve damage is important in the pathogenesis of POAG. Patients with POAG and ocular hypertension (OHT) have elevated IOP. Raised IOP is a significant risk factor for the progression from OHT to POAG. Raised IOP is the only common clinical finding in a wide variety of secondary glaucomas. Reduction of IOP was shown to lower the risk of progression in NTG. In animal models, raised IOP precedes glaucomatous nerve damage. In general, the etiology of elevated IOP may be due to reduced aqueous outflow. [0006] Pharmaceutical treatment of glaucoma is directed to lowering IOP which may slow disease progression in some patients. Drawbacks of current treatments include lack of efficacy and side effects of medications.
[0007] What is needed are effective methods and compositions for glaucoma, as well as modalities for lowering IOP and improving ocular outflows.
[0008] There is an urgent need for methods, kits, and compositions for detecting, identifying and treating glaucoma.
BRIEF SUMMARY
[0009] This invention provides methods, compositions, devices, kits and reagents for detecting, identifying and treating glaucoma diseases.
[0010] In some aspects, this invention provides methods and compositions for reducing intraocular pressure and increasing ocular outflows in glaucoma subjects. Aspects of this invention can reduce formation and presence of aggregational features and structures in ocular humor.
[0011] In further aspects, this disclosure provides therapeutic compositions for glaucoma.
[0012] Embodiments of this invention provide devices for measuring and characterizing glaucoma aggregational features, as well as intraocular pressure and ocular outflows.
[0013] Additional aspects of this disclosure include diagnostic and screening modalities for glaucoma. Further embodiments include kits and reagents for carrying out the foregoing.
[0014] Embodiments of this invention include the following:
[0015] An aqueous pharmaceutical composition for ophthalmic use comprising an active agent selected from cetylpyridinium chloride, polymyxin B sulfate, a mycin, and heparin sodium. The mycin can be selected from neomycin, salinomycin, azithromycin, rapamycin, gentamycin, erythromycin, adriamycin, bleomycin, dactinomycin, mitomycin, plicamycin, dihydrostreptomycin, kanamycin, natamycin, rifamycin, and tobramycin. The active agent may comprise 0.01-2% w/v of the composition. The active agent can comprise 0.01-0.2% w/v of the composition. The composition can have a pH of about 7.3.
[0016] The composition above may reduce intraocular pressure when administered to the eye.
[0017] The composition above may reduce ocular extracellular vesicle complexes when administered to the eye. [0018] The composition above can be effective for treating a glaucoma disease when administered to the eye.
[0019] The composition above can further comprise one or more of a solubilizer, a surfactant, a tonicifier, and a preservative. The solubilizer may be selected from a phosphate, a citric acid monohydrate, a trisodium citrate, and combinations thereof. The surfactant can be selected from a phospholipid, a polyglycerol ester, a propylene glycol ester, a polyethylene glycol ester, a copolymer ester, a polyoxyethylene sorbitan ester, a cyclodextrin, a polyvinyl alcohol, povidone, a hydroxypropyl methyl cellulose, a poloxamer, a carboxymethyl cellulose, a hydroxyethyl cellulose, a polyacrylate, and combinations thereof. The tonicifier may be selected from sodium chloride, trehalose, mannitol, sorbitol, dextrose, potassium chloride, and combinations thereof. The preservative can be selected from benzalkonium chloride, polyquaternium-1, benzododecinium bromide, sorbic acid, methyl paraben, propyl paraben, chlorobutanol, benzylic alcohol, phenylethyl alcohol, an oxychloro complex, thimerosal, sodium perborate, disodium edetate, and combinations thereof.
[0020] A composition above may be used in medical therapy, in the treatment of the human or animal body, in reducing intraocular pressure in the human or animal body, in reducing ocular extracellular vesicle complexes in the human or animal body, or in preparing or manufacturing a medicament for preventing, ameliorating, or treating a disease or condition associated with glaucoma in a subject in need.
[0021] Embodiments of this invention further contemplate methods for treating a glaucoma disease, reducing intraocular pressure, or reducing ocular extracellular vesicle complexes in a subject in need thereof, the method comprising administering a composition above to the eye of the subject. The administration may be by injection. The ocular extracellular vesicle complexes can be aggregates of extracellular vesicles having a diameter greater than about 300 nanometers.
BRIEF DESCRIPTION OF THE DRAWINGS
[0022] FIG. 1 shows an illustration of normal eye (left) anatomy compared to glaucomatous eye (right).
[0023] FIG. 2 shows an electron micrograph of a sample of trabecular meshwork (left), and an illustration of aqueous humor flow in eye trabecular meshwork (right). [0024] FIG. 3 shows a diagram of an embodiment of a device for detecting flow and pressure of a fluid composition in a channel. The channel may contain a meshwork having properties like a trabecular meshwork of the eye. The channel meshwork may have a uveal meshwork portion, a corneoscleral meshwork portion, and a justacanalicular meshwork portion. The channel can be a microfluidic channel.
[0025] FIG. 4 shows an embodiment of a series of test channels for detecting the effect or various compounds, compositions and substances on the flow and pressure of a fluid composition in a channel.
[0026] FIG. 5 shows an embodiment of a device and system for detecting flow and pressure of a fluid composition in a channel. A channel may contain a meshwork having properties like a trabecular meshwork of the eye. Alternatively, the device may utilize a reservoir for a test sample of a fluid composition. The channel can be a microfluidic channel.
[0027] FIG. 6 shows imaging of extracellular vesicles with conventional fixation techniques result in inefficient EV imaging due to failure of EVs to adhere. Imaging is surprisingly improved using a non-reversible crosslinking reagent (a) Representative photomicrographs of isolated bovine vitreous EVs, 4 million loaded, fixed to the copper grid with glutaraldehyde and subsequent UA and lead citrate solution, show few negatively stained EVs (arrowhead) at low (left) magnification, and in other photographs no EVs are visualized (middle and right). Negatively stained EVs are shown with signal (black) surrounding the perimeter of the EV and lower signal (white or grey) in the center (b) Schematic diagram shows that EVs in solution that were applied to the electron microscopy grid surface fail to attach. The EVs are present in the discarded solution (black box) and we quantitated the size and number of EVs using nanoparticle tracking analysis (NT A) (c) NTA shows the size and concentration of EVs applied to the TEM grid surface (d) NTA shows the size and concentration of EVs that were present in the discarded solution. This number represents the size and number of EVs that fail to adhere to the TEM grid surface (g) Graphical representation comparing the amount of EVs applied to the electron microscopy grid surface (black bar) and the size and concentration of EVs present in the discarded solution (grey bars, n = 3). (f) Representative TEM photomicrographs of isolated bovine vitreous EVs after EDC-glutaraldehyde-fixation, negative staining and TEM imaging reveal substantially more EVs visualized at low (left), medium (middle) and high (right) magnification (g) Graphical representation (log2) of the mean and ± standard deviation that shows significantly more EVs counted per image from EDC fixed specimens (350- fold), when compared to Glut fixed grids (n = 3, counted on average seven images per biological replicate, *p <0.05). (h) Representative TEM photomicrographs of isolated bovine aqueous humor after EDC-glutaraldehyde-fixation show robust negative staining surrounding the border of the EV. (i) TEM images from human aqueous humor, without performing EV isolation, show multiple EVs present, in situ. Scale bars are (a) 1000 nm (left), 600 nm (middle), 125 nm (right); (f) 600 nm (left), 125 nm (right); (h) 500 nm; and (i) 1 pm.
[0028] FIG. 7 shows healthy human aqueous humor, control, Patient #1, shows a diffuse distribution of non-aggregated EVs. (a-c) Representative photomicrographs of diluted human healthy control aqueous humor EVs (EVs were NOT isolated with ultracentrifugation, only diluted with buffered saline), fixed to the copper grid with EDC, glutaraldehyde and subsequently stained with UA solution. Photographs were captured with transmission electron microscopy and recorded. The images show many negatively stained EVs of various sizes, and the majority of EVs exist in the fluid independent without aggregation. One EV-aggregate was observed and was in the minority of samples imaged. Scale bars are marked on the photographs.
[0029] FIG. 8 shows healthy human aqueous humor, control, Patient #2, shows a diffuse distribution of non-aggregated EVs. (a-d) Representative photomicrographs of diluted human healthy control aqueous humor EVs (EVs were NOT isolated with ultracentrifugation, only diluted with buffered saline), fixed to the copper grid with EDC, glutaraldehyde and subsequently stained with UA solution. Photographs were captured with transmission electron microscopy and recorded. The images show many negatively stained EVs of various sizes. No EV-aggregates larger than 2 pm were observed, nor were large clumps of EVs visualized. Scale bars are marked on the photographs. [0030] FIG. 9 shows POAG aqueous humor and shows large glaucoma-associated-EV- aggregates in Patient #1. (a-c) Representative transmission electron microscopy photographs show POAG aqueous humor samples (EVs were NOT isolated with ultracentrifugation, only diluted with buffered saline), fixed to the copper grid with EDC, glutaraldehyde and subsequently stained with UA solution. Photographs were captured with transmission electron microscopy and recorded. The diluted POAG specimens show evidence of glaucoma-associated-EV-aggregates present in the fluid that are large in size. Images show few free EVs observed (a-c). Scale bars are marked on the photographs.
[0031] FIG. 10 shows POAG aqueous humor and shows large glaucoma-associated-EV- aggregates in Patient #2. (a-c) Representative transmission electron microscopy photographs from a second POAG sample (EVs were NOT isolated with ultracentrifugation, only diluted with buffered saline), fixed to the copper grid with EDC, glutaraldehyde and subsequently stained with UA solution. Photographs were captured with transmission electron microscopy and recorded. The second POAG aqueous humor specimens show evidence of sizeable glaucoma-associated-EV- aggregates and larger free EVs. Scale bars are marked on the photographs.
[0032] FIG. 11 shows a known glaucoma treatment, bimatoprost, reduces the size of POAG- associated EV complexes in the aqueous humor of a patient with glaucoma, when compared to untreated glaucoma samples (a-b) Representative transmission electron microscopy photographs show human aqueous humor collected from a patient with POAG and no treatment (placebo, control, buffered saline) shows evidence of extracellular matrix and glaucoma associated-EV-complexes in the aqueous humor. Images show large collagen-like matrix in all panels and these electron dense structures measure several microns in size (c-d) Representative photographs show POAG aqueous humor samples treated with a glaucoma medication, bimatoprost, and show no evidence of large extracellular matrix nor glaucoma-associated-EV-aggregates. On high power imaging, there appears to be larger globules that are not aggregated. Scale bars are marked on the figures.
[0033] FIG. 12 shows treatment of a glaucoma patient’s aqueous humor with buffered saline has no effect on PO AG-associated EV complexes of a second subject diagnosed with glaucoma. (FIG. 12) Representative transmission electron microscopy photographs show human aqueous humor collected from a patient with POAG and no treatment (placebo, control, buffered saline) shows evidence of glaucoma associated-EV-complexes. Images show large electron dense glaucoma associated-EV-complexes in all panels. The placebo treatment had no effect the glaucoma associated-EV-complexes. Scale bars are marked on the figures.
[0034] FIG. 13 shows bimatoprost reduces the size of PO AG-associated EV complexes in the aqueous humor of a second subject diagnosed with glaucoma, when compared to control -treated glaucoma samples. (FIG. 13) Representative photographs show POAG aqueous humor from Subject #2 samples treated with bimatoprost show a disruption of the large electron dense glaucoma- associated-EV-aggregates. The glaucoma-associated-EV-aggregates were smaller in size, when compared to the controls (shown in FIG. 12). On high power imaging, we do not observe many aggregated EVs. Scale bars are marked on the figures.
[0035] FIG. 14 shows glaucoma patients’ aqueous humor contains larger electron dense structures in the aqueous humor that are not present in healthy controls. Graphical representation that depicts the size and number of an unidentified material that we termed, “glaucoma-associated- EV-aggregates” in healthy controls or POAG specimens. We obtained healthy control or POAG human aqueous humor, fixed the samples with EDC, and imaged the specimens with transmission electron microscopy. Photographs were analyzed and the number of glaucoma-associated-EV- aggregates were identified and plotted for each variable. In aqueous humor obtained from a single healthy control subject, the data shows that most EVs did not have glaucoma-associated-EV- aggregates. The data show that three subjects with a diagnosis of POAG had numerous glaucoma- associated-EV-aggregates that are several micrometers in size. Theses aggregates were not observed in healthy controls. The graph shows a substantial difference in the size of the glaucoma-associated- EV-aggregates in POAG, when compared to healthy controls.
[0036] FIG. 15 shows glaucoma patients' aqueous humor contains EVs that aggregate and contact each other, when compared to healthy controls that have fewer EVs touching each other. Graphical representation that depicts the number of EVs that are in contact with each other (X-axis) and the count frequency (percent of total). We obtained healthy control or POAG human aqueous humor, fixed the samples with EDC, and imaged the specimens with transmission electron microscopy. Photographs were analyzed and the number of EVs contacting each other as determined for each variable. In aqueous humor obtained from a single healthy control subject, the data shows that most EVs are free and not present in aggregates. The data shows that two subjects with a diagnosis of POAG have aqueous humor that contains EVs that contact a large number of other EVs. The graph shows a substantial difference between the number of EVs contacting each other in POAG, when compared to healthy controls.
[0037] FIG. 16 shows a curvilinear chart of the data in FIG. 15. Glaucoma patients' aqueous humor contains EVs that aggregate and contact each other, when compared to healthy controls that have fewer EVs touching each other.
[0038] FIG. 17 shows extracellular vesicles are present in human aqueous humor obtained from healthy control patients and have a dominant population of EVs between 100 to 200 nm. Graphical representation that depicts the EV population in human aqueous humor obtained from a single healthy control patient. The EV count frequency is shown as a function of size. We fixed healthy control human aqueous humor after measuring EVs diameter after fixing human aqueous humor from a healthy control that was fixed with EDC fixation and imaged with transmission electron microscopy. The data shows that healthy control human aqueous humor contains EVs. The majority of EVs between 100-200 nm in diameter for this patient. All EVs that were visualized were free from contact with other EVs (not aggregated).
[0039] FIG. 18 shows extracellular vesicles in the aqueous humor of subject #1 with the diagnosis of POAG are located within the “glaucoma-associated-EV-aggregates,” shows all EVs located within the glaucoma-associated-EV-aggregate. (a) Graphical representation of the EV population in human aqueous humor obtained from subject #1 with the diagnosis of POAG. We fixed the aqueous humor with EDC fixation and imaged with transmission electron microscopy. The photographs were analyzed and EV size and number were quantitated and graphed. We observed that EVs were present within an aggregate (defined as EVs that contact each other or glaucoma- associated-EV-aggregate). The data show the number and size of individual EVs present within the glaucoma-associated-EV-aggregate (gray bar) as a function of the total number EVs counted. A substantial number of EVs are between 36 nm and 300 nm with a high number of EVs 100 - 200 nm in size. In Subject #l’s aqueous humor, we did not observe free EVs (EVs that do not contact each other).
[0040] FIG. 19 shows extracellular vesicles in aqueous humor obtained from human subjects with the diagnosis of primary open angle glaucoma (POAG) are contacting each other to create an aggregate or the EVs were present as free EVs (non-aggregated). (a-b) Graphical representation of the EV population in human aqueous humor obtained from a single subject with the diagnosis of POAG. We fixed the aqueous humor with EDC fixation and imaged with transmission electron microscopy. The photographs were analyzed and EV size and number were quantitated. We observed EVs that were present within an aggregate (defined as EVs that contact each other) or a free EVs (EVs that do not contact each other). The data shows that a population of EVs that are free from contact with each other (non-aggregated EVs). There was a substantial number of EVs between 100-500 nm, and some that are larger in size.
[0041] FIG. 20 shows a graph representing the size and frequency of EVs that are contacting other EVs and were located within a “glaucoma-associated-EV-aggregate” for the patient of FIG. 19. A substantial amount of the EVs were between 36 nm and 300 nm, with a few larger free EVs observed.
[0042] FIG. 21 shows extracellular vesicles in the aqueous humor of a single subject with the diagnosis of POAG are located within the “glaucoma-associated-EV-aggregates,” with a substantial population of EVs present within the glaucoma-associated-EV-aggregate. (a) Graphical representation of the EV population in human aqueous humor obtained from a single subject with the diagnosis of POAG. We fixed the aqueous humor with EDC fixation and imaged with transmission electron microscopy. The photographs were analyzed and EV size and number were quantitated. We observed EVs that were present within an aggregate (defined as EVs that contact each other) or a free EVs (EVs that do not contact each other). The data show the number and size of individual EVs present within the glaucoma-associated-EV-aggregate (black bar) or the number and size of EVs that are not aggregated (free EVs, black and white stripe bar), as a function of the total number EVs counted. A substantial number of EVs were located within the glaucoma- associated-EV-aggregate. A substantial number of EVs within the aggregate, show a diameter from 100-300 nm in size. The larger EVs had higher populations show a substantial number of free EVs (non-aggregate EVs) in the larger size range.
[0043] FIG. 22 shows extracellular vesicles in two separate glaucoma patient shows similar sizes and number of EVs that are located within the “glaucoma-associated-EV-aggregate.” (a) Graphical representation of the EV population in human aqueous humor obtained from two subjects with the diagnosis of POAG. We fixed the aqueous humor of each subject with EDC and imaged with the specimen with transmission electron microscopy. The photographs were analyzed and EV size and number were quantitated. We observed EVs that were present within an aggregate (defined as EVs that contact each other). The data show the size and number of EVs present within the glaucoma- associated-EV-aggregate from Subject #1 (grey bar) or Subject #2 (black bar). The data was normalized and shows that both samples have a similar distribution of EVs present within the glaucoma-associated-EV-aggregate.
[0044] FIG. 23 shows extracellular vesicles in the aqueous humor of human subjects with the diagnosis of POAG differ in size and frequency, when compared to aqueous humor of healthy control subjects (a) Graphical representation of the EV population in human aqueous humor obtained from a subject with the diagnosis of POAG and normal healthy control. We fixed the aqueous humor of each subject with EDC and imaged with the specimen with transmission electron microscopy. The photographs were analyzed and EV size and number were quantitated. We observed EVs that were free (non-aggregate, defined as EVs that do not contact each other) were different is size and frequency when compared to healthy controls. The data show the size and number of free EVs from healthy controls (white bar) or POAG from Subject #2 (black bar). We observed that free EVs present in patient #2’s aqueous humor has substantially larger EVs, when compared to healthy controls.
[0045] FIG. 24 shows extracellular vesicles POAG aggregates are similar in size and frequency to healthy human subjects (a) Graphical representation of the EV population from human subject’s aqueous humor obtained from healthy controls (free EVs) or POAG subjects (aggregated EVs). We fixed the aqueous humor of each subject with EDC and imaged with the specimen with transmission electron microscopy. The photographs were analyzed and EV size and number were quantitated. We observed that free-EVs (non-aggregate, defined as EVs that do not contact each other) were similar in size and frequency when compared to EVs located within the aggregates of two separate POAG subjects. The data show the size and number of free EVs from healthy controls (white bar), aggregate-EVs from POAG Subject #1 (grey bar), aggregate-EVs from POAG Subject #2 (stripe bar).
[0046] FIG. 25 shows that agent cetylpridinium chloride reduced intraocular pressure (IOP) in a glaucoma model as compared to control. The agent was tested by controlling flow and measuring relative IOP using in a microfluidic device. The agent was compared against placebo (buffered saline) by preparing each in bovine vitreous humor (BVH) and pre-incubating at 37°C for 24 hours. The timepoint of injection into the device is denoted by an arrow and the letter “a.” Referring to FIG. 25, the IOP for placebo (dashed line) increased greatly after injection of the placebo sample.
The IOP rose steadily to a maximum pressure of about 64 mmHg. To the contrary, the IOP after injection of the agent cetylpridinium chloride-BVH sample (solid line) was markedly lower than for placebo, and the difference was sustained. This result showed that the agent cetylpridinium chloride was surprisingly effective to reduce IOP in the glaucoma model.
[0047] FIG. 26 shows that agent polymyxin B reduced intraocular pressure (IOP) in a glaucoma model as compared to control. The agent was tested by controlling flow and measuring relative IOP using in a microfluidic device. The agent was compared against placebo (buffered saline) by preparing each in bovine vitreous humor (BVH) and pre-incubating at 37°C for 24 hours. The timepoint of injection into the device is denoted by an arrow and the letter “a.” Referring to FIG. 26, the IOP for placebo (dashed line) increased greatly after injection of the placebo sample. The IOP rose steadily to a maximum pressure of about 250 mmHg. To the contrary, the IOP after injection of the agent polymyxin B (solid line) was 78% lower than for placebo, and the difference was sustained. This result showed that the agent polymyxin B was surprisingly effective to reduce IOP in the glaucoma model.
[0048] FIG. 27 shows that agent neomycin reduced intraocular pressure (IOP) in a glaucoma model as compared to control. The agent was tested by controlling flow and measuring relative IOP using in a microfluidic device. The agent was compared against placebo (buffered saline) by preparing each in bovine vitreous humor (BVH) and pre-incubating at 37°C for 24 hours. The timepoint of injection into the device is denoted by an arrow and the letter “a.” Referring to FIG. 27, the IOP for placebo (dashed line) increased greatly after injection of the placebo sample. The IOP rose steadily to a maximum pressure of about 64 mmHg. To the contrary, the IOP after injection of the agent neomycin (solid line) was 72% lower than for placebo, and the difference was sustained. This result showed that the agent neomycin was surprisingly effective to reduce IOP in the glaucoma model.
[0049] FIG. 28 shows that agent heparin sodium reduced intraocular pressure (IOP) in a glaucoma model as compared to control. The agent was tested by controlling flow and measuring relative IOP using in a microfluidic device. The agent was compared against placebo (buffered saline) by preparing each in bovine vitreous humor (BVH) and pre-incubating at 37°C for 24 hours. The timepoint of injection into the device is denoted by an arrow and the letter “a.” Referring to FIG. 28, the IOP for placebo (dashed line) increased greatly after injection of the placebo sample. The IOP rose steadily to a maximum pressure of about 67 mmHg. To the contrary, the IOP after injection of the agent heparin sodium (solid line) was 32% lower than for placebo, and the difference was sustained. This result showed that the agent heparin sodium was surprisingly effective to reduce IOP in the glaucoma model.
[0050] FIG. 29 shows that compound sodium dodecyl sulfate was a negative control for intraocular pressure (IOP) in a glaucoma model. The compound was tested by controlling flow and measuring relative IOP using in a microfluidic device microfluidic. The compound was compared against placebo (buffered saline) by preparing each in bovine vitreous humor (BVH) and pre- incubating at 37°C for 24 hours. The timepoint of injection into the device is denoted by an arrow and the letter “a.” Referring to FIG. 29, the IOP for placebo (dashed line) increased greatly after injection of the placebo sample. The IOP rose steadily to a maximum pressure of about 60 mmHg. However, the IOP after injection of sodium dodecyl sulfate (solid line) was significantly higher than for placebo. This result showed that sodium dodecyl sulfate was a negative control that did not reduce IOP in the glaucoma model.
DETAILED DESCRIPTION OF THE INVENTION
[0051] This invention provides methods, compositions, devices, kits and reagents for detecting, identifying and treating glaucoma disease. Embodiments of this invention utilize ultrastructural features of ocular aqueous humor as guides and markers for glaucoma therapeutic modalities.
[0052] In some aspects, this invention provides methods and compositions for reducing intraocular pressure and increasing ocular outflows in glaucoma subjects. Aspects of this invention can reduce formation and presence of aggregational features and structures in ocular humor.
[0053] In further aspects, this disclosure provides therapeutic compositions for glaucoma.
[0054] Embodiments of this invention provide devices for measuring and characterizing glaucoma aggregational features, as well as intraocular pressure and ocular outflows.
[0055] Additional aspects of this disclosure include diagnostic and screening modalities for glaucoma. Further embodiments include kits and reagents for carrying out the foregoing.
[0056] Embodiments of this invention can provide glaucoma diagnosis based on a unique and reliable ultrastructural biomarker herein identified. The ultrastructural component can block the trabecular meshwork, increasing IOP and, over time, ocular aqueous outflow resistance increases leading to elevated intraocular pressure, and eventual vision loss. The ultrastructural component in the humor fluid of a patient with POAG can be reflected in EV aggregates formed together in large EV-complexes. The EV-complexes can be multiple microns in size and are glaucoma-associated-EV-complexes. The EV- complexes may be present in glaucoma patient samples and sizeable enough to block the trabecular meshwork.
[0057] Embodiments of this invention can provide compositions and methods for purifying and/or synthesizing EV-complexes of this ultrastructural component for use in therapeutic and biological methods.
[0058] Embodiments of this invention can provide compositions and methods for therapeutics and treatment of POAG and testing POAG aqueous humor specimens.
[0059] In some embodiments, glaucoma-associated-EV-complexes can be reduced by dissociation and other routes. [0060] In additional embodiments, compositions and methods of this invention can reduce intraocular pressure and/or increase ocular outflows.
[0061] Embodiments of this invention further contemplate methods for treating glaucoma.
[0062] In certain aspects, a glaucoma disease may be treated by administering a surface active agent for affecting EV-complexes. A surface active agent may be used for ameliorating, alleviating, inhibiting, lessening, delaying, and/or preventing at least one symptom or condition of a glaucoma disorder.
[0063] The eye can be viewed as a closed chamber. (FIG. 1, left) IOP can be determined by the rate of aqueous humor formation and the rate fluid exit. (FIG. 1, right) In general, reduced aqueous outflow in glaucoma can be related to raised IOP. Aqueous humor outflow can be related to elevated IOP and glaucomatous visual damage. Aqueous humor exits the eye via two pathways: the trabecular meshwork and to a lesser extent the uveolscleral outflow. (FIG. 2)
[0064] Abnormal aqueous humor outflow can cause elevated IOP. The trabecular meshwork (TM) can be a major site of outflow. The TM is a filter-like tissue composed of a series of fenestrated striations that allow aqueous humor to flow and exit the anterior chamber via Schlemm's canal. The primary function of the TM is to allow aqueous humor to exit the eye and establish IOP.
[0065] The juxtacanalicular tissue (JCT) or cribriform region is next to Schlemm's canal and is the region of the TM that may be implicated in establishing IOP. The site of most resistance to the aqueous outflow can be the JCT tissue, which measures approximately 2- 20 pm. JCT is composed of the loosely arranged extracellular matrix (ECM) into which cells are embedded.
[0066] Abnormal regulation of aqueous flow through the TM may be associated with elevated IOP. The ECM of the TM can be a barrier that may isolate the ocular fluid outflow.
[0067] Ultrastructural features or compositions in the aqueous humor of patients with glaucoma that are physically larger than the fenestrations of the JCT outlet, or that of other TM tissues, can block the TM. [0068] Ultrastructural features or compositions in the aqueous humor can include structures based on extracellular vesicles (EV). EVs are transport nano-vesicles related to inter-cellular communication via transfer of biomolecules such as proteins, lipids, and nucleic acids from one cell to another.
[0069] In general, various cell types secrete EVs into fluids like blood, cerebrospinal fluid, and urine. Examples include exomeres approximately 35 nm, exosomes about 40 100 nm, larger micro-vesicles about 100-1000 nm, and apoptotic bodies about 1-5 pm.
EVs can be associated with pathophysiology of disease.
[0070] In some embodiments of this invention, ultrastructural features and compositions based on EVs are utilized in characterizing ocular fluids.
[0071] In further embodiments, ultrastructural features and compositions based on EVs can be utilized in devices for determining IOP. Ultrastructural features and compositions based on EVs can be monitored for determining therapeutic effects in reducing IOP. Ultrastructural features and compositions based on EVs can be monitored as biomarkers for determining therapeutic effects in reducing IOP.
[0072] In additional embodiments, ultrastructural features and compositions based on EVs can be utilized in devices for measuring ocular outflows. Ultrastructural features and compositions based on EVs can be monitored for determining therapeutic effects in increasing ocular outflows. Ultrastructural features and compositions based on EVs can be monitored as biomarkers for determining therapeutic effects in increasing ocular outflows. [0073] In further embodiments, ultrastructural features and compositions based on EVs are utilized in reducing formation and presence of aggregational features, structures and particles in ocular humor.
[0074] In certain embodiments, ultrastructural features and compositions based on EVs are utilized in devices for detecting ocular conditions and parameters.
[0075] In additional embodiments, ultrastructural features and compositions based on EVs are utilized in identifying glaucoma in a subject.
[0076] In further embodiments, ultrastructural features and compositions based on EVs are utilized in methods, kits and reagents for glaucoma. [0077] Without wishing to be bound by any particular theory, ultrastructural features and compositions based on EVs in glaucoma may have larger structures that block the TM and/or other outflows.
[0078] Glaucoma disorders, referred to herein as “glaucoma,” that can be treated with the methods and compositions as described herein include, but are not limited to, preglaucoma open angle with borderline findings, open angle, low risk, anatomical narrow angle primary angle closure suspect, steroid responder, ocular hypertension, primary angle closure without glaucoma damage (PAS or high IOP with no optic nerve or visual field loss), unspecified open-angle glaucoma, primary open-angle glaucoma, chronic simple glaucoma, low-tension glaucoma, pigmentary glaucoma, capsular glaucoma with pseudo exfoliation of lens, residual stage of open-angle glaucoma, unspecified primary angle- closure glaucoma, acute angle-closure glaucoma attack, chronic angle-closure glaucoma, intermittent angle-closure glaucoma, residual stage of angle-closure glaucoma, glaucoma secondary to eye trauma, glaucoma secondary to eye inflammation, glaucoma secondary to other eye disorders including, retinal vascular occlusions, diabetes type 1 complicated, diabetes type 2 complicated, disorders of lens, disorders of intraocular lens, disorders after other ocular symptoms, neoplasms, benign neoplasms, or malignant. Also included is glaucoma secondary to drugs, glaucoma with increased episcleral venous pressure, hypersecretion glaucoma, aqueous misdirection malignant glaucoma, glaucoma in diseases classified elsewhere, congenital glaucoma, axenfeld’s anomaly, buphthalmos, glaucoma of childhood, glaucoma of newborn, hydrophthalmos, keratoglobus, congenital glaucoma macrocornea with glaucoma, macrophthalmos in congenital glaucoma, megalocornea with glaucoma, absolute glaucoma. Also included are adverse effect of ophthalmological drugs and preparations, acute follicular conjunctivitis, adverse effect of carbonic anhydrase inhibitors, and adverse effect of under dosing of ophthalmological drugs and preparations. [0079] In some embodiments, a composition of this disclosure can be administered systemically. Systemic administration can be achieved via intravenous administration, oral administration, intraarterial administration, inhalation, intranasal administration, intra- peritoneal administration, intra-abdominal administration, subcutaneous administration, intra-articular administration, intrathecal administration, transdural administration, transdermal administration, submucosal administration, sublingual administration, enteral administration, parenteral administration, percutaneous administration, periarticular administration, or intraventricular administration.
[0080] In further embodiments, a composition of this disclosure can be administered locally. A composition may be administered locally to ocular tissue. As used herein, the term ocular tissue refers to the eye, including tissues within the sclera, e.g., the retina, and outside the sclera, e.g., ocular muscles within the orbit. Ocular tissue also includes tissues neurologically connected to, but distinct from the eye, such as the optic nerve, the geniculate nucleus and the visual cortex. Local administration to ocular tissue can be achieved via intraocular administration. Intraocular administration can be carried out via intracameral administration, intravitreal administration, or subretinal administration.
[0081] In additional embodiments, local administration to ocular tissue can be achieved via periocular administration. Periocular administration can be carried out via sub conjunctival injection, sub-Tenon’s injection, direct periocular injection, or depot periocular injection.
[0082] A subject may be administered a therapeutically effective amount of the composition. A therapeutically effective amount can be an amount effective to ameliorate, alleviate, inhibit, lessen, delay, and/or prevent at least one symptom or condition of the condition being treated.
[0083] In certain embodiments, a therapeutically effective amount can be the amount effective to ameliorate the ocular condition being treated. The dose may be determined according to various parameters, especially according to the severity of the condition, age, and weight of the patient to be treated; the route of administration; and the required regimen. A physician will be able to determine the required route of administration and dosage for any particular patient. Dosages may vary depending on the relative potency of the composition being administered, and can generally be estimated based on the half maximal effective concentration (EC50) found to be effective in in vitro and in vivo models.
Extracellular vesicles and aggregates in glaucoma
[0084] Embodiments of this invention provide methods for detecting EVs in biological fluids. In certain methods, a cross-linking agent can be used to provide robust imaging of EV ultrastructures with, for example, electron microscopy. In further methods, a glutaraldehyde-alternative cross-linker can be used.
[0085] Additional embodiments of this invention contemplate detecting and characterizing EV-complexes in glaucoma. EV-complexes in glaucoma can block the TM or JCT and inhibit ocular aqueous outflow pathways.
[0086] In certain aspects, EVs in glaucoma can be aggregated together in EV- complexes. Glaucoma-associated EV-complexes may be up to multiple microns in size or diameter.
[0087] In glaucoma, EV-complexes can be an ultrastructural feature of the disease. This ultrastructural feature can be a target for characterizing glaucoma. EV-complexes can be used for detecting therapeutic parameters and modalities for glaucoma. In some embodiments, EV-complexes can be used for diagnosis, prognostication, and/or screening of glaucoma compositions. EV-complexes can also be used in devices for determining therapeutic compositions, doses and regimens.
[0088] As used herein, the term diameter refers to the longest linear dimension of an irregularly- shaped particle such as an extracellular vesicle complex. For a regularly-shaped particle, such as a spherical vesicle, the term diameter has its usual meaning as the line segment passing through the center with endpoints on the sphere.
[0089] In some aspects, this disclosure provides compositions of purified EV-complexes from glaucoma. Purified EV-complexes from glaucoma can be used in a device for assaying and detecting changes in EV ultrastructural components which can be related to intraocular pressure and ocular outflows. This invention provides devices containing purified EV-complexes which can be used for characterizing and measuring ocular blockage and ocular outflows. Purified EV-complexes from glaucoma can be used in a device for screening effects of therapeutic agents on ocular EV ultrastructural components. [0090] In further aspects, this disclosure provides compositions of synthetic EV- complexes for characterizing glaucoma. Synthetic EV-complexes for characterizing glaucoma can be used in a device for assaying and detecting changes in EV ultrastructural components which can be related to intraocular pressure and ocular outflows. This invention provides devices containing synthetic EV-complexes which can be used for characterizing and measuring ocular blockage and ocular outflows. Synthetic EV- complexes from glaucoma can be used in a device for screening effects of therapeutic agents on ocular EV ultrastructural components.
[0091] EV ultrastructural components such as EV-complexes can be composed of complexes or aggregates of extracellular vesicles. Examples of extracellular vesicles include exomeres, exosomes, multivesicular bodies, intraluminal vesicles (ILVs), multivesicular endosomes (MVEs), oncosomes, micro-vesicles, apoptotic bodies, and vesicles originating from endosome or plasma membranes.
[0092] Complexes or aggregates of extracellular vesicles can be protein-EV structures having micrometer diameters, or diameters greater than about 1 micrometer.
[0093] Extracellular vesicle aggregates can have a size of from about 360 to about 21,000 nanometers (nm).
[0094] For example, exomeres can be about 35 nm in diameter, exosomes can be about 40-100 nm in diameter, micro-vesicles can be about 100-1000 nm in diameter, and apoptotic bodies can be about 1-5 micrometers in diameter.
[0095] Complexes or aggregates of extracellular vesicles may contain 10, 20, 30, 40, 50, 100, 200, 500 or more extracellular vesicles.
[0096] For example, a healthy subject may have free EVs, which are non-aggregated EVs, about 100-200 nm in diameter, which are mainly exosomes, along with some micrometer sized vesicles. A healthy subject may not have EV-aggregates or EV ultrastructural features larger than 0.4-20 micrometers in diameter in aqueous humor.
[0097] For example, in glaucoma, a subject may have EV-aggregates larger than 0.4-20 micrometers in diameter. A healthy subject may have small EV aggregates of about 36-300 nm, which are mainly exomeres, along with some micro-vesicles. A glaucoma subject may have reduced amounts of free EVs, or very few remaining free EVs. Free EVs in glaucoma may be of larger sizes than free EVs in a healthy subject. EV aggregates in glaucoma may be composed of any of exomeres, exosomes, micro-vesicles, and/or apoptotic bodies, as well as other kinds of vesicles or bodies.
Devices for glaucoma aggregational features
[0098] A device of this invention can be used to characterize the activity of a biologically active agent toward glaucoma. A device of this invention can be used to detect or characterize ocular conditions or parameters in a model system or patient pathology.
[0099] An active agent may be capable of providing a therapeutic benefit, especially in glaucoma. In some embodiments, an active agent may be a known drug effective for treating a disease of the eye.
[00100] In some aspects, a fluid composition in a device of this invention can be analyzed by various techniques. For example, a fluid composition can be analyzed by an imaging technique.
[00101] Examples of imaging techniques include electron microscopy, stereoscopic microscopy, wide-field microscopy, polarizing microscopy, phase contrast microscopy, multiphoton microscopy, differential interference contrast microscopy, fluorescence microscopy, laser scanning confocal microscopy, multiphoton excitation microscopy, ray microscopy, and ultrasonic microscopy.
[00102] Examples of imaging techniques include positron emission tomography, computerized tomography, and magnetic resonance imaging.
[00103] Examples of assay techniques include colorimetric assay, chemiluminescence assay, spectrophotometry, and light scattering.
[00104] In some embodiments, this invention can provide a device for measuring pressure and flow rate of a fluid composition. (FIG. 3) The device may have a channel having an inlet at a first end and an outlet at a second end, wherein the inlet and outlet are in fluid communication. The device can have a meshwork composition lodged in the channel for providing resistance to flow. The meshwork composition may have any one or more, or all of the following portions. A uveal meshwork, a corneoscleral meshwork, and a juxtacanalicular meshwork.
[00105] In some embodiments, a meshwork composition can be composed of glass beads, micro beads, magnetic beads, gel particles, dextran particles, or polymer particles. A meshwork composition may also be composed of glass fibers, polymeric fibers, inorganic fibers, organic fibers, or metal fibers.
[00106] In certain embodiments, a uveal meshwork may have fenestrations of about 25 micrometers. A corneoscleral meshwork may have fenestrations of about 2-15 micrometers. A juxtacanalicular meshwork may have fenestrations of about 1 to 4 micrometers or less.
[00107] A device may further include a fluid reservoir for holding the fluid composition, so that the fluid reservoir is in fluid communication with the inlet of the channel for introducing the fluid composition into the inlet of the channel.
[00108] A device of this disclosure can have a pressure source for applying pressure to the fluid composition in the fluid reservoir for introducing the fluid composition into the inlet of the channel.
[00109] A device of this invention can have a flow sensor in fluid communication with the fluid composition for measuring the flow rate and pressure of the fluid composition at the inlet of the channel and transmitting the flow rate and pressure to a processor.
[00110] Signals and data from the device can be received by a processor. The processor can display the flow rate and pressure. Memory or media can store instructions or files, such as a machine-readable storage medium. A machine-readable storage medium can be non-transitory.
[00111] A processor of this disclosure can be a general purpose or special purpose computer. A processor can execute instructions stored in a machine readable storage device or medium. A processor can include an integrated circuit chip, a microprocessor, a controller, a digital signal processor, any of which can be used to receive and/or transmit data and execute stored instructions. A processor can also transform data, and/or store data in memory, media or a file. A processor may receive and execute instructions which may include performing one or more steps of a method of this invention. A device of this invention can include one or more non-transitory machine-readable storage media, one or more processors, one or more memory devices, and/or one or more user interfaces. A processor my have an integral display for displaying data or transformed data.
[00112] In some aspects, a device may have a microfluidic channel. One or more channels can also be arranged in a microfluidic chip.
[00113] A device of this disclosure can include one or more detectors for analyzing the fluid composition within the channel or at the inlet or exiting the outlet of the channel.
One or more detectors can also be arranged to detect the fluid composition within the channel. [00114] A device of this invention may include a meshwork composition which contains extracellular vesicles or extracellular vesicle complexes. An EV-complex for use in a meshwork composition may be purified from glaucoma ocular humor, aqueous humor, or vitreous humor. The ocular humor may be from animal or clinical sources. An EV- complex for use in a meshwork composition may be composed of extracellular vesicles, and may have a diameter from about 360 to about 21,000 nanometers.
[00115] In certain embodiments, an EV-complex for use in a meshwork composition may include a fixative, a stabilizing component, or a cross linking component which can transform the structure to a stable, uniform composition.
[00116] Examples of stabilizing components include fixatives as described herein, cross linking compounds as described herein, organic solvents, polypeptides, and pharmaceutically-acceptable organic salts.
[00117] Examples of salts include ammonium salts, alkali metal salts including sodium, lithium, and potassium salts, alkaline earth metal salts including calcium and magnesium salts, salts with organic bases, for example, organic amines, such as benzathines, dicyclohexylamines, hydrabamines formed with N,N-bis(dehydroabietyl)ethylenediamine), N-methyl-D-glucamines, N-methyl-D-glucamides, t-butyl amines, and salts with amino acids including arginine and lysine.
[00118] Examples of salts include acetates, adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, hydrochlorides, hydrobromides, hydroiodides, 2-hydroxyethanesulfonates, lactates, maleates, methanesulfonates, 2- napthalenesulfonates, nicotinates, nitrates, oxalates, pectinates, persulfates, digluconates, dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, 3-phenylpropionates, phosphates, picrates, pivalates, propionates, salicylates, succinates, sulfates, sulfonates, tartarates, thiocyanates, toluenesulfonates, and undecanoates.
[00119] Extracellular vesicle complexes that are cross linked can be reversibly cross linked, or non-reversibly cross linked.
[00120] Extracellular vesicles that are cross linked can be reversibly cross linked, or non- reversibly cross linked. [00121] In some embodiments, a device of this invention may contain an EV-complex meshwork composition that can be used for identifying or screening active agents for effects in reducing IOP and/or increasing ocular outflows. An EV-complex for use in a meshwork composition may include a drug delivery excipient. An EV-complex meshwork composition for a device may be a synthetic EV-complex or a purified EV-complex.
[00122] An embodiment of an arrangement of channels of this invention is illustrated in FIG. 4.
[00123] An embodiment of a device of this invention is illustrated in FIG. 5.
[00124] In additional embodiments, a device of this invention may be used for measuring the quantity or level of an EV-complex in a test sample. Measuring the quantity or level of an EV-complex in a test sample can provide a diagnostic marker level for the test sample.
A device of this invention can be used to identify glaucoma or pre-glaucoma in a subject. [00125] In further embodiments, a device of this invention may be used for measuring a pressure which can be related to a quantity or level of an EV-complex in a test sample. A pressure value in a channel can be related directly to a quantity or level of an EV-complex in a test sample.
[00126] In certain embodiments, a device of this invention may be used for measuring an assay value which can be related to a quantity or level of an EV-complex in a test sample. An assay value of a composition in a channel can be related directly to a quantity or level of an EV-complex in a test sample. For example, an assay may be a colorimetric assay, a chemiluminescence assay, a spectrophotometry assay, or a light scattering assay.
[00127] In some aspects, an aqueous humor sample from a subject can be provided and analyzed for a quantity of glaucoma extracellular vesicle complexes. The subject can be identified as having glaucoma or pre-glaucoma based on the quantity exceeding a reference value. A reference value can be a quantity or level of glaucoma extracellular vesicle complexes in a reference population of healthy individuals. The subject can be diagnosed as having glaucoma or pre-glaucoma. Subsequent test samples from the subject can be used to monitor a quantity or level of glaucoma extracellular vesicle complexes exceeding or not exceeding a previous test sample, which can be related to reducing IOP and/or increasing ocular outflows in the subject. [00128] In certain embodiments, a quantity or level of glaucoma extracellular vesicle complexes may include one or more of the number, size, density, morphology, and spatial distribution of the extracellular vesicle complexes.
[00129] In some embodiments, a reference value can be a quantity or level of glaucoma extracellular vesicle complexes in a reference population of healthy individuals. The reference value can be the average value in samples from the reference population.
[00130] Glaucoma may be found in a subject where a test sample from the subject contains a quantity or level of glaucoma extracellular vesicle complexes exceeding a glaucoma reference value.
[00131] In certain embodiments, a glaucoma reference value can be that the number of extracellular vesicle complexes which contain 10 or more aggregated extracellular vesicles is zero per sample. In certain embodiments, a glaucoma reference value can be that the number of extracellular vesicle complexes which contain 10 or more aggregated extracellular vesicles is 10 per sample. In certain embodiments, a glaucoma reference value can be that the number of extracellular vesicle complexes which contain 10 or more aggregated extracellular vesicles is 50 per sample. In certain embodiments, a glaucoma reference value can be that the number of extracellular vesicle complexes which contain 10 or more aggregated extracellular vesicles is 100 per sample.
[00132] In certain embodiments, a glaucoma reference value can be that the number of extracellular vesicle complexes which contain 10 or more aggregated extracellular vesicles, wherein the complexes are larger than 360 nm, is zero per sample. In certain embodiments, a glaucoma reference value can be that the number of extracellular vesicle complexes which contain 10 or more aggregated extracellular vesicles, wherein the complexes are larger than 360 nm, is 10 per sample. In certain embodiments, a glaucoma reference value can be that the number of extracellular vesicle complexes which contain 10 or more aggregated extracellular vesicles, wherein the complexes are larger than 360 nm, is 50 per sample. In certain embodiments, a glaucoma reference value can be that the number of extracellular vesicle complexes which contain 10 or more aggregated extracellular vesicles, wherein the complexes are larger than 360 nm, is 100 per sample.
[00133] In certain embodiments, a glaucoma reference value can be the number of extracellular vesicle complexes larger than 360 nm is 10 per sample. In certain embodiments, a glaucoma reference value can be the number of extracellular vesicle complexes larger than 360 nm is 50 per sample. In certain embodiments, a glaucoma reference value can be the number of extracellular vesicle complexes larger than 360 nm is 100 per sample. In certain embodiments, a glaucoma reference value can be the number of extracellular vesicle complexes larger than 360 nm is 200 per sample.
[00134] In additional aspects, a meshwork composition in a device of this invention can be an anterior half or portion of an animal eye with lens, wherein the TM of the eye is oriented in between the inlet and the outlet of the channel.
Methods
[00135] Extracellular vesicles in the aqueous humor in patients with POAG may be compared to a population of healthy controls. EV complex ultrastructure in the aqueous humor in subjects with ocular pathology such as glaucoma can be compared to healthy controls such as subjects with no ocular pathology aside from cataracts. The level of EV complexes in the aqueous humor in glaucoma subjects can exceed the level in healthy subjects.
[00136] The kind of EVs in glaucoma aqueous humor can be larger than in healthy subjects. In some embodiments, the level of larger EV structures can be reduced to un-block the aqueous humor meshwork and increase humor outflows. The EV complexes in glaucoma aqueous humor can be larger than any EV in a healthy subject. In some embodiments, the level of EV complexes can be reduced to un-block the aqueous humor meshwork and increase humor outflows.
[00137] In certain embodiments, EVs in healthy human aqueous humor can be diffusely and evenly distributed without aggregation. Healthy control aqueous humor may contain EVs that are non-aggregated and have diffuse distribution.
[00138] Glaucoma EV-complexes can be larger than EVs observed in healthy controls and may block the trabecular meshwork.
[00139] In some embodiments, purified EV-complexes can be obtained from aqueous humor in POAG. The purified EV-complexes may be several microns in size. The glaucoma EV-complex can be larger than the opening of the JCT (1 to 4 pm, or up to 2 to 20 pm), which may be large enough to block the juxtacanalicular tissue. The EV-complexes in POAG may be used to block the trabecular meshwork and reduce aqueous outflow. In certain embodiments, the level of EV- complexes can be reduced to un-block the trabecular meshwork and increase aqueous outflow. [00140] For example, EV complexes can be contacted with a composition containing an active agent such as bimatoprost. In these embodiments, the level of EV-complexes can be reduced to un block a trabecular meshwork and increase aqueous outflow.
[00141] In certain aspects, the level or quantity of glaucoma EV-complexes can be reduced in a POAG subject by administering an active agent such as bimatoprost.
[00142] In further embodiments, purified EV-complexes can have a size from about 360 nm to 21,000 nm. A purified EV-complex can be substantially larger than any particle found in healthy aqueous humor.
[00143] In additional embodiments, a purified EV-complex can have a size from about 360 nm to about 21,000 nm, or 360 nm to about 10,000 nm, or 360 nm to about 5,000 nm, or 360 nm to about 3,000 nm, or 360 nm to about 2,000 nm, or 360 nm to about 1,000 nm.
[00144] In a purified EV complex, the number of EVs contacting each other can be from about 5 to about 300, or from 10 to 300, or from 10 to 200, or from 10 to 100, or from 10 to 50, or from 10 to 40, or from 10 to 20.
[00145] In a purified EV complex, the number of EVs contacting each other can be from 20 to 300, or from 30 to 300, or from 40 to 300, or from 50 to 300.
[00146] In a purified EV complex, the number of EVs contacting each other can be from 20 to 200, or from 20 to 100, or from 30 to 200, or from 30 to 100, or from 40 to 200, or from 40 to 100, or from 50 to 200, or from 50 to 100.
[00147] In some embodiments, purified EV-complexes can provide particles of a size for a uveal meshwork. Purified EV-complexes for a uveal meshwork can be about 10,000 nm to about 25,000 nm, or 15,000 nm to 25,000 nm, or 20,000 nm to 25,000 nm.
[00148] In further embodiments, purified EV-complexes can provide particles of a size for a corneoscleral meshwork. Purified EV-complexes for a corneoscleral meshwork can be about 1,000 nm to about 15,000 nm, or 2,000 nm to 10,000 nm, or 2,000 nm to 5,000 nm.
[00149] In additional embodiments, purified EV-complexes can provide particles of a size for a juxtacanalicular meshwork. Purified EV-complexes for a juxtacanalicular meshwork can be about 360 nm to about 1,000 nm, or 360 nm to 2,000 nm, or 260 nm to 3,000 nm, or 1,000 nm to 3,000 nm.
[00150] The region of the TM that may be implicated in establishing IOP is next to Schlemm's canal and is called the juxtacanalicular tissue (JCT) or cribriform region. [00151] EV complexes can be synthesized by contacting EVs with reagents to form larger structures. Reagents can include fixatives, cross linkers, and buffer suspensions. Synthesized EV complexes may be composed of many EVs contacting each other to form aggregates.
[00152] In a synthesized EV complex, the number of EVs contacting each other can be from about 5 to about 300, or from 10 to 300, or from 10 to 200, or from 10 to 100, or from 10 to 50, or from 10 to 40, or from 10 to 20.
[00153] In a synthesized EV complex, the number of EVs contacting each other can be from 20 to 300, or from 30 to 300, or from 40 to 300, or from 50 to 300.
[00154] In a synthesized EV complex, the number of EVs contacting each other can be from 20 to 200, or from 20 to 100, or from 30 to 200, or from 30 to 100, or from 40 to 200, or from 40 to 100, or from 50 to 200, or from 50 to 100.
[00155] In additional embodiments, a synthesized EV-complex can have a size from about 360 nm to about 25,000 nm, or 360 nm to 21,000 nm, or 360 nm to about 10,000 nm, or 360 nm to about 5,000 nm, or 360 nm to about 3,000 nm, or 360 nm to about 2,000 nm, or 360 nm to about 1,000 nm. [00156] In some embodiments, synthesized EV-complexes can provide particles of a size for a uveal meshwork. Synthesized EV-complexes for a uveal meshwork can be about 10,000 nm to about 25,000 nm, or 15,000 nm to 25,000 nm, or 20,000 nm to 25,000 nm.
[00157] In further embodiments, synthesized EV-complexes can provide particles of a size for a corneoscleral meshwork. Synthesized EV-complexes for a corneoscleral meshwork can be about 1,000 nm to about 15,000 nm, or 2,000 nm to 10,000 nm, or 2,000 nm to 5,000 nm. [00158] In additional embodiments, synthesized EV-complexes can provide particles of a size for a juxtacanalicular meshwork. Synthesized EV-complexes for a juxtacanalicular meshwork can be about 360 nm to about 1,000 nm, or 360 nm to 2,000 nm, or 260 nm to 3,000 nm, or 1,000 nm to 3,000 nm.
Synthesis and purification of extracellular vesicles and EV-complexes [00159] In some embodiments, extracellular vesicles including exosomes and EV- complexes can be synthesized, isolated, and/or purified by size exclusion chromatography or gel filtration chromatography.
[00160] In certain embodiments, extracellular vesicles including exosomes and EV- complexes can be synthesized, isolated, and/or purified by centrifugation, differential centrifugation, density gradient centrifugation, or ultracentrifugation. [00161] In additional embodiments, extracellular vesicles including exosomes and EV- complexes can be synthesized, isolated, and/or purified using precipitation reagents, for example polymeric precipitation reagents, protamine, sodium acetate, or organic solvents. [00162] In some embodiments, extracellular vesicles including exosomes and EV- complexes can be synthesized, isolated, and/or purified using immunoaffmity capture techniques.
[00163] In further embodiments, extracellular vesicles including exosomes and EV- complexes can be synthesized, isolated, and/or purified using microfluidic devices, acoustic fluidic devices, and microfluidic chips.
[00164] In additional embodiments, extracellular vesicles including exosomes and EV- complexes can be synthesized, isolated, and/or purified using sequential filtration techniques.
[00165] In further embodiments, extracellular vesicles including exosomes can be detected by resistive pulse sensing using a tunable pore sensor, or tunable resistive pulse sensing.
[00166] In certain embodiments, extracellular vesicles including exosomes can be detected by electron microscopy, light microscopy and flow cytometry.
[00167] In additional embodiments, extracellular vesicles including exosomes can be detected by dynamic light scattering and/or mass spectrometry.
[00168] In some aspects, extracellular vesicles including exosomes and EV-complexes can be synthesized, isolated, and/or purified by first isolating the vesicles from cell culture. [00169] In certain aspects, extracellular vesicles including exosomes and EV-complexes can be synthesized, isolated, and/or purified by first isolating the vesicles from bodily fluids, such as ocular humor. The isolated vesicles can be diluted, filtered and protected with protease inhibitors.
[00170] In further embodiments, steps for purification of extracellular vesicles including exosomes and EV-complexes include contacting with a fixative.
[00171] In some aspects, extracellular vesicles including exosomes can be synthesized by controlled biogenesis and release from in vitro grown cell lines. Active agents
[00172] Examples of active agents include small molecule drugs, proteins, nucleic acids, polysaccharides, biologies, and combinations thereof.
[00173] Examples of active agents include cytokines, growth factors, proteins, peptides, anti-metabolites, signaling modulators, antibiotics, antibodies, chemotherapeutic compounds, and combinations thereof.
[00174] Examples of active agents include antiinfective agents, anesthetic agents, anti- VEGF agents, anti-inflammatory agents, an intraocular pressure reducing agent, and combinations thereof.
[00175] Examples of active agents include anesthetics, analgesics, and combinations thereof.
[00176] Examples of active agents include cell transport or mobility impending agents such as colchicine, vincristine, cytochalasin B, and combinations thereof.
[00177] Examples of active agents include antiglaucoma drugs.
[00178] Examples of active agents include beta-blockers such as timolol, betaxolol, atenolol, prostaglandins, and combinations thereof.
[00179] Examples of active agents include lipid-receptor agonists or prostaglandin analogues such as bimatoprost, travoprost, tafluprost, latanoprost, unoprostone, and combinations thereof.
[00180] Examples of active agents include alpha-adrenergic agonists including brimonidine, dipivefrine, and combinations thereof.
[00181] Examples of active agents include carbonic anhydrase inhibitors such as acetazolamide, methazolamide, dichlorphenamide, diamox, and combinations thereof. [00182] Examples of active agents include and neuroprotectants such as nimodipine. [00183] Examples of active agents include agents for dry AMD such as rapamycin, glatiramer acetate, complement C5aR blocker, ciliary neurotrophic factor, fenretinide, rheopheresis, and combinations thereof.
[00184] Examples of active agents include agents for wet AMD such as mecamylamine; VEGF trap eye, complement inhibitor POT-4.
[00185] Examples of active agents include kinase inhibitors such as bevacizumab, BIBW 2992, cetuximab, imatinib, trastuzumab, gefitinib, ranibizumab, pegaptanib, sorafenib, dasatinib, sunitinib, erlotinib, nilotinib, lapatinib, panitumumab, vandetanib, E7080, and combinations thereof.
[00186] Examples of active agents include antibiotics such as tetracycline, chlortetracycline, bacitracin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, gentamycin, and erythromycin.
[00187] Examples of active agents include antibacterials such as sulfonamides, sulfacetamide, sulfamethizole and sulfisoxazole.
[00188] Examples of active agents include anti-fungal agents such as fluconazole, nitrofurazone, amphotericin B, and ketoconazole.
[00189] Examples of active agents include anti-viral agents such as trifluorothymidine, acyclovir, ganciclovir, DDI, AZT, foscamet, vidarabine, trifluorouridine, idoxuridine, ribavirin, protease inhibitors, and anti-cytomegalovirus agents.
[00190] Examples of active agents include antiallergenics such as methapyriline; chlorpheniramine, pyrilamine and prophenpyridamine.
[00191] Examples of active agents include anti-inflammatories such as hydrocortisone, dexamethasone, fluocinolone, prednisone, prednisolone, methylprednisolone, fluorometholone, betamethasone and triamcinolone.
[00192] Examples of active agents include decongestants such as phenylephrine, naphazoline, and tetrahydrazoline; miotics, and muscarinics.
[00193] Examples of active agents include anti-cholinesterases such as pilocarpine, carbachol, di-isopropyl fluorophosphate, phospholine iodine, and demecarium bromide. [00194] Examples of active agents include mydriatics such as atropine sulfate, cyclopentolate, homatropine, scopolamine, tropicamide, eucatropine.
[00195] Examples of active agents include sympathomimetics such as epinephrine. [00196] Examples of active agents include ranibizumab, bevacizamab, and triamcinolone. [00197] Examples of active agents include antiinflammatories, such as non-steroidal anti inflammatories (NSAID) including acetylsalicylic acid, ibuprofen, indomethacin; and COX-2 inhibitors.
[00198] Examples of active agents include immunosuppressive agents including sirolimus. [00199] Examples of active agents include matrix metalloproteinase (MMP) inhibitors such as tetracycline.
[00200] Examples of active agents include anticlotting agents such as heparin, antifibrinogen, fibrinolysin, and anti-clotting activase.
[00201] Examples of active agents include antidiabetic agents including acetohexamide, chlorpropamide, glipizide, glyburide, tolazamide, tolbutamide, insulin, and aldose reductase inhibitors.
[00202] Examples of active agents include amines such as Thonzonium.
[00203] Examples of active agents include detergents such as Taurocholic acid, Glycocholic acid, Glycochenodeoxycholic Acid, Benzalkonium, Cetylpyridinium, Taurochenodeoxycholic acid, Polidocanol, and Tyloxapol.
[00204] Examples of active agents include lipids such as Sodium lauryl sulfate.
[00205] Examples of active agents include antibacterials such as Polymyxin B.
[00206] Examples of active agents include amines such as Thonzonium and related compounds Thonzylamine, mepyramine and Piribedil.
[00207] Examples of active agents include Ophthalmics such as Aceclidine, Acetazolamide, Acetylcysteine, Acyclovir, Aflibercept, Alcaftadine, Alclometasone, Alteplase, Ampicillin, Anecortave, Ascorbic acid, Atropine, Azelastine, Azithromycin, Befunolol, Bendazac, Benzylpenicillin, Besifloxacin, Betamethasone, Betaxolol, Bibrocathol, Bimatoprost, Brimonidine, Brinzolamide, Bromfenac, Carbamoylcholine, Carteolol, Cefuroxime, Cenegermin, Chloramphenicol, Chlorhexidine, Chlortetracycline, Chymotrypsin, Cinchocaine, Ciprofloxacin, Clobetasone, Clonidine, Cocaine, Cortisone, Cromoglicic acid, Cyclopentolate, Cyclosporine, Cysteamine, Dapiprazole, Demecarium, Desonide, Dexamethasone, Dexpanthenol, Dibrompropamidine, Diclofenac, Diclofenamide, Dihydrostreptomycin, Dipivefrin, Dorzolamide, Echothiophate, Edetate sodium, Emedastine, Ephedrine, Epinastine, Epinephrine, Erythromycin, Ethylmorphine, Famciclovir, Fludrocortisone, Fluocinolone acetonide, Fluocortolone, Fluorescein, Fluorometholone, Flurbiprofen, Fomivirsen, Formocortal, Framycetin, Fusidic acid, Ganciclovir, Gatifloxacin, Gentamicin, Guaiazulen, Guanethidine, Heparin, Hexamidine, Homatropine, Hyaluronic acid, Hydrocortisone, Hypromellose, Ibopamine, Idoxuridine, Indomethacin, Inosine, Kanamycin, Ketorolac, Ketotifen, Latanoprost, Levobunolol, Levocabastine, Levofloxacin, Lidocaine, Lifitegrast, Lodoxamide, Lomefloxacin, Loteprednol, Medrysone, Methazolamide, Methscopolamine, Methylprednisolone, Metipranolol, Micronomicin, Moxifloxacin, Nandrolone, Naphazoline, Natamycin, Nedocromil, Neomycin, Neostigmine, Nepafenac, Netarsudil, Netilmicin, Nitrofural, Norfloxacin, Ocriplasmin, Ofloxacin, Olopatadine, Oxybuprocaine, Oxymetazoline, Oxyphenbutazone, Oxytetracycline, Paraoxon, Pegaptanib, Phenylephrine, Physostigmine, Picloxydine, Pilocarpine, Piroxicam, Polymyxin B, Potassium Iodide, Povidone-iodine, Pranoprofen, Prednisolone, Procaine, Propamidine, Propanoic acid, Proparacaine, Ranibizumab, Resorcinol, Riboflavin, Rifamycin, Rimexolone, Rose bengal free acid, Salicylic acid, Scopolamine, Sirolimus, Sodium borate, Spaglumic Acid, Sulfacetamide, Sulfadicramide, Sulfamethizole, Sulfaphenazole, Sulfisoxazole, Synephrine, Tafluprost, Tetracaine, Tetracycline, Tetryzoline, Timolol, Tobramycin, Travoprost, Triamcinolone, Trifluridine, Tropicamide, Tyrothricin, Unoprostone, Verteporfin, Vidarabine, Vitamin A, and Xylometazoline.
[00208] Examples of active agents include anti-cancer agents such as 5-fluorouracil, adriamycin, asparaginase, azacitidine, azathioprine, bleomycin, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, cyclosporine, cytarabine, dacarbazine, dactinomycin, daunorubicin, doxorubicin, estramustine, etoposide, etretinate, filgrastin, floxuridine, fludarabine, fluorouracil, fluoxymesterone, flutamide, goserelin, hydroxyurea, ifosfamide, leuprolide, levamisole, lomustine, nitrogen mustard, melphalan, mercaptopurine, methotrexate, mitomycin, mitotane, pentostatin, pipobroman, plicamycin, procarbazine, sargramostin, streptozocin, tamoxifen, taxol, teniposide, thioguanine, uracil mustard, vinblastine, vincristine and vindesine.
[00209] Examples of active agents include hormones, peptides, steroids, nucleic acids, saccharides, lipids, glycolipids, and glycoproteins.
[00210] Examples of active agents include endocrine hormones such as pituitary, insulin, insulin-related growth factor, thyroid, and growth hormones.
[00211] Examples of active agents include heat shock proteins.
[00212] Examples of active agents include immunological response modifiers such as muramyl dipeptide, cyclosporins, interferons, interleukin-2, cytokines, tacrolimus, tumor necrosis factor, pentostatin, thymopentin, transforming factor beta2, and erythropoietin. [00213] Examples of active agents include brain nerve growth factor (BNGF), ciliary nerve growth factor (CNGF), and vascular endothelial growth factor (VEGF).
[00214] Examples of active agents include anti-coagulants, anti-proliferatives, quinoxalines, and potassium channel blockers.
[00215] Examples of active agents include guanylate cyclase inhibitor, such as methylene blue, butylated hydroxyanisole, N-methylhydroxylamine, 2-(4-methylaminobutoxy) diphenylmethane, and apraclonidine.
[00216] Examples of active agents include prostaglandins such as metabolite derivatives of arachidonic acid.
[00217] Examples of active agents include sugars, such as trehalose.
[00218] Examples of active ingredients include viscoelastic agents including hyaluronic acid, dimethicone, and Hypromellose.
[00219] Examples of active ingredients include ophthalmic viscosurgical devices, sodium hyaluronate, chondroitin sulfate, hydroxypropyl methycellulose, hydroxy-propyl- methylcellulose, hyaluronic acid, dimethicone, and hypromellose.
[00220] Examples of active agents include detergents, purifying or cleansing agents, for example salts of long-chain aliphatic bases or acids, which can have cleansing, oil dissolving, and/or antimicrobial effects. Examples of active agents include Glycochenodeoxycholic Acid, Glycocholic acid, Peanut oil, Benzalkonium, Cetylpyridinium, Taurochenodeoxycholic acid, Polidocanol, Tyloxapol, Taurocholic acid, and N-Dodecyl-N,N-Dimethyl-3-Ammonio-l-Propanesulfonate.
[00221] Embodiments of this invention further contemplate use of active agents for treating glaucoma disorders. In some aspects, a glaucoma disorder may be treated by administering a surface active agent for affecting EV-complexes. An effective amount a surface active agent can be administered for ameliorating, alleviating, inhibiting, lessening, delaying, and/or preventing at least one symptom or condition of a glaucoma disorder. As used herein, the term surface active agent refers broadly to surfactants, detergents, purifying or cleansing agents, soaps, and modified variations thereof.
[00222] Examples of active agents include surfactants including Lucinactant, Calfactant, Beractant, Tyloxapol, Sodium lauryl sulfoacetate, Thonzonium, Nonoxynol-9 Cetalkonium, Dimethicone, Polyethylene glycol 400, Sinapultide, Palmitoyloleoyl-phosphatidylglycerol, Lapyrium, Sodium Lauryl Sulfate (SLS), Polyethylene glycol 300, Trolamine, Polysorbate 80, Poloxamer 407, Sodium tetradecyl sulfate, Polysorbate 20, Docusate, Poractant alfa, Colfosceril palmitate, Castor oil, Benzalkonium, N-alkyl ethylbenzyl dimethyl ammonium (cl2-cl4), Quaternium-15, Ambroxol, Pumactant, Ethanolamine, Lecithin, soybean, and Cocamidopropyl betaine.
[00223] Examples of active agents include agents as described herein can be modified for delivery or metabolic acceptability, or can be PEGylated with a polyethylene glycol chain, or have a polypropylene glycol chain attached. This disclosure includes the agents described above as modified active agents, or PEGylated, or with other chain modifications.
[00224] Examples of active agents include antibodies, antibody fragments, VEGF inhibitors, small molecules, corticosteroids, and combinations thereof.
[00225] Examples of active agents include tyrosine kinase inhibitors, monoclonal antibodies, and combinations thereof.
[00226] Examples of active agents include antibodies and antibody fragments. The term "antibody" as referred to herein includes whole antibodies, e.g., two heavy chains and two light chains, antibody binding fragments thereof, e.g., single chain antibodies (scFv), single domain antibodies, e.g., nanobodies or Fv, Fab, Fab’, F(ab’)2, and, variants thereof, e.g., tandem scFv, Fd fragments, diabodies, triabodies. Antibody fragments may be obtained using conventional techniques known to those of skill in the art, and the fragments may be used in the same manner as intact antibodies.
[00227] Antibody and antibody fragments as disclosed herein can be mono-valent, bi valent, or tri-valent with regard to binding domains, and the binding domains may be mono-specific, bi-specific, or tri-specific in binding specificity by design. Suitable antibodies include monoclonal antibodies or a polyclonal antibody mixture. The antibody may be a chimeric antibody, a CDR-grafted antibody, a humanized antibody or an antigen binding portion of any of the foregoing thereof. Therapeutic antibodies may be derived from a variety of species, including, without limitation, mouse, human, camel, llama, goat, rabbit, bovine, and cartilaginous fish.
[00228] In some embodiments, an antibody or antigen binding fragment thereof can be used for the treatment of an ocular disease or condition. Examples of antibodies or antigen binding fragments include those that bind to and preferentially block or reduce the activity of integrins associated with disease, such as an anti-avP3 integrin antibody and an anti- a4b1 integrin antibody, anti-epidermal growth factor receptor antibody, anti-vascular endothelial growth factor (VEGF) receptor antibody, anti-VEGF antibodies, e.g., bevacizumab, ranibizumab, anti-TNFa antibodies, e.g., infliximab and adalimumab, an anti-fibroblast growth factor antibody, an anti-epidermal growth factor antibody, an anti- CD20 antibody, an anti-CD52 antibody, an anti-CDl la antibody, and anti-IL-2 antibody. [00229] In further embodiments, a therapeutic protein can be an antibody mimetic. [00230] As used herein, the term “antibody mimetic” encompasses any organic compound, e.g., a peptide or polypeptide, that can specifically bind an antigen like an antibody and is about 3-20 kDa. An antibody mimetic may comprise a scaffold which binds its target antigen via amino acids in exposed loops similar to the CDR loops of an antibody. Antibody mimetics include adnectins, lipocalins, Kunitz domain-based binders, avimers, knottins, fynomers, atrimers, and cytotoxic T-lymphocyte associated protein-4 (CTLA4)-based binders. Some examples are given in Weidle et ak, The Emerging Role of New Protein Scaffold-based Agents for the Treatment of Cancer , Cancer Genomics & Proteomics 10:155-168 (2013).
[00231] Examples of active agents include agents used for Parkinson’s such as Benzatropine, Ropinirole, Tolcapone, Trihexyphenidyl, Procyclidine, Pramipexole, Entacapone, Biperiden, Amantadine, Selegiline, Bromocriptine, Levodopa, Dexetimide, Piribedil, Budipine, Melevodopa, Profenamine, Cabergoline, Lisuride, Progabide, Gabapentin, Memantine, Orphenadrine, 3,5-Dinitrocatechol, Pimavanserin, Ifenprodil, Opicapone, Benserazide, Metixene, Apomorphine, Pergolide, Rasagiline, Rotigotine, Etilevodopam, Tropatepine, Dihydroergocryptine, Phenglutarimide, Mazaticol, Etybenzatropine, Bornaprine, Etanautine, Carbidopa, Safmamide, and Dexpramipexole [00232] [0002] Examples of active agents include prostaglandins such as
Epoprostenol, Dinoprost, Carboprost tromethamine, Dinoprost tromethamine, Dinoprostone, Prostaglandin D2, Prostalene, Reidispongiolide C, Unoprostone, Gemeprost, Limaprost, Iloprost, Latanoprost, Cloprostenol, Sepetaprost, Bimatoprost, Fenprostalene, Latanoprostene Bunod, Travoprost, Carboprost Tromethamine, Dinoprost, Tafluprost, Cabazitaxel, Cloprostenol Sodium, Bimatoprost, (-)-Corey Lactone 4- Phenylbenzoate Alcohol, Dutasteride, Isopropyl Unoprostone, Beraprost Sodium, Prostaglandin El, Cloprostenol, Remodulin, Trenbolone Cyclohexylmethylcarbonate, Prostaglandin F2a, Iloprost, Misoprostol Acid, Gemeprost, 9-deoxy-9-methylene-16, 16- dimethyl Prostaglandin E2, Enoprostil, Ornoprostil, epoprostenol, Sulprostone, Iloprost, Rosaprostol, (+)-Cloprostenol sodium, Carboprost tromethamine, Carboprost, Misoprostol, Prostacyclin sodium salt, Prostaglandin E2, and Limaprost.
[00233] Examples of active agents include vitamins such as 1-alpha, 25-dihydroxyl-20- epi-22-oxa-24, 26 ,27-trihomovitamin D3.
[00234] Examples of active agents include antibotics such as Brefeldin A, Fusidic acid, Ovalicin, Narasin, and Salinomycin.
[00235] Examples of active agents include steroids such as Hydrocortisone cypionate, Hydrocortisone valerate, Hydrocortisone butyrate, Hydrocortisone probutate, Hydrocortisone aceponate, Prednisolone tebutate, Trilostane Hydrocortisone acetate, Cholesteryl Linoleate, Methylprednisolone aceponate, Eldecalcitol Pregnenolone acetate, Testosterone propionate Drospirenone Clascoterone Norethindrone enanthate, Prednisolone hemisuccinate, Hydroxyprogesterone caproate, Trenbolone acetate, Fluprostenol Anecortave acetate Oleandrin Cortisone acetate, Calcipotriol Gestodene Dimethyl carbate, Calcipotriol lalpha,24S-Dihydroxyvitamin D2, Ethynodiol diacetate, Nandrolone decanoate, Testosterone cypionate, Testosterone undecanoate, Carbenoxolone, progesterone- 11-alpha-ol-hemisuccinate, Eplerenone, Testosterone succinate, and Boldenone undecylenate.
[00236] Examples of active agents include statins such as Lovastatin, atorvastatin, pravastatin, rosuvastatin, fluvastatin, and simvastatin.
[00237] Examples of active agents include aggregation inhibitors such as Pentoxifylline, Argatroban, and Von Willebrand Factor Human.
[00238] Examples of active agents include prostacyclin such as Treprostinil.
[00239] Examples of active agents include amyloid targeting agents such as caprospinol and similar compounds including Cholesteryl Linoleate, Pregnenolone acetate, and P- 57AS3.
[00240] Examples of active agents include lactones such as Reidispongiolide A and Soraphen A, and Canrenone. [00241] Examples of active agents include Benzoquinones such as Antroquinonol.
[00242] Examples of active agents include Oxepanes such as Triptolide PG-701.
[00243] Examples of active agents include Lipids such as gibberellin A4 and Fumagillin. [00244] Examples of active agents include blood glucose lowering agents such as Mitiglinide.
[00245] Examples of active agents include central nervous system depressant such as Glutethimide.
[00246] Examples of active agents include benzenoids such as sildenafil, udenafil, and vardenafil.
[00247] Examples of active agents include carbohydrates such as Fusicoccin and treholose.
[00248] Examples of active agents include Cholinergic Agents such as Biperiden, Cycrimine, Procyclidine, and Trihexyphenidyl.
[00249] Examples of active agents include Terpenes such as Cyclohexanes.
[00250] The molecules, compounds and/or compositions of this disclosure may be asymmetric, having one or more chiral stereocenters. A compound containing one or more chiral centers can include substances described as an "isomer," a "diastereomer," a "stereoisomer," an "optical isomer," an "enantiomer," or as a "racemic mixture." Conventions for stereochemical nomenclature, for example the stereoisomer naming rules of Cahn, Ingold and Prelog, as well as methods for the determination of stereochemistry and the separation of stereoisomers are known in the art. See, e.g., March’s Advanced Organic Chemistry (7th ed., 2013). The compounds, composition and structures of this disclosure are intended to encompass all possible isomers, stereoisomers, diastereomers, enantiomers, and/or optical isomers that exist for the compound, composition and/or structure, including any mixture, racemate, or racemic or other mixtures thereof.
[00251] A compound can exist in un-solvated and solvated forms, or hydrated forms. In this disclosure, solvated forms, with pharmaceutically acceptable solvents, such as water or ethanol, are to be taken as equivalent to the un-solvated forms. Compounds and salts, or solvates thereof, may also exist in tautomeric forms, which are to be taken as equivalent. [00252] The molecules, compounds and/or compositions of this disclosure may be found in different crystalline forms, which are intended to be encompassed by this disclosure. Compositions and formulations
[00253] An active agent of this disclosure can include drugs and agents for diseases of the eye, including small molecule drugs, peptides, antibodies and protein agents.
[00254] A formulation of an active agent may be prepared by dissolving a composition in water to produce an aqueous solution and rendering the solution sterile.
[00255] A formulation of this disclosure can be in the form of a sterile injectable aqueous or oily suspension. A suspension can be formulated including a dispersing or wetting agent. A sterile injectable preparation can be a sterile injectable solution or suspension in a non-toxic, pharmaceutically acceptable diluent or solvent.
[00256] Examples of solvents include water, water for injection, Ringer's solution, balanced salt saline, isotonic sodium chloride solution, 1,3-butanediol, synthetic mono-or diglycerides, and fatty acids such as oleic acid.
[00257] A formulation of this disclosure can be in the form of eye drops for topical delivery.
[00258] An ophthalmic formulation can be a solution or suspension for topical administration. A composition can be a viscous or semi-viscous gel, or other solid or semi solid compositions.
[00259] An ophthalmic formulation can be locally delivered by direct injection or by use of an infusion pump.
[00260] An ophthalmic formulation can include artificial tears carriers.
[00261] An ophthalmic formulation can include a phospholipid carrier.
[00262] An ophthalmic formulation can include a surfactant, a preservative, an antioxidant, a tonicity adjusting excipient, a buffer, a co-solvent, and a viscosity excipient. [00263] An ophthalmic formulation may include an excipient to adjust osmolarity of the formulation.
[00264] An ophthalmic formulation can include a viscosity excipient such as a polysaccharide, hyaluronic acid, chondroitin sulfate, a dextran, a cellulose polymer, a vinyl polymer, and an acrylic acid polymer.
[00265] An ophthalmic formulation may have a viscosity of from 1 to 400 centipoises, or from 1 to 100 centipoises, or from 2 to 40 cps. An ophthalmic formulation may have a viscosity of about 15, 20, 25, 30, 40, or 50 centipoises. [00266] Examples of excipients or carriers for a formulation of this invention include ophthalmologically acceptable preservatives, viscosity enhancers, penetration enhancers, buffers, sodium chloride, sterile water, water for injection, and combinations thereof. [00267] A dosage form of a composition of this invention can be liquid or an emulsion.
A dosage form of the composition of this invention can be solid, which can be reconstituted in a liquid prior to administration.
[00268] A composition of this disclosure can also be in the form of an oil-in-water emulsion. The oily phase can be a vegetable oil or a mineral oil.
[00269] Examples of emulsifying agents include naturally-occurring gums, gum acacia, gum tragacanth, phosphatides, esters of fatty acids, hexitol, sorbitan monooleate, and polyoxyethylene sorbitan monooleate.
[00270] Embodiments of this invention can advantageously provide effective activity of an active agent at dosage levels significantly lower than conventional dosage levels.
[00271] An effective amount of an active agent composition of this disclosure can be an amount sufficient to ameliorate or reduce a symptom of the disease treated.
[00272] A composition may be administered as a single dosage or may be administered in a regimen with repeated dosing.
[00273] An appropriate dosage level of an active agent can be determined by a skilled artisan. In some embodiments, an active agent can be present in a composition in an amount from about 0.001% to about 40%, or from about 0.01 % to about 20%, or from about 0.1% to 10% by weight of the total formulation.
[00274] An active agent of this disclosure can be combined with one or more pharmaceutically acceptable carriers. A carrier can be in a variety of forms including fluids, viscous solutions, gels, or solubilized particles. Examples of carriers include pharmaceutically acceptable diluents, solvents, saline, and various buffers.
[00275] Some examples of carriers, excipients and additives are given in U.S. Pharmacopeia National Formulary (2014); Handbook of Pharmaceutical Excipients (7th ed., 2013); Handbook of Preservatives (2004, Synapse Information Resources);
Remington: The Science and Practice of Pharmacy (22nd ed. 2013); Remington's Pharmaceutical Sciences (Mack Publishing Co. 1990). Some examples of drugs and delivery are given in Goodman and Gilman, The Pharmacological Basis of Therapeutics (13th ed. 2018, McGraw Hill, NY).
[00276] In certain embodiments, an active agent may be delivered without a carrier for reducing extracellular vesicle complexes in glaucoma ocular humor.
[00277] Examples of carriers include pyrogen free water; isotonic saline, Ringer's solution, ethyl alcohol, and phosphate buffer solution.
[00278] A formulation of this disclosure may include a polymer such as a polyethylene glycol (PEG), polypropylene glycol, or poly(lactic-co-glycolic acid) having a molecular weight of about 0.2 to about 50 kDa.
[00279] Examples of carrier polymers include polyvinyl acetate, polyvinyl alcohol, polyvinylpyrrolidone, chitosan, collagen, sodium alginate, gelatin, hyaluronic acid, polylactic acid, poly(lactic acid-glycolic acid) copolymer, polyhydroxybutyric acid, poly(hydroxybutyric acid-glycolic acid) copolymer, cellulose, hydroxymethylcellulose, hydroxypropylcellulose, fatty acid esters, and polyglycerins.
[00280] Examples of additives include saccharides, sucrose, mannitol, lactose, L- arabinose, D-erythrose, D-ribose, D-xylose, D-mannose, D-galactose, lactulose, cellobiose, gentibiose, glycerin, polyethylene glycol, N-methylpyrrolidone, oligovinyl alcohol, ethanol, ethylene glycol, and propylene glycol.
[00281] Examples of solubility enhancing agents include cyclodextrins.
[00282] A formulation can include galactose, lactose, mannitol, monosaccharide, fructose, maltose, galactose, glucose, D-mannose, sorbose, disaccharide, lactose, sucrose, trehalose, cellobiose, polysaccharide, maltodextrin, dextran, starch, mannitol, or xylitol. [00283] An ophthalmic formulation may include a lipid such as dipalmitoylethylphosphocholine, dioleoyl phosphatidylethanolamine, or 3B-[N-(N',N'- Dimethylaminoethane)-carbamoyl] cholesterol.
[00284] An ophthalmic formulation may include a lipid such as 1,2-Dioleoyl-sn-Glycero- 3-[Phospho-L-Serine], l,2-Dioleoyl-sn-Glycero-3 -Phosphate.
[00285] An ophthalmic formulation may include a lipid such as 1,2-Dipalmitoyl-sn- Glycero-3-Phosphocholine, distearoylphosphatidylcholine, diarachidoylphosphatidylcholin, dipalmitoyl phosphatidylethanolamine. [00286] An ophthalmic formulation may include a fatty acid, oleic acid, myristoleic, or aracadonic acid.
[00287] An ophthalmic formulation may include a phospholipid such as phosphatidylcholine, lecithin, phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, and phosphatidylethanolamine.
[00288] An ophthalmic formulation may include a polymer such as polyvinylpyrrolidone, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, hydroxyethylstarch, cyclodextrin, 2-hydroxypropyl-P-cyclodextrin, sulfobutylether-b- cyclodextrin, polyethylene glycol, pectin, poly(lactide-co-glycolide), polylactide, polyethylene imine, or poly-L-lysine.
[00289] In some embodiments, an ophthalmic formulation may include one or more of a pH adjusting excipient, a buffering excipient, a tonicity excipient, a viscosity excipient, or a wetting excipient. In certain embodiments, an ophthalmic formulation may include an acidifying excipient, a preservative, an antioxidant, a solubilizing excipient, a humectant, or a suspending excipient.
[00290] An ophthalmic formulation may include additives, diluents, delivery vehicles, or carrier materials such as a polymer, a polyethylene glycol, a dextran, a diethylaminoethyl dextran, a cyclodextrin, or a carboxymethyl cellulose.
[00291] Examples of excipients include sodium chloride, sodium dihydrogen phosphate monohydrate, and disodium hydrogen phosphate anhydrous.
[00292] Examples of formulation additives include vegetable oils, olive oil, sesame oil, coconut oil, mineral oil, and paraffin.
[00293] Examples of dispersing or wetting agents include lecithin, polyoxyethylene stearate, heptadecaethyleneoxycetanol, polyoxyethylene sorbitol monooleate, and polyethylene sorbitan monooleate.
[00294] Examples of antioxidants include ascorbic acid, cysteine hydrochloride, sodium bisulfite, sodium metabisulfite, sodium sulfite, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, lecithin, propyl gallate, alpha-tocopherol, citric acid, ethylenediamine tetraacetic acid, sorbitol, tartaric acid, and phosphoric acid.
[00295] Examples of formulation additives include a thickening agent, for example beeswax, paraffin, or cetyl alcohol. [00296] Examples of formulation excipients include a suspending excipient, sodium carboxymethylcellulose, methylcellulose, hydropropyl-methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth, or gum acacia.
[00297] An ophthalmic formulation may include a carrier or co-solvent such as Polysorbate 20, 60 or 80, Pluronic F-68, F-84 or P-103, Tyloxapol, Cremophor, sodium dodecyl sulfate, glycerol, PEG 400, propylene glycol, cyclodextrin, and combinations thereof. A carrier or co-solvent can be used in concentrations from about 0.01% to about 2% by weight.
[00298] An ophthalmic formulation may include a gel excipient such as gellan, xanthan gum, and combinations thereof.
[00299] An ophthalmic formulation may include a viscosity enhancer such as polyvinyl alcohol, methyl cellulose, hydroxy propyl carboxymethyl cellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, polyvinylpyrrolidone, and combinations thereof. A viscosity enhancer can be used in concentrations from about 0.01% to about 2% by weight.
[00300] An ophthalmic formulation may include a preservative such as benzalkonium chloride, chlorobutanol, benzododecinium bromide, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, onamer, polyquaternium-1, hydroxybenzoate, sodium benzoate, phenol, cresol, p-chloro-m-cresol, benzyl alcohol, thimerosal, sorbic acid, benzethonium chloride, and combinations thereof. A preservative can be used in concentrations from about 0.001% to about 1.0% by weight.
[00301] A unit dose composition can be sterile, but may not contain a preservative. [00302] An ophthalmic formulation may include a pH adjusting excipient such as citric acid buffer, acetic acid buffer, succinic acid buffer, malic acid buffer, and gluconic acid buffer.
[00303] An ophthalmic formulation may include an additional acid such as hydrochloric acid, or and additional base, such as sodium hydroxide for pH adjustment.
[00304] Examples of pH control agents include arginine, sodium hydroxide, glycine, hydrochloric acid, and citric acid. [00305] An ophthalmic formulation may include a buffer such as citric acid, ascorbic acid, gluconic acid, carbonic acid, tartaric acid, succinic acid, acetic acid, phthalic acid, tris, tromethamine hydrochloride, and phosphate buffer.
[00306] An ophthalmic formulation may include a surfactant.
[00307] Examples of a surfactant include nonionic surfactants, polysorbate-80, polysorbate-20, polysorbates, sorbitan esters, a lipid, a phospholipid, lecithin, a phosphatidylcholine, a phosphatidylethanolamine, a phosphatidylglycerol, a fatty acid, a fatty ester, a cholesterol.
[00308] Examples of surfactants include oleic acid, sorbitan trioleate, and long chain diglycerides.
[00309] Examples of surfactants include beractant, poractant alfa, and calfactant.
[00310] An ophthalmic formulation may include a tonicifier tonicity adjusting excipient. [00311] Examples of a tonicity adjusting excipient, isotonizing excipient, include sodium chloride, mannitol, and sorbitol.
[00312] Examples of a tonicity adjusting excipient include sugars, polyols, amino acids, and organic and inorganic salts.
[00313] Embodiments of this invention include kits containing any of reagents, pharmaceutical excipients, active agents, and instructions for use.
[00314] A kit may include a container or formulation that contains one or more active agents formulated in a pharmaceutical preparation for delivery. An ophthalmic formulation kit can be a multidose form.
[00315] A kit may include a dispenser or dropping device for topical delivery and use. [00316] A kit can include one or more unit doses of a composition for delivery. A unit dose can be hermetically sealed to preserve sterility.
Sample preparation and detection of ultrastructural target
[00317] Sample preparation and processing is described. Aqueous humor or vitreous humor specimens collected for EV isolation were processed immediately without fixation. EVs were isolated from bovine vitreous humor or aqueous humor; or 4T1 cells by using ultracentrifugation protocols described below. EVs were isolated using methods described. Patients aqueous humor was NOT isolated and imaged without processing. The samples were diluted as described. [00318] Extracellular vesicle isolation and purification is described. We adapted methods for isolating extracellular vesicles from fluids. For bovine vitreous or aqueous humor, approximately 8 ml of vitreous (or 100 mΐ of aqueous humor) was placed in 15 ml tubes and centrifuged in Sorvall legend RT Swinging bucket (Sorvall) at 2,000 g (2500 rpm) at 4°C for 30 minutes. The supernatant was then transferred to a new 15 ml tube. Then the centrifugation step was repeated. The supernatant was then transferred to new tube and centrifuged at 10,000 g in a Sorvall RC-58 centrifuge (Sorvall) using an SS-34 rotor (DuPont) for 30 min at 4°C. The supernatant was then transferred and the step was repeated. The sample was transferred to an ultracentrifuge tube (Beckman) and in a swinging bucket rotor (SW-41, Beckman) and centrifuged at 100,000 g in an L7-55 ultracentrifuge (Beckman) at 4°C for 1 hour. The supernatant was transferred to a new tube. The step was repeated. Samples were resuspended in 50 mΐ of sterile tris buffered saline (TBS, pH 8) and placed in a siliconized tube. Samples for imaging were immediately processed, and remaining sample was frozen at -80 °C.
[00319] Nanoparticle tracking analysis is described. The NanoSight NS300 system (Malvern) was used to perform nanoparticle tracking analysis to characterize particles from 30 - 800 nm in solution. We re-suspended extracellular vesicles isolated from vitreous humor, aqueous humor, or 4T1 cells in 100 mΐ of tris buffered saline (TBS, pH 7.0). Particles were loaded, the camera was focused, and 5 videos were captured for 60 sec each. Videos were recorded and then analyzed using NanoSight software (Version 3.0) to determine the size distribution and particle concentration of EVs. Graphs were created. The Brownian motion of each particle is tracked between frames, ultimately allowing calculation of the size through application of the Stokes-Einstein equation.
[00320] Conventional glutaraldehyde only fixation of liquid samples for electron microscopy is described. EV solutions that were processed with conventional TEM fixation methods are referred to as, “glutaraldehyde only,” or “Glut only”. EVs were obtained and resuspended in buffered solution as described above. We obtained Formvar/carbon-coated EM grids (Electron Microscopy Sciences) and coated the surface with Poly-L-lysine solution (%, Sigma Aldrich). We applied approximately 15 mΐ of poly- L-lysine to the formvar/carbon-coated surface of the EM grid and incubated the sample in a humidified chamber for 15 min at room temperature. We removed the poly-L-lysine solution with a pipette. We allowed the grid to dry for 10 minutes at room temperature. [00321] Next, 5 pL of EV-containing solution was pipetted onto a poly-L-lysine- formvar/carbon-coated EM grid and incubated in a humidified chamber for 30 minutes at room temperature. Next, EV solution was removed with a pipette. The samples were fixed in a “glutaraldehyde fixation solution”; consisting of 2.5% glutaraldehyde, 4% paraformaldehyde, 0.02% picric acid in 0.1M sodium cacodylate buffer. We pipetted 15 mΐ of glutaraldehyde solution on the EM grid and incubated the sample for 15 min at room temperature 19. After, the glutaraldehyde fixation solution was removed with a pipette. Grids were washed with 15 mΐ of double distilled water for 5 minutes at room temperature. Samples were washed 2 times for 5 min each at room temperature. Samples were dried at room temperature and viewed on a JEM 1400 electron microscope (JEOL, USA, Inc) as described below. EDC-formalin fixed specimens were processed further as described below.
[00322] EDC-ETT solution preparation is described. Methods for EDC solution fixation were adapted from previous reportsl7, 18. We prepared 0.1 M 1-Methylimidazole buffer solution (0.1 M 1-methylimidazole, 300 mM NaCl, with an adjusted pH to 8.0 with 12 N NaOH) and stored the solution for up to 3 months at room temperature. Next, we freshly prepared the EDC solution for each experiment. We measured 0.96 ml of 0.1 M 1- Methylimidazole buffer solution and added 13 mg of 5-(Ethylthio)-lH-tetrazole (ETT, Sigma Aldrich, final concentration was 0.1 M). The pH was adjusted to 8.0 with 12 N NaOH. Next, we added 19.2 mg of l-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) (Sigma Aldrich, final concentration 0.10 M) and then readjusted the pH to 8.0 using 12 M HC1. The EDC-ETT solution was placed on ice until use.
[00323] EDC-glutaraldehyde fixation of liquid samples on electron microscopy is described. All isolated EVs were resuspended in 20 mΐ of TBS (pH 8.0) and kept at 4°C. We obtained Formvar/carbon-coated EM grids (Electron Microscopy Sciences) and coated the surface with Poly-L-lysine solution (%, Sigma Aldrich). We applied approximately 15 mΐ of poly-L-lysine to the formvar/carbon-coated surface of the EM grid and incubated the sample in a humidified chamber for 15 min at room temperature. We removed the poly-L- lysine solution with a pipette and set aside the grid in a humidified chamber until it is ready for use. Next, we combined equal parts of freshly made EDC/ETT solution and the EVs solution, by adding 5 mΐ of ice cold EDC/ETT solution with 5 mΐ of ice-cold EVs suspended in TBS (pH 8.0) into a 1.5 ml pre-chilled siliconized tube. The sample was incubated for 30 min on ice. We then applied 10 mΐ of the EDC/ETT-EV solution to the surface of the formvar/carbon-coated EM grids and incubated the sample for 30 min at 4°C in a humidified chamber. In order too active the EDC regent’s crosslinking capability, we placed the samples in a humidified chamber in an incubator for 3 h at 50°C. The samples were removed from the incubator and the EDC-solution was removed using a pipette. The samples were fixed with a secondary fixation using a glutaraldehyde-based crosslinking solution containing; 2.5% glutaraldehyde, 4% paraformaldehyde, 0.02% picric acid in 0.1M sodium cacodylate buffer and incubated for 15 min at room temperature. The glutaraldehyde solution was removed by pipetting the bubble from the EM grid. The grid was washed by placing 15 mΐ of double distilled water onto the grid and incubating for 5 minutes at room temperature. The water was removed and washed a second time. Finally, the samples were negatively stained or stained for DNA, RNA and protein as described below. For negative staining, the samples were contrasted successively in 2% uranyl acetate, pH 7, and 2% methylcellulose/0.4% uranyl acetate, pH 4. After staining with the respective stain(s), the EM grids were then mounted for imaging on the electron microscope as described below.
[00324] Transmission electron microscope imaging is described. All EM grids were viewed on a JEM 1400 electron microscope (JEOL, USA, Inc) operated at lOOkV. Digital images were captured on a Veleta 2K x 2K CCD camera (Olympus-SIS). Electron microscopy images were recorded and analyzed for size and frequency of EVs using ImageJ software.
[00325] Transmission Electron microscopy of vitreous humor and ocular tissues is described. Human or bovine vitreous tissue was obtained as described above. Samples were cleared of cells with low speed centrifugation and whole mount specimens tested with H and E staining and imaging as described below. For vitreous, 2 pL was pipetted onto a block and fixed in a solution of 2.5% glutaraldehyde, 4% paraformaldehyde, 0.02% picric acid in 0.1M sodium cacodylate buffer and incubated for 60 min at room temperaturel9. Specimens were washed with excess volume of buffer (pH 7.3) for 5 minutes each at room temperature. Samples were post-fixed with 1% 0s04-1.5% K-ferri cyanide (aqueous) for 60 min at room temperature20. Samples were washed with buffer 3 times for 5 min each at room temperature. Samples were set en bloc and stained with 1.5% uranyl acetate for 60 min at room temperature. Samples were dehydrated through graded ethanol series and transitioned through acetonitrile. Samples were infiltrated and embedded in Embed 812 resin (Electron Microscopy Sciences). Tissue sections were cut at 60-65 nm using a Diatome diamond knife (Diatome) on Leica Ultracut T ultramicrotome (Leica Microsystems). Sections were contrasted with lead citrate21 and viewed on a JEM 1400 electron microscope (JEOL, USA, Inc) operated at lOOkV. Digital images were captured on a Veleta 2K x 2K CCD camera (Olympus-SIS). Electron microscopy images were recorded and analyzed for size and frequency of EVs using ImageJ software. For TEM staining of nucleic acids, we incubated Acridine Orange stain solution (Exo-Red Exosome RNA Fluorescent Label, System Biosciences) with 5 mΐ of ultracentrifuge purified EVs for 30 min at 25°C. For ethidium bromide (EtBr) stained EVs, we mixed 5 pg/ml of EtBr solution with 5 mΐ of ultracentrifuge purified EVs for 30 min at 25°C. For protein staining on TEM, we mixed 500 mM CFSE diluted in TBS (pH 7.4) with 5 mΐ of ultracentrifuge purified EVs for 30 min at 25°C. All samples above were then fixed, mounted, and imaged with TEM as above.
[00326] Statistical analyses are described. Graph visualization and calculations were performed using Excel (version 2011, Microsoft). All experiments, unless otherwise stated, were performed with n ^ 3. For nanoparticle tracking analysis we calculated particle size, concentration, and distribution using Stokes- Einstein equation. Statistical analyses were carried out using unpaired Student’s t-test using SPSS software, and p values < 0.05 were taken to be significant.
[00327] Methods for imaging healthy control aqueous humor samples and POAG aqueous humor samples are described. Samples are shown in Table 1.
Table 1: Reagents/Samples
Figure imgf000048_0001
Figure imgf000049_0001
[00328] Methods:
[00329] For 1 mis of EDC/ETT solution in 0.1 M 1-Methylimidazole buffer (pH 8.0):
1. EDC-HC1 powder should be stored at -20 °C under argon. To avoid condensation of humidity, only open bottles after they reached room temperature, i.e. take the bottle out of freezer 1 h before weighing out sample.
2. EDC/5-ETT solution should be made at most 1 h prior to use.
3. Pipette 5.76 ml of 0.1 M 1-Methylimidazole buffer (pH 8.0) into a 15 ml tube, vortex vigorously.
4. Carefully spoon out the 0.078 g of ETT found in the "G" group, onto a piece of paper. Carefully pour the 0.078 g into the tube.
5. Tising the pH paper and pipet to check to be pH 8.0
6. Else a weighing paper to measure out 0.12 g of EDC. Carefully pour into the tube. Vortex vigorously.
7. Discard unused solution.
8. Elsing the pH paper and pipet to check to be pH 8.0
[00330] Poly L-lysine grids, EDC fixation, Glut-fixation, CIA stain
1. Use formvar coated grids.
2. Place them facing formvar side down to poly-lysine drops and let them sit for 5-10min.
3. Then you will withdraw the Poly-L-lysine
4. Fasten down a piece of parchment paper to a 100mm dish with tape or weight. Place grid down on parchment paper.
[00331] Mix EDC solution with EVs.
1. Mix 10 ul of (Cold) EVs with 10 ul of (Cold) EDC solution in 1.5 ml siliconized tube.
2. In the cold room, apply 10 mΐ sample (Aqueous humor) to the grid and wait 30 minutes to dry and for the EVs to settle to the bottom of the grid.
3. Place in a humidified chamber and incubate at 50 deg for at least 3 hours.
[00332] Secondary Fixation with Glut. 1. Remove EDC-EV solution from the sample using a pipette.
2. Fix with Glut, add 2-5 ul of glut fix and wait for 5 min
3. Remove Glut with Pipet or lens paper [00333] Rinse Glut and EDC
1. Apply water bubble to grid for 5 min
2. Remove water bubble with pipette
3. Add 5 ul of uranyl acetate onto grid (4 drops, blotting between each drop)
4. Let grid dry, and place in grid box
5. Take off stain with pipette
[00334] Imaging with TEM. Image shortly after completion at 25k (about 50 pictures) with few 50K magnifications.
[00335] Methods for treating POAG aqueous humor samples with bimatoprost, and fixation of fluid with EDC, negative staining and TEM imaging. We sought to determine the effect of bimatoprost on EVs in aqueous humor of patients with glaucoma. To do this, we diluted the POAG aqueous humor sample with tris buffered saline (1:10 dilution) and added 1:1 volume of diluted POAG sample with either tris buffered saline (control) or bimatoprost.
[00336] Lumigan was obtained directly from the dispensing bottle and was NOT diluted. 10 ul of POAG sample was mixed with lOul of TBS or lOul POAG sample was mixed with 10 ul of undiluted Lumigan. The tubes were then incubated in a thermocycler PCR machine and were allowed to sit for 72 hours at 37°C. The samples were then diluted (1:10). Next, we fixed with EDC on an electron microscopy grid using the following protocol.
[00337] For 1 mis of EDC/ETT solution in 0.1 M 1-Methylimidazole buffer (pH 8.0).
1. EDC-HC1 powder should be stored at -20 °C under argon. To avoid condensation of humidity, only open bottles after they reached room temperature, i.e. take the bottle out of freezer 1 h before weighing out sample.
2. EDC/5-ETT solution should be made at most 1 h prior to use.
3. Pipette 5.76 ml of 0.1 M 1-Methylimidazole buffer (pH 8.0) into a 15 ml tube, vortex vigorously. 4. Carefully spoon out the 0.078 g of ETT found in the "G" group, onto a piece of paper. Carefully pour the 0.078 g into the tube.
5. Using the pH paper and pipet to check to be pH 8.0
6. Use a weighing paper to measure out 0.12 g of EDC. Carefully pour into the tube. Vortex vigorously.
7. Discard unused solution.
8. Using the pH paper and pipet to check to be pH 8.0
[00338] Poly L-lysine grids, EDC fixation, Glut-fixation, UA stain.
1. Use formvar coated grids.
2. Place them facing formvar side down to poly-lysine drops and let them sit for 5-10min.
3. Then you will withdraw the Poly-L-lysine
4. Fasten down a piece of parchment paper to a 100mm dish with tape or weight. Place grid down on parchment paper.
[00339] Mix EDC solution with EVs
1. Mix 2.5 ul of (Cold) EVs with 5 ul of (Cold) EDC solution in 1.5 ml siliconized tube.
2. In the cold room, apply 5 mΐ sample (Aqueous humor) to the grid and wait 15 minutes to dry and for the EVs to settle to the bottom of the grid.
3. Place in a humidified chamber and incubate at 50 deg for at least 3 hours.
[00340] Secondary Fixation with Glut
1. Remove EDC-EV solution from the sample using a pipette.
2. Fix with Glut, add 2-5 ul of glut fix and wait for 5 min
3. Remove Glut with Pipet or lens paper [00341] Rinse Glut and EDC
1. Apply water bubble to grid for 5 min
2. Remove water bubble with pipette
3. Add 5 ul of uranyl acetate onto grid (1 drop, blotting after the drop)
4. Let grid dry, and place in grid box
5. Take off stain with pipette
[00342] Samples were then imaged with TEM.
[00343] Additional embodiments of this invention are as follows. [00344] A method of identifying glaucoma or pre-glaucoma in a subject, said method comprising: providing an aqueous humor sample from a subject potentially having glaucoma; analyzing the sample for glaucoma-associated-extracellular vesicle-complexes which are either: aggregates of extracellular vesicles, or individual extracellular vesicles having a diameter greater than 300 nanometers, or from 300 to 3,000 nm, or from 300 to 5,000 nm, or from 300 to 10,000 nm; and identifying, based on said analyzing, the subjects having glaucoma or pre-glaucoma.
[00345] The glaucoma-associated-extracellular vesicle complexes are complexes of extracellular vesicles selected from the group consisting of exomeres, exosomes, multivesicular bodies, intraluminal vesicles (ILVs), multivesicular endosomes (MVEs), oncosomes, micro-vesicles, apoptotic bodies, and vesicles originating from endosome or plasma membranes.
[00346] The glaucoma-associated extracellular vesicle complexes are complexes of individual extracellular vesicles, where the complexes may have a diameter of from 360 to 21,000 nanometers.
[00347] The glaucoma-associated extracellular vesicle complexes can be aggregates of 10, 20, 30, 40 or more extracellular vesicles.
[00348] The glaucoma-associated extracellular vesicle complexes can be aggregates of 50, 100 or 200 or more extracellular vesicles.
[00349] The method above, further comprising: fixing the glaucoma-associated extracellular vesicles in the sample prior to said analyzing. The fixing the glaucoma- associated extracellular vesicles comprises: contacting the sample with a non-reversible cross-linking agent; and contacting the sample with an aldehyde-containing fixative before, after, or at the same time as said contacting the sample with a non-reversible cross-linking agent to fix the glaucoma- associated-extracellular vesicle-complexes.
[00350] The method above, wherein the non-reversible cross-linking agent is selected from the group consisting of a water-soluble carbodiimide, cyanogen halide, and mixtures thereof.
[00351] The method above, wherein the non-reversible cross-linking agent is 1 -ethyl-3 - (3 - dimethylaminopropylj-carbodiimide. [00352] The method above, wherein the non-reversible cross-linking agent is a cyanogen halide selected from the group consisting of cyanogen bromide, cyanogen fluoride, cyanogen chloride, and cyanogen iodide.
[00353] The method above, further comprising: contacting the sample with a further cross-linking agent, independently of, and before, after, or at the same time as said contacting with said non-reversible cross-linking agent and as said contacting with said aldehyde-containing fixative, said further cross-linking agent being selected from the group consisting of ethylene glycol di(meth)acrylate, ethylene glycol diacrylate, di(ethylene glycol) diacrylate, tetra(ethyleneglycol) diacrylate, ethylene glycol dimethacrylate, di(ethylene glycol) dimethacrylate, tri(ethylene glycol) dimethacrylate, derivatives of methylenebisacrylamide, N,N- methylenebisacrylamide, N,N- methylenebisacrylamide, N,N- (l,2-dihydroxyethylene)bisacrylamide, formaldehyde-free cross- linking agents, N- (1 -hydroxy-2, 2-dimethoxyethyl)acrylamide, divinylbenzene, formalin fixatives, formal calcium, formal saline, zinc formalin (unbuffered), Zenker's fixative, Helly's fixative, B-5 fixative. Bouin's solution. Hollande's solution, Gendre's solution. Clarke' s solution, Carney's solution methacam, alcoholic formalin, and formol acetic alcohol.
[00354] The method above, wherein said analyzing comprises: imaging the fixed glaucoma-associated-extracellular vesicle-complexes.
[00355] The method above, wherein said imaging is carried out by transmission electron microscopy, scanning electron microscopy, cryoelectron microscopy, binocular stereoscopic microscopy, wide-field microscopy, polarizing microscopy, phase contrast microscopy, multi-photon. microscopy, differential interference contrast microscopy, fluorescence microscopy, laser scanning confocal microscopy, multiphoton excitation microscopy, ray microscopy, ultrasonic microscopy, color metric assay, chemiluminescence assay, spectrophotometry, positron emission tomography, computerized tomography, and magnetic resonance imaging.
[00356] The method above, further comprising: detecting the glaucoma-associated- extracellular vesicle-complexes in the aqueous humor sample based on said imaging. [00357] The method above, wherein said identifying is based on said detecting.
[00358] The method above, wherein said identifying comprises: providing a standard image of a clinical aqueous humor sample containing the glaucoma- associated- extracellular vesicle-complexes fixed with the non-reversible cross-linking agent and the aldehyde containing fixative, from a subject having glaucoma; comparing the image of the clinical sample of the subject to the standard image with regard to size, density, morphology, or spacial distribution of the fixed glaucoma-associated- extracellular vesicle- complexes; and determining if the subject has glaucoma or pre-glaucoma based on said comparing.
[00359] The method above, further comprising: administering a therapeutic agent to the subject based on said determining.
[00360] The method above, wherein the therapeutic agent reduces the size of glaucoma- associated extracellular-vesicle complexes by disrupting two or more extracellular vesicles that are in contact with each other.
[00361] The method above, wherein said identifying involves monitoring progression or regression of glaucoma and comprises: providing a prior image of a clinical aqueous humor sample of the subject, containing glaucoma-associated-extracellular vesicle-complexes fixed with a non-reversible cross-linking agent and the aldehyde containing fixative; comparing the image of the clinical aqueous humor sample of said subject containing the glaucoma-associated-extracellular vesicle-complexes fixed with the non-reversible cross- linking agent and the aldehyde containing fixative to the prior image with regard to size, density, morphology, or spacial distribution of the fixed glaucoma-associated-extracellular vesicle- complexes; and determining if the glaucoma is progressing or regressing based on said comparing.
[00362] The method above, wherein said identifying of glaucoma or pre-glaucoma is carried out before the subject providing the aqueous humor sample experiences any vision loss.
[00363] A method of screening compounds for their ability to treat glaucoma, said method comprising: providing candidate agents potentially useful in treating glaucoma; providing a sample containing glaucoma-associated extracellular vesicle-complexes, wherein the extracellular vesicles are either: aggregates of extracellular vesicles, or individual extracellular vesicles, having a diameter greater than 300 nanometers; contacting the candidate agents with the glaucoma-associated extracellular vesicle- complexes; and identifying candidate compounds which are effective in reducing the size of glaucoma- associated-extracellular vesicle-complexes based on said contacting.
[00364] The method above, wherein the glaucoma-associated extracellular vesicle- complexes are in aqueous humor.
[00365] The method above, further comprising: contacting a second sample containing the glaucoma-associated extracellular vesicle- complexes with a placebo and comparing size reduction of the glaucoma-associated extracellular vesicle-complexes of the samples contacted with the placebo versus that achieved with the candidate agent, to identify candidate compounds which are effective in reducing the size of glaucoma-associated- extracellular vesicle-complexes.
[00366] A reagent for detection of glaucoma comprising: an isolate sample comprising glaucoma-associated-extracellular vesicle-complexes which are either: aggregates of extracellular vesicles, or individual extracellular vesicles having a diameter over 300 nanometers.
[00367] The reagent above, wherein the glaucoma-associated extracellular vesicle- complexes are in aqueous humor.
[00368] Embodiments of this invention further contemplate compositions for ophthalmic use.
[00369] In some embodiments, an aqueous pharmaceutical composition for ophthalmic use may contain an active agent selected from cetylpyridinium chloride, polymyxin B sulfate, neomycin sulfate, and heparin sodium. The active agent may comprise 0.01-2% w/v of the composition. In some embodiments, the active agent can be 0.01-0.2% w/v of the composition.
[00370] The pH of a composition can be adjusted using, for example, sodium hydroxide and hydrochloric acid. The composition may have a pH of from 6.8 to 7.9, or about 7.3. [00371] In some embodiments, the composition can reduce intraocular pressure when administered to the eye.
[00372] In additional embodiments, the composition can reduces ocular extracellular vesicle complexes when administered to the eye. [00373] In further embodiments, the composition may be effective for treating a glaucoma disease when administered to the eye.
[00374] A composition of this invention may further contain one or more of a solubilizer, a surfactant, a tonicifier, and a preservative.
[00375] Examples of a solubilizer include a phosphate, a citric acid monohydrate, a trisodium citrate, and combinations thereof.
[00376] Examples of a phosphate include monosodium dihydrogen phosphate, disodium monohydrogen phosphate, dipotassium monohydrogen phosphate, monopotassium dihydrogen phosphate, and combinations thereof.
[00377] Examples of a surfactant include a phospholipid, a polyglycerol ester, a propylene glycol ester, a polyethylene glycol ester, a copolymer ester, a polyoxyethylene sorbitan ester, a cyclodextrin, a polyvinyl alcohol, povidone, a hydroxypropyl methyl cellulose, a poloxamer, a carboxymethyl cellulose, a hydroxyethyl cellulose, a polyacrylate, and combinations thereof.
[00378] Examples of a tonicifier include sodium chloride, trehalose, mannitol, sorbitol, dextrose, potassium chloride, and combinations thereof.
[00379] Examples of a preservative include benzalkonium chloride, polyquatemium-1, benzododecinium bromide, sorbic acid, methyl paraben, propyl paraben, chlorobutanol, benzylic alcohol, phenylethyl alcohol, an oxychloro complex, thimerosal, sodium perborate, disodium edetate, and combinations thereof.
[00380] In the context of an ophthalmic composition, a solubilizer can also have effect as a buffer, or as a stabilizer, or as a thickener.
[00381] In the context of an ophthalmic composition, a surfactant can also have effect as a solubilizer.
[00382] A composition of this invention may consist only of an active agent and a carrier.
[00383] For example, a composition may be an aqueous solution of an active agent.
[00384] Examples of a carrier include water, sterile water, water for injection, water for irrigation, a phosphate buffer, and combinations thereof.
[00385] A composition of this invention can be used in medical therapy.
[00386] A composition of this invention can be used in the treatment of the human or animal body. [00387] A composition of this invention can be used in reducing intraocular pressure in the human or animal body.
[00388] A composition of this invention can be used in reducing ocular extracellular vesicle complexes in the human or animal body.
[00389] A composition of this invention can be used in preparing or manufacturing a medicament for preventing, ameliorating, or treating a disease or condition associated with glaucoma in a subject in need.
[00390] Embodiments of this invention also contemplate methods for treating a glaucoma disease, reducing intraocular pressure, or reducing ocular extracellular vesicle complexes in a subject in need thereof, by administering a composition of this disclosure to the eye of the subject.
[00391] The administration may be by injection.
[00392] The ocular extracellular vesicle complexes can be aggregates of extracellular vesicles having a diameter greater than about 300 nanometers.
[00393] All publications including patents, patent application publications, and non patent publications referred to in this description are each expressly incorporated herein by reference in their entirety for all purposes.
[00394] Although the foregoing disclosure has been described in detail by way of example for purposes of clarity of understanding, it will be apparent to the artisan that certain changes and modifications are comprehended by the disclosure and may be practiced without undue experimentation within the scope of the appended claims, which are presented by way of illustration not limitation. This invention includes all such additional embodiments, equivalents, and modifications. This invention includes any combinations or mixtures of the features, materials, elements, or limitations of the various illustrative components, examples, and claimed embodiments.
[00395] The terms “a,” “an,” “the,” and similar terms describing the invention, and in the claims, are to be construed to include both the singular and the plural.
EXAMPLES
[00396] Example 1. Eising improved fixation to enhance imaging of extracellular vesicles in biological fluids. EV ultrastructure in fluids can be detected with transmission electron microscopy (TEM) combined with negative staining. However, in our laboratory, we found that this technique led to inconsistent or often negative results. When examining known quantities of EVs applied to a solution, we observed a substantial discrepancy between the high number of EVs applied and the few EVs that were ultimately imaged. Often, the results were inconsistent and technical replicates would vary. Therefore, a methodological gap exists and hinders efficient, consistent and representative EV imaging in solutions. Therefore, we evaluated each step of the EV imaging protocol and attempted to identify points at which EVs may be lost. We found that conventional TEM protocols result in inefficient binding of EVs to the electron microscopy grid surface and that the majority of EVs fail to adhere. To more efficiently attach EVs, we crosslink with 1 -ethyl-3 -(3- dimethylaminopropyl) carbodiimide (EDC), which retains EVs and enables robust TEM imaging. Finally, we demonstrate that this method can be used to image EVs in a variety of biological fluids, including: blood (plasma); cerebrospinal fluid; nipple aspirate fluid; aqueous humor, or isolated EVs suspended in buffers.
[00397] Example 2. Imaging EVs suspended in liquids with conventional methods has a low yield due to massive loss of vesicles to the discarded solution. To improve established TEM and negative staining procedures, we used EVs isolated from the bovine vitreous humor (gel-like matrix, located between the lens and the retina of the eye) and aqueous as a model system. First, we dissected the vitreous humor from the posterior chamber of the eye, homogenized the sample, isolated EVs using ultracentrifugation, and re-suspended the sample in buffered saline. Next, we quantified the number and size of EVs using nanoparticle-tracking analysis (NTA; 3.98 x 108 EVs per ml). To visualize the ultrastructure of vitreous EVs suspended in a fluid, we followed conventional glutaraldehyde-based TEM imaging protocols (FIG. 6, top row). We applied approximately 4 x 106 EVs to an electron microscopy grid and followed standard protocols for glutaraldehyde fixation and negative staining with a uranyl acetate solution. We subsequently imaged the specimens using TEM and the results showed few EVs were present (0.033 ± 0.182 EVs observed per 25,000x high-powered micrographic field, n = 3 biological replicates, and 10 photos captured), which is an unexpectedly low number and incongruent with loading 4 million EVs. At low power, we observed sparsely spaced EVs (FIG. 6, top row, left) and in most photographic frames, we were unable to identify clearly negatively stained EVs (FIG. 6, top row, middle and right). These results suggest that EVs were either destroyed during specimen processing, failed to adhere to the surface of the TEM grid or were lost during the protocol. To verify that EVs were present in the vitreous specimen, we imaged the vitreous base, a tightly adherent section of the gel- like matrix attached to the retina, sectioned the sample, and prepared it for TEM. Indeed, we observed many EV shaped electron dense signals in vitreous tissue sections (data not shown), confirming that EVs should be present in our sample prepared for TEM. Therefore, we hypothesized that the millions of EVs applied to the surface of the electron microscopy grid were discarded in the cast off solution and not attached to the grid surface (FIG. 6, 2nd row, left diagram). To determine if there were significant amounts of EVs present in the discarded solution, we measured and compared the number and size of EVs that were isolated from 4T1 breast cancer cell lines and re-suspended in a buffered saline. We found that the concentration of 4T1 EVs was 8.63 x 108 particles per ml (± 4.96 x 108 particles per ml), and we applied 8.63 x 106 EVs to the grid surface (FIG. 6, 2nd row, middle and Table 2). Next, we measured the amount of EVs present in the cast-off solution using nanoparticle tracking analysis (NTA) and found that in 3 separate trials, at least 8.16 x 108 particles per ml (± 2.43 x 107 particles per ml) or 8.16 x 106 particles were lost to the wash buffer (FIG. 6, 2nd row, right, FIG. 6, 3rd row, left and Table 2). These data show that a majority of the EVs applied to the surface of the grid failed to adhere to the electron microscopy grid surface and were lost to the cast-off solution (FIG. 6, 3rd row, left). Therefore, we have inferred that imaging EVs suspended in liquids using conventional fixation, negative staining and electron microscopy is severely hindered by poor cross-linking for EV to the grid surface.
[00398] Table 2 shows extracellular vesicles poorly adhere to electron microscopy grids. We determined the size and concentration of EVs that were applied over the grid surface and compared this value to the EVs present in the discarded fraction. We isolated EVs from mouse mammary tumor cell line, 4T1 cell media using ultracentrifugation methods and measurements were conducted using nanoparticle tracking analysis (NTA), using identical settings for all variables in NTA 2.3 build 17 software. The mean size, mode size and mean concentration of EVs applied over the TEM grid surface, and EVs present in the discarded fraction are shown (n = 3).
Table 2: Extracellular vesicles and electron microscopy grids
Figure imgf000059_0001
Figure imgf000060_0001
Samples were analyzed using NTA 3.1 build 54 software (Malvern)
[00399] Example 3. Using formalin-EDC fixation retains EVs and allows for robust imaging of EVs suspended in liquids. We assumed that EVs were poorly bound to the TEM grid and attempted to permanently adhere EVs suspended in a liquid on the grid by adding a heat stable fixative, EDC, a carbodiimide that creates a non-reversible crosslink between positively charged amino group side chains and carboxyl groups of proteins. To test our hypothesis, we combined 4 million isolated bovine vitreous EVs and EDC fixation solution, applied this to the surface of a poly-l-lysine coated formvar TEM grid, and activated the EDC solution by applying heat (50°C) for 3 hr (FIG. 6, 3rd row, middle). After crosslinking, we removed the EDC solution, applied glutaraldehyde fixation solution, washed the sample, and conducted negative staining. The images show an abundant number of EVs in each photographic frame with 16.5 EVs (± 16.9) per 25,000x high-powered field under matching conditions of conventional negative staining and TEM imaging. Moreover, we identified at least 357-fold more EVs in EDC fixed samples, when compared to glutaraldehyde only (FIG. 6, 4th row, left, p < 0.05, n=3). To broaden the scope of this technique to other fluids, we visualized EVs isolated from bovine aqueous humor, which shows robust detection of EVs with electron dense negative stain surrounding the EV perimeter (FIG. 6, 4th row, middle). We also imaged native aqueous humor fluid from a healthy patent to visualize the EVs in situ. We define in situ imaging as, “imaging a solution without EV isolation, and visualizing the contents of the biological fluid, in place.” This is method of visualizing EVs is fluids differs from previous methods to images EVs, since we do not concentrate the EVs. Here, the images show a heterogeneous population of EVs with well-defined negative staining (FIG. 6, 4th row, right). Overall, we found that cross-linking EVs suspended in multiple fluids with EDC resulted in substantial improvement transmission electron microscopy imaging. These data show that for imaging EVs in a fluid, EDC fixation significantly improves the number of EV observed, when compared to conventional aldehyde fixation.
[00400] Example 4. Comparing extracellular vesicles in the aqueous humor from healthy controls and patients with POAG. The aqueous humor is a transparent, water-like biological fluid that is like plasma, but contains 98% water, along with amino acids, electrolytes, ascorbic acid, glutathione, and immunoglobulins. Aqueous humor has been shown to contain EVs. In these studies, the EVs were isolated using ultracentrifugation protocols and they did not observe any glaucoma-associated-EV-aggregates. We hypothesized that there are differences in the EV ultrastructure of the aqueous in subjects with ocular pathology (such as glaucoma), as compared to healthy controls (subjects with no ocular pathology aside from cataracts). We choose to study the aqueous because it is normally lost during cataract surgery and obtaining the samples did not pose any additional risk to the subjects. To observe the most natural state of the aqueous humor, we did not isolate EVs using ultracentrifugation or other EV-related protocols. We collected aqueous humor from healthy patient cohorts and those with a clinical diagnosis of POAG. We predicted that EVs in glaucoma patients’ aqueous humor shall be larger, thus allowing these structures to block the aqueous humor outflow. To complete this study, we obtained aqueous humor specimens from 1) healthy control patients undergoing elective cataract surgery (control cohort) or 2) from patients with a diagnosis of glaucoma (POAG cohort). The study design is listed below.
[00401] Example 5. Study design; obtaining aqueous humor from healthy and glaucoma patients. To determine the ultrastructure of EVs from aqueous humor donated by healthy controls or glaucoma patients, we conducted a prospective clinical trial. Control samples were those with a diagnosis of cataracts, but no other ocular comorbidity, nor another systemic comorbidity. All patients in the control cohort were undergoing elective outpatient, ambulatory cataract surgery and were generally healthy. We collected a small sample (50 to 100 mΐ) of the aqueous (which would normally be lost as medical waste) at the beginning of the cataract surgery. We then fixed the samples with EDC crosslinking agent, negatively stain the samples, and performed transmission electron microscopy. Study samples will be those who in addition to the cataract also have POAG and none of the following conditions: diabetic retinopathy, or age-related macular degeneration. The pool of glaucoma patients will be chosen from patients who will have cataract extraction and lens implantation surgery. Inclusion criteria include the following; outpatient cataract surgery patients, age 18 years or older, who have either no ocular co-morbidities besides cataract, or who also have a documented clinical diagnosis of POAG. Exclusion criteria include ocular comorbidities, other than cataracts. An Institutional Review Board approved the protocol to collect samples and complete these studies.
[00402] Example 6. Obtaining aqueous humor samples from patients with and without glaucoma: During cataract surgery, incisions are made to enter the anterior chamber and access the cataractous lens. The aqueous egresses from the eye during the surgery and is replaced by irrigation solution infused through the instruments. We collected a small sample the aqueous, which would normally be lost as medical waste, at the beginning of the cataract surgery. The sample was assigned a numerical study ID code to de-identify it and transferred immediately from the OR to the laboratory for TEM imaging analysis. Patients did not undergo surgery or additional interventions for the purposes of this study, but were instead those individuals who were scheduled to undergo cataract surgery for therapeutic purposes. The cataract surgical schedule was reviewed to identify those patients that meet the inclusion and exclusion criteria delineated above, for control or POAG cohorts. Informed consent was obtained from each patient prior to inclusion in the study. Patients then underwent standard cataract surgery with the following exception. At the beginning of the cataract surgery a 30-gauge needle on a TB syringe was be inserted through the clear cornea to aspirate 0.05 - O.lcc of aqueous humor. The wound self-sealed. Subsequently, the corneal paracentesis incision was made as per standard cataract surgery as per the surgeon. We collected samples and transported the sample on ice to the laboratory. The study sample was identified a random study ID code to ensure it is de-identified. For all experiments, we did not isolate EVs using ultra-centrifugation methods, rather imaged the biological fluid in situ.
[00403] Example 7. Imaging the ultrastructure of healthy control aqueous humor in situ shows a diffuse distribution of EVs: To understand the morphology of EVs in the normal physiological state, we imaged healthy patients aqueous humor in situ. No prior glaucoma studies have used the EDC fixation to visualize EVs in aqueous humor in situ. To understand the ultrastructural content of aqueous humor, we diluted the sample 1:10 with buffered saline (note: we did not isolate EVs), fixed the sample with EDC, then glutaraldehyde, negatively stained the specimen, and imaged with TEM. The data showed that healthy human aqueous humor contains an abundant number of EVs from multiple control human subjects (FIG. 7-8). These studies suggest that EVs in healthy human aqueous humor are present, diffusely distributed and there is no evidence of aggregating of the EVs. Moreover, most EVs were not attached to another and had a relatively even distribution. Therefore, healthy control aqueous humor contains EVs that are non-aggregated and diffuse distribution. [00404] Example 8. Imaging the ultrastructure of POAG aqueous humor in situ shows a sizeable glaucoma-associated-EV-complex that is larger than EVs observed in healthy controls. We hypothesized that POAG patients have a previously unidentified material present in the aqueous humor that is responsible for blocking the trabecular meshwork. We hypothesize that this unidentified material has yet to be described, because it has been below the threshold of detection using current imaging technology. Therefore, we applied EDC fixation, negative staining, and transmission electron microscopy imaging to observe the morphology of EVs in the aqueous humor of a POAG patient. The aqueous humor imaged from two different POAG patients was imaged in situ, without processing (no EV isolation), under identical conditions that were used for healthy controls. Surprisingly, the aqueous humor of patients with POAG showed numerous groups of EVs aggregated together in large EV-complexes, which are several microns in size, which we term “glaucoma-associated-EV-complex” (FIG. 9 and FIG. 10). The glaucoma-associated-EV-complex was present is two different patient samples and measure larger than the opening of the JCT (1 to 4 pm, or up to 2 to 20 pm), which is large enough to block the juxtacanalicular tissue. These data suggest that patients with POAG have an ultrastructural material present in the aqueous humor that could be responsible for blocking the trabecular meshwork, reducing aqueous outflow, and potentially causing vision loss. We propose that the glaucoma-associated-EV-complex is the unidentified material that contributes to the pathology of glaucoma.
[00405] Example 9. Treating large EV complexes with Bimatoprost breaks up the EV-complex, when compared to controls. To determine if glaucoma-associated-EV-aggregates visualized using the EDC fixation method were indeed a potential mediator of POAG, we hypothesized that treating it with a known glaucoma medication would change the morphology of the glaucoma-associated- EV-aggregates. Therefore, we opted to use Bimatoprost (lumigan), which is a ocular hypotensive agent that lowers IOP in normal, ocular hypertensive, and glaucomatous eyes. Moreover, bimatoprost is known to enhance the outflow of aqueous humor by remodeling the extracellular matrix, via regulation of matrix metallo-proteinases and remodeling of extracellular matrix. Here, we hypothesized that the glaucoma-associated-EV-complex would be reduced in size by the addition of bimatoprost. To test this, we incubated a POAG patient’s aqueous humor with bimatoprost or buffered saline (placebo or control condition) at 37°C for 72 hours, and imaged the EV ultrastructure using EDC fixation, negative staining and transmission electron microscopy (FIG. 11-13). After bimatoprost treatment, we noted a substantial reduction in the number of glaucoma-associated-EV- complex in the POAG-bimatoprost sample, when compared to POAG sample with placebo treatment (FIG. 11). In a second human subject with a diagnosis of glaucoma, repeated the experiment and mixed POAG aqueous humor with placebo (buffered saline), incubated the sample at 37°C for 72 hours and we observed many glaucoma-associated-EV-complexes (Fig. 12). However, under identical conditions, except we used bimatoprost, we observed a substantial reduction in the number of glaucoma-associated-EV-complexes (FIG. 13). These data suggest that a known treatment for POAG reduces size and alters the morphology of the glaucoma-associated-EV-complex, suggesting that this complex may be a potential pathological mediator of POAG.
[00406] Example 10. Glaucoma patients’ aqueous humor contains larger electron dense structures in the aqueous humor that are not present in healthy controls. The electron microscopy images showed large electron dense structure in the POAG specimen aqueous humor that were not present in the healthy controls. We hypothesized that the POAG glaucoma-associated-EV- aggregates were larger in size and present in higher numbers when compared to healthy controls. Therefore, we obtained the electron microscopy photographs from healthy controls or POAG samples and measured the number and size of glaucoma-associated-EV-aggregates. The data showed that POAG aqueous humor has substantially larger glaucoma-associated-EV-aggregates that measure from 361 nm to 20,214 nm (FIG. 14). Moreover, we observed substantially more glaucoma-associated-EV-aggregates in the POAG samples when compared to healthy controls.
These data suggest that POAG aqueous humor EVs contain a large ultrastructural complex that is not present in healthy controls (FIG. 14). Moreover, the glaucoma-associated-EV-aggregates are large enough to block the drainage system of the eye, the trabecular meshwork. It has been postulated that abnormal aqueous humor outflow causes elevated IOP, which is a major risk factor for glaucoma. The region of the TM implicated in establishing IOP is next to Schlemm's canal and is called the juxtacanalicular tissue (JCT) or cribriform region. The site of most resistance to the aqueous outflow is the JCT, and it measures approximately 2-20 pm (J. Ocular Biology 2013 June 1(1):3), with fenestrations of 1 to 4 pm or larger. JCT is composed of the loosely arranged extracellular matrix (ECM) into which cells are embedded. ECM of JCT has been implicated as a barrier that may isolate the ocular fluid outflow. Therefore, we hypothesize that this material (glaucoma-associated-EV-aggregate) in the aqueous humor of patients with glaucoma, that is physically larger than the diameter of the JCT outlet, may block the aqueous outflow and be related to glaucoma pathology.
[00407] Example 11. Glaucoma patients’ aqueous humor contains EVs that contact each other that form larger structures called, “glaucoma-associated-EV-aggregates”, that are not present in healthy control aqueous humor. To determine the composition of the glaucoma-associated-EV- aggregates we analyzed the TEM images and found that these ultra-structures are composed of many EVs contacting each other to form larger aggregates. To quantify the number of EVs found within the glaucoma-associated-EV-aggregates, we counted the total number of EVs present in the image, quantified the number of EVs in each aggregate, or calculated the number of EVs that were not contacting another EV (Free EVs). We classified the number of EVs contacting each other from 0 (free EVs, without contact), less than 5 EVs contacting each other, 5 to 10 EVs contacting each other, 10 to 50 EVs contacting each other, 50 to 100 EVs contacting each other, or 100 to 300 EVs contacting each other. The data showed that in healthy controls, few EVs were found in aggregates (FIG. 15 and FIG. 16), with most EVs contacting less than 5 other EVs. The data suggest that in healthy controls most EVs are “free EVs.” Interestingly, for patients with glaucoma, a substantial amount of EVs contacted between 50 to 300 other EVs. The data suggests that most EVs in glaucoma are found within the glaucoma-associated-EV-aggregate, more than the healthy control sample (FIG. 15 and FIG. 16). These data suggest that patients with glaucoma have EVs that contact each other, in stark contrast to healthy controls, in which the majority of EVs are free.
[00408] Example 12. Extracellular vesicles in the aqueous humor of healthy control subjects exist as “Free-EVs” and with a majority of EVs between 100 to 200 nm in size. We sought to determine and quantify the EV population in healthy controls aqueous humor. To determine the size distribution of EVs in healthy control aqueous humor, we characterized the EV population in human aqueous humor obtained from a single healthy control patient (FIG. 17). We fixed healthy control human aqueous humor using EDC, negatively stained the sample and imaged with TEM. We analyzed the photographs and measured the EVs diameter. The data shows that healthy control human aqueous humor contains EVs with a majority of EVs between 100-200 nm in diameter for this patient (FIG. 17). Furthermore, we observed that most EVs in the control cohort were free from contact from other EVs. This data suggests that healthy control aqueous humor contain exosomes and some microvesicles. We did not observe larger apoptotic bodies in these samples, nor glaucoma-associated-EV-aggregates.
[00409] Example 13. Extracellular vesicles in the aqueous humor of subjects with the diagnosis of POAG are located within the glaucoma-associated-EV-aggregates are similar in size to “Free- EVs” found in healthy controls. To study the EV population in the aqueous humor of human subject #1 who has a diagnosis of POAG, we obtained the aqueous humor, fixed the sample with EDC, negatively stained the specimen and imaged with TEM. We analyzed the photographs and measured the EV size and count frequency of those EVs located within the glaucoma-associated-EV-aggregate or we counted the free EVs. In POAG specimen #1, we did not observe “free-EVs ” We then counted and measured the number and size of EVs that were located in the glaucoma-associated-EV- aggregate (FIG. 18). The data shows that a substantial number of EVs located within the glaucoma- associated-EV-aggregate measure in size between 36 nm and 300 nm in size with a peak number of EVs measuring 100 - 200 nm in size (FIG. 18). In a second human subject with the diagnosis of POAG, we again found that the POAG aqueous humor has several glaucoma-associated-EV- aggregates. We observed EVs that were present within an aggregate (defined as EVs that contact each other) or as free EVs (EVs that do not contact each other, FIG. 19-20). Furthermore, we found that a substantial number of EVs located within the glaucoma-associated-EV-aggregate were 36- 300 nm in size (FIG. 21). Next we compared the number and size of EVs that were present in the glaucoma-associated-EV-aggregate and the two sample EV populations were similar (FIG. 22).
These data suggest that the EV size population in patients with POAG are located within the glaucoma-associated-EV-aggregate and the data is consistent between samples.
[00410] Example 14. Free-EVs in the aqueous humor of human subjects with the diagnosis of POAG differ in size and frequency, when compared to aqueous humor of healthy control subjects.
To determine if there is a difference in free EVs in the aqueous humor of patients with glaucoma and healthy controls, we compared the size and count frequency of glaucoma and control conditions.
We found that the EVs differ in size and frequency between POAG patients and healthy controls (FIG. 23). These data suggest that the EVs that do not contact other EVs are larger in POAG patients, relative to the healthy controls. These data may have implications for the function of the free EVs.
[00411] Example 15. Extracellular vesicles from POAG aqueous humor that are present with the glaucoma-associated-EV-aggregates are similar in size and frequency too free EVs obtained from healthy human subjects. We hypothesized that the EVs present in the glaucoma-associated-EV- aggregate are similar in size and count frequency to the healthy control EVs. To test this, we compared the count frequency and size of EVs from POAG and healthy control specimens. The EVs from POAG aqueous humor located within the glaucoma-associated-EV-aggregate are similar in size and frequency to the non-aggregated EVs in healthy human subjects (FIG. 24). These data suggest that the normal population of EVs from healthy controls may be blocked from functioning due to the EVs in POAG being caught in the glaucoma-associated-EV-aggregates.
[00412] Example 16. An active agent for use in treating glaucoma can be cetylpyridinium Formula XI, which may be used in a prodrug form or in a pharmaceutically-acceptable salt form.
[00413]
Figure imgf000067_0001
Formula XI which is 1-hexadecylpyridin-l-ium.
[00414] A solution of the agent compound was prepared by weighing out the compound in a microcentrifuge tube and dissolving the solid material in lx PBS buffer at pH 7.2. For a compound that was less soluble in water, a stock solution was prepared in ethanol or DMSO, and then diluted ten-fold to achieve the final concentration with a 10% ethanol or DMSO vehicle. Heat (37°C) and vortex mixing were applied to the solution of the compound to facilitate dissolution.
[00415] The concentration of cetylpyridinium chloride was 43 mg/ml.
[00416] To determine the effect of the compound on intraocular pressure (IOP), the compound was tested in bovine vitreous humor (BVH) in the microfluidic chip device. [00417] A solution of 25% homogenized bovine vitreous humor (BVH) was prepared by diluting 100% homogenized BVH with PBS buffer. 50 uL BVH was aliquoted into 0.5 mL PCR tubes. 50 uL of the solution of the compound was added to the BVH, bringing the BVH total concentration to 12.5%. The sample was briefly vortexed and then incubated at 37°C overnight. For a control experiment, 50 uL of either PBS buffer or PBS with 10% ethanol or DMSO were prepared and incubated with 25% BVH in the same conditions. [00418] The test BVH solution was introduced into the reservoir of the device. A fluidic probe was attached to the inlet of the microfluidic chip and a flow rate of 2ul/min was established with PBS as the source fluid. Once fluid began exiting from the outlet of the chip and a steady flow of 2 ul/min was achieved, the flow rate and the pressure change within the microfluidic chip were recorded. Baseline flow rate and pressure readings were recorded for 5 minutes, after which 7 ul of the test BVH solution was injected into the chip through a sample injector. Recording of the flow rate and pressure change was continued for 50 additional minutes after the sample injection. Recording was stopped after 55 minutes. The relative change in chip pressure for the entire course of the experiment was plotted on a graph.
[00419] FIG. 25 shows that agent cetylpridinium chloride reduced intraocular pressure (IOP) in a glaucoma model as compared to control. The agent was tested by controlling flow and measuring relative IOP using in a microfluidic device. The agent was compared against placebo (buffered saline) by preparing each in bovine vitreous humor (BVH) and pre-incubating at 37°C for 24 hours. The timepoint of injection into the device is denoted by an arrow and the letter “a.” Referring to FIG. 25, the IOP for placebo (dashed line) increased greatly after injection of the placebo sample. The IOP rose steadily to a maximum pressure of about 64 mmHg. To the contrary, the IOP after injection of the agent cetylpridinium chloride-BVH sample (solid line) was markedly lower than for placebo, and the difference was sustained. This result showed that the agent cetylpridinium chloride was surprisingly effective to reduce IOP in the glaucoma model.
[00420] Example 17. An active agent for use in treating glaucoma can be polymyxin B Formula XXI, which may be used in a prodrug form or in a pharmaceutically-acceptable salt form.
[00421]
Figure imgf000069_0001
Formula XXL
[00422] A solution of the agent compound was prepared by weighing out the compound in a microcentrifuge tube and dissolving the solid material in lx PBS buffer at pH 7.2. For a compound that was less soluble in water, a stock solution was prepared in ethanol or DMSO, and then diluted ten-fold to achieve the final concentration with a 10% ethanol or DMSO vehicle. Heat (37°C) and vortex mixing were applied to the solution of the compound to facilitate dissolution.
[00423] The concentration of Polymyxin B sulfate was 10 mg/ml.
[00424] To determine the effect of the compound on intraocular pressure (TOP), the compound was tested in bovine vitreous humor (BVH) in the microfluidic chip device. [00425] A solution of 25% homogenized bovine vitreous humor (BVH) was prepared by diluting 100% homogenized BVH with PBS buffer. 50 uL BVH was aliquoted into 0.5 mL PCR tubes. 50 uL of the solution of the compound was added to the BVH, bringing the BVH total concentration to 12.5%. The sample was briefly vortexed and then incubated at 37°C overnight. For a control experiment, 50 uL of either PBS buffer or PBS with 10% ethanol or DMSO were prepared and incubated with 25% BVH in the same conditions. [00426] The test BVH solution was introduced into the reservoir of the device. A fluidic probe was attached to the inlet of the microfluidic chip and a flow rate of 2ul/min was established with PBS as the source fluid. Once fluid began exiting from the outlet of the chip and a steady flow of 2 ul/min was achieved, the flow rate and the pressure change within the microfluidic chip were recorded. Baseline flow rate and pressure readings were recorded for 5 minutes, after which 7 ul of the test BVH solution was injected into the chip through a sample injector. Recording of the flow rate and pressure change was continued for 50 additional minutes after the sample injection. Recording was stopped after 55 minutes. The relative change in chip pressure for the entire course of the experiment was plotted on a graph.
[00427] FIG. 26 shows that agent polymyxin B reduced intraocular pressure (IOP) in a glaucoma model as compared to control. The agent was tested by controlling flow and measuring relative IOP using in a microfluidic device. The agent was compared against placebo (buffered saline) by preparing each in bovine vitreous humor (BVH) and pre-incubating at 37°C for 24 hours. The timepoint of injection into the device is denoted by an arrow and the letter “a.” Referring to FIG. 26, the IOP for placebo (dashed line) increased greatly after injection of the placebo sample. The IOP rose steadily to a maximum pressure of about 250 mmHg. To the contrary, the IOP after injection of the agent polymyxin B (solid line) was 78% lower than for placebo, and the difference was sustained. This result showed that the agent polymyxin B was surprisingly effective to reduce IOP in the glaucoma model.
[00428] Example 18. An active agent for use in treating glaucoma can be neomycin Formula XI, which may be used in a prodrug form or in a pharmaceutically-acceptable salt form.
[00429]
Figure imgf000070_0001
Formula XI. [00430] A solution of the agent compound was prepared by weighing out the compound in a microcentrifuge tube and dissolving the solid material in lx PBS buffer at pH 7.2. For a compound that was less soluble in water, a stock solution was prepared in ethanol or DMSO, and then diluted ten-fold to achieve the final concentration with a 10% ethanol or DMSO vehicle. Heat (37°C) and vortex mixing were applied to the solution of the compound to facilitate dissolution.
[00431] The concentration of neomycin sulfate was 35 mg/ml.
[00432] To determine the effect of the compound on intraocular pressure (TOP), the compound was tested in bovine vitreous humor (BVH) in the microfluidic chip device. [00433] A solution of 25% homogenized bovine vitreous humor (BVH) was prepared by diluting 100% homogenized BVH with PBS buffer. 50 uL BVH was aliquoted into 0.5 mL PCR tubes. 50 uL of the solution of the compound was added to the BVH, bringing the BVH total concentration to 12.5%. The sample was briefly vortexed and then incubated at 37°C overnight. For a control experiment, 50 uL of either PBS buffer or PBS with 10% ethanol or DMSO were prepared and incubated with 25% BVH in the same conditions. [00434] The test BVH solution was introduced into the reservoir of the device. A fluidic probe was attached to the inlet of the microfluidic chip and a flow rate of 2ul/min was established with PBS as the source fluid. Once fluid began exiting from the outlet of the chip and a steady flow of 2 ul/min was achieved, the flow rate and the pressure change within the microfluidic chip were recorded. Baseline flow rate and pressure readings were recorded for 5 minutes, after which 7 ul of the test BVH solution was injected into the chip through a sample injector. Recording of the flow rate and pressure change was continued for 50 additional minutes after the sample injection. Recording was stopped after 55 minutes. The relative change in chip pressure for the entire course of the experiment was plotted on a graph.
[00435] FIG. 27 shows that agent neomycin reduced intraocular pressure (IOP) in a glaucoma model as compared to control. The agent was tested by controlling flow and measuring relative IOP using in a microfluidic device. The agent was compared against placebo (buffered saline) by preparing each in bovine vitreous humor (BVH) and pre-incubating at 37°C for 24 hours. The timepoint of injection into the device is denoted by an arrow and the letter “a.” Referring to FIG. 27, the IOP for placebo (dashed line) increased greatly after injection of the placebo sample. The IOP rose steadily to a maximum pressure of about 64 mmHg. To the contrary, the IOP after injection of the agent neomycin (solid line) was 72% lower than for placebo, and the difference was sustained. This result showed that the agent neomycin was surprisingly effective to reduce IOP in the glaucoma model.
[00436] Example 19. An active agent for use in treating glaucoma can be heparin, which may be used in a prodrug form or in a pharmaceutically-acceptable salt form.
[00437] A solution of the agent compound was prepared by weighing out the compound in a microcentrifuge tube and dissolving the solid material in lx PBS buffer at pH 7.2. For a compound that was less soluble in water, a stock solution was prepared in ethanol or DMSO, and then diluted ten-fold to achieve the final concentration with a 10% ethanol or DMSO vehicle. Heat (37°C) and vortex mixing were applied to the solution of the compound to facilitate dissolution.
[00438] The concentration of heparin sodium was 10 mg/ml.
[00439] To determine the effect of the compound on intraocular pressure (IOP), the compound was tested in bovine vitreous humor (BVH) in the microfluidic chip device. [00440] A solution of 25% homogenized bovine vitreous humor (BVH) was prepared by diluting 100% homogenized BVH with PBS buffer. 50 uL BVH was aliquoted into 0.5 mL PCR tubes. 50 uL of the solution of the compound was added to the BVH, bringing the BVH total concentration to 12.5%. The sample was briefly vortexed and then incubated at 37°C overnight. For a control experiment, 50 uL of either PBS buffer or PBS with 10% ethanol or DMSO were prepared and incubated with 25% BVH in the same conditions. [00441] The test BVH solution was introduced into the reservoir of the device. A fluidic probe was attached to the inlet of the microfluidic chip and a flow rate of 2ul/min was established with PBS as the source fluid. Once fluid began exiting from the outlet of the chip and a steady flow of 2 ul/min was achieved, the flow rate and the pressure change within the microfluidic chip were recorded. Baseline flow rate and pressure readings were recorded for 5 minutes, after which 7 ul of the test BVH solution was injected into the chip through a sample injector. Recording of the flow rate and pressure change was continued for 50 additional minutes after the sample injection. Recording was stopped after 55 minutes. The relative change in chip pressure for the entire course of the experiment was plotted on a graph. [00442] FIG. 28 shows that agent heparin sodium reduced intraocular pressure (IOP) in a glaucoma model as compared to control. The agent was tested by controlling flow and measuring relative IOP using in a microfluidic device. The agent was compared against placebo (buffered saline) by preparing each in bovine vitreous humor (BVH) and pre-incubating at 37°C for 24 hours. The timepoint of injection into the device is denoted by an arrow and the letter “a.” Referring to FIG. 28, the IOP for placebo (dashed line) increased greatly after injection of the placebo sample. The IOP rose steadily to a maximum pressure of about 67 mmHg. To the contrary, the IOP after injection of the agent heparin sodium (solid line) was 32% lower than for placebo, and the difference was sustained. This result showed that the agent heparin sodium was surprisingly effective to reduce IOP in the glaucoma model.
[00443] Example 20. Sodium dodecyl sulfate was a negative control for intraocular pressure (IOP) in a glaucoma model.
[00444] A solution was prepared by weighing out the compound in a microcentrifuge tube and dissolving the solid material in lx PBS buffer at pH 7.2. For a compound that was less soluble in water, a stock solution was prepared in ethanol or DMSO, and then diluted ten-fold to achieve the final concentration with a 10% ethanol or DMSO vehicle. Heat (37°C) and vortex mixing were applied to the solution of the compound to facilitate dissolution.
[00445] The concentration of sodium dodecyl sulfate was 24 mg/ml.
[00446] To determine the effect of the compound on intraocular pressure (IOP), the compound was tested in bovine vitreous humor (BVH) in the microfluidic chip device. [00447] A solution of 25% homogenized bovine vitreous humor (BVH) was prepared by diluting 100% homogenized BVH with PBS buffer. 50 uL BVH was aliquoted into 0.5 mL PCR tubes. 50 uL of the solution of the compound was added to the BVH, bringing the BVH total concentration to 12.5%. The sample was briefly vortexed and then incubated at 37°C overnight. For a control experiment, 50 uL of either PBS buffer or PBS with 10% ethanol or DMSO were prepared and incubated with 25% BVH in the same conditions. [00448] The test BVH solution was introduced into the reservoir of the device. A fluidic probe was attached to the inlet of the microfluidic chip and a flow rate of 2ul/min was established with PBS as the source fluid. Once fluid began exiting from the outlet of the chip and a steady flow of 2 ul/min was achieved, the flow rate and the pressure change within the microfluidic chip were recorded. Baseline flow rate and pressure readings were recorded for 5 minutes, after which 7 ul of the test BVH solution was injected into the chip through a sample injector. Recording of the flow rate and pressure change was continued for 50 additional minutes after the sample injection. Recording was stopped after 55 minutes. The relative change in chip pressure for the entire course of the experiment was plotted on a graph.
[00449] FIG. 29 shows that compound sodium dodecyl sulfate was a negative control for intraocular pressure (IOP) in a glaucoma model. The compound was tested by controlling flow and measuring relative IOP using in a microfluidic device. The compound was compared against placebo (buffered saline) by preparing each in bovine vitreous humor (BVH) and pre-incubating at 37°C for 24 hours. The timepoint of injection into the device is denoted by an arrow and the letter “a.” Referring to FIG. 29, the IOP for placebo (dashed line) increased greatly after injection of the placebo sample. The IOP rose steadily to a maximum pressure of about 60 mmHg. However, the IOP after injection of sodium dodecyl sulfate (solid line) was significantly higher than for placebo. This result showed that sodium dodecyl sulfate was a negative control that did not reduce IOP in the glaucoma model.
[00450] In general, intraocular administration can be carried out via intracameral administration, intravitreal administration, or subretinal administration. Periocular administration can be carried out via sub -conjunctival injection, sub-Tenon’s injection, direct periocular injection, or depot periocular injection. Systemic administration may be carried out via intravenous administration, oral administration, intraarterial administration, inhalation, intranasal administration, intra-peritoneal administration, intra-abdominal administration, subcutaneous administration, intra-articular administration, intrathecal administration, transdural administration, transdermal administration, submucosal administration, sublingual administration, enteral administration, parenteral administration, percutaneous administration, periarticular administration, or intraventricular administration.
[00451] An ophthalmic formulation can be locally delivered by an eye drop, by direct injection or by use of an infusion pump. Intraocular administration can be carried out via intracameral administration, intravitreal administration, or subretinal administration.

Claims

WHAT IS CLAIMED IS:
1. An aqueous pharmaceutical composition for ophthalmic use comprising an active agent selected from cetylpyridinium chloride, polymyxin B sulfate, a mycin, and heparin sodium.
2. The composition of claim 1, wherein the mycin is selected from neomycin, salinomycin, azithromycin, rapamycin, gentamycin, erythromycin, adriamycin, bleomycin, dactinomycin, mitomycin, plicamycin, dihydrostreptomycin, kanamycin, natamycin, rifamycin, and tobramycin.
3. The composition of claim 1, wherein the active agent comprises 0.01-2% w/v of the composition.
4. The composition of claim 1, wherein the active agent comprises 0.01-0.2% w/v of the composition.
5. The composition of claim 1, wherein the composition has a pH of about 7.3.
6. The composition of claim 1, wherein the composition reduces intraocular pressure when administered to the eye or administered systemically.
7. The composition of claim 1, wherein the composition reduces ocular extracellular vesicle complexes when administered to the eye or administered systemically.
8. The composition of claim 1, wherein the composition is effective for treating a glaucoma disease or ocular hypertension when administered to the eye or administered systemically.
9. The composition of claim 1, further comprising one or more of a solubilizer, a surfactant, a tonicifier, and a preservative.
10. The composition of claim 1, wherein the solubilizer is selected from a phosphate, a citric acid monohydrate, a trisodium citrate, and combinations thereof.
11. The composition of claim 1, wherein the surfactant is selected from a phospholipid, a polyglycerol ester, a propylene glycol ester, a polyethylene glycol ester, a copolymer ester, a polyoxyethylene sorbitan ester, a cyclodextrin, a polyvinyl alcohol, povidone, a hydroxypropyl methyl cellulose, a poloxamer, a carboxymethyl cellulose, a hydroxyethyl cellulose, a polyacrylate, and combinations thereof.
12. The composition of claim 1, wherein the tonicifier is selected from sodium chloride, trehalose, mannitol, sorbitol, dextrose, potassium chloride, and combinations thereof.
13. The composition of claim 1, wherein the preservative is selected from benzalkonium chloride, polyquaternium-1, benzododecinium bromide, sorbic acid, methyl paraben, propyl paraben, chlorobutanol, benzylic alcohol, phenylethyl alcohol, an oxychloro complex, thimerosal, sodium perborate, disodium edetate, and combinations thereof.
14. A composition of any one of claims 1-13 for use in medical therapy.
15. A composition of any one of claims 1-13 for use in the treatment of the human or animal body.
16. A composition of any one of claims 1-13 for use in reducing intraocular pressure in the human or animal body.
17. A composition of any one of claims 1-13 for use in reducing ocular extracellular vesicle complexes in the human or animal body.
18. A composition of any one of claims 1-13 for use in preparing or manufacturing a medicament for preventing, ameliorating, or treating a disease or condition associated with glaucoma or ocular hypertension in a subject in need.
19. A method for treating a glaucoma disease, reducing intraocular pressure, or reducing ocular extracellular vesicle complexes in a subject in need thereof, the method comprising administering a composition of any one of claims 1-13 to the eye of the subject.
20. The method of claim 19, wherein the administration is by injection, wherein intraocular administration is carried out via intracameral administration, intravitreal administration, or subretinal administration, periocular administration is carried out via sub -conjunctival injection, sub-Tenon’s injection, direct periocular injection, or depot periocular injection.
21. The method of claim 19, wherein the administration is systemic administration carried out via intravenous administration, oral administration, intraarterial administration, inhalation, intranasal administration, intra-peritoneal administration, intra-abdominal administration, subcutaneous administration, intra-articular administration, intrathecal administration, transdural administration, transdermal administration, submucosal administration, sublingual administration, enteral administration, parenteral administration, percutaneous administration, periarticular administration, or intraventricular administration.
22. The method of claim 19, wherein the ocular extracellular vesicle complexes are aggregates of extracellular vesicles having a diameter greater than about 300 nanometers.
PCT/US2020/024592 2018-09-21 2020-03-25 Processes and agents for glaucoma Ceased WO2021055013A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2020348176A AU2020348176A1 (en) 2018-09-21 2020-03-25 Processes and agents for glaucoma
CA3151625A CA3151625A1 (en) 2018-09-21 2020-03-25 Processes and agents for glaucoma
EP20864492.2A EP4031244A4 (en) 2018-09-21 2020-03-25 METHODS AND AGENTS AGAINST GLAUCOMA
JP2022517878A JP7617085B2 (en) 2018-09-21 2020-03-25 Methods and agents for glaucoma
CN202080080832.2A CN114929340B (en) 2018-09-21 2020-03-25 Methods and agents for glaucoma
US17/696,625 US20220211800A1 (en) 2018-09-21 2022-03-16 Processes and agents for glaucoma
JP2025001749A JP2025069138A (en) 2018-09-21 2025-01-06 Methods and agents for glaucoma

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862734699P 2018-09-21 2018-09-21
US16/578,320 2019-09-21
PCT/US2019/052310 WO2020061550A1 (en) 2018-09-21 2019-09-21 Compositions and methods for glaucoma
USPCT/US2019/052310 2019-09-21
US16/578,320 US11752175B2 (en) 2018-09-21 2019-09-21 Compositions and methods for glaucoma

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/052310 Continuation-In-Part WO2020061550A1 (en) 2018-09-21 2019-09-21 Compositions and methods for glaucoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/696,625 Continuation US20220211800A1 (en) 2018-09-21 2022-03-16 Processes and agents for glaucoma

Publications (1)

Publication Number Publication Date
WO2021055013A1 true WO2021055013A1 (en) 2021-03-25

Family

ID=69887956

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2019/052310 Ceased WO2020061550A1 (en) 2018-09-21 2019-09-21 Compositions and methods for glaucoma
PCT/US2020/024592 Ceased WO2021055013A1 (en) 2018-09-21 2020-03-25 Processes and agents for glaucoma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2019/052310 Ceased WO2020061550A1 (en) 2018-09-21 2019-09-21 Compositions and methods for glaucoma

Country Status (7)

Country Link
US (2) US11752175B2 (en)
EP (2) EP3852608A4 (en)
JP (4) JP7520851B2 (en)
CN (2) CN113164043B (en)
AU (2) AU2019343188A1 (en)
CA (2) CA3113528A1 (en)
WO (2) WO2020061550A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023159114A3 (en) * 2022-02-16 2023-09-28 The Cleveland Clinic Foundation Lymphatic delivery of nanoparticles to treat neurodegenerative, neurological, and eye conditions
EP4125994A4 (en) * 2020-03-25 2024-06-12 Aufbau Medical Innovations Limited METHODS AND AGENTS AGAINST GLAUCOMA
WO2025120597A1 (en) * 2023-12-06 2025-06-12 Universidade De Aveiro Secretome-based biomaterial, method for its production and uses thereof

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021046550A1 (en) * 2019-09-06 2021-03-11 Mantra Bio, Inc. Extracellular vesicle-fenretinide compositions, extracellular vesicle-c-kit inhibitor compositions, methods of making and uses thereof
JP7562682B2 (en) 2020-01-27 2024-10-07 マントラ バイオ，インコーポレイテッド Non-naturally occurring vesicles containing chimeric vesicle localization moieties, methods for producing same, and uses thereof
US20210338666A1 (en) * 2020-04-30 2021-11-04 Eye Therapies, Llc Brimonidine combinations and uses thereof
CN112275336B (en) * 2020-10-20 2021-11-19 大连理工大学 Multi-channel integrated micro-fluidic chip and method for preparing monodisperse gel microspheres by using same in high throughput
ES2948624T3 (en) 2020-11-19 2023-09-14 Fis Fabbrica Italiana Sintetici Spa Improved process for the preparation of trenbolone and/or trenbolone acetate
ES3032945T3 (en) 2020-11-19 2025-07-29 Fis Fabbrica Italiana Sintetici Spa Process for the preparation of trenbolone acetate having a definite particle size distribution and a irregular hexagon plates crystal habit
ES3055468T3 (en) 2020-11-19 2026-02-12 Fis Fabbrica Italiana Sintetici Spa Process for the preparation of trenbolone acetate having a definite particle size distribution
EP4039269A1 (en) * 2021-02-05 2022-08-10 Dompe' Farmaceutici S.P.A. Ngf isoform for use in the treatment of ocular pathologies
CN113456675A (en) * 2021-07-26 2021-10-01 山东大学齐鲁医院 Application of acellular SIS in inhibition of scar tissue hyperplasia after glaucoma operation
KR20250149620A (en) * 2024-04-09 2025-10-16 의료법인 성광의료재단 Drug-loaded extracellular vesicle delivered to retina via trans-scleral route and composition for preventing or treating optic nerve degenerative disorder comprising thereof
WO2025235305A1 (en) 2024-05-06 2025-11-13 Baxter International Inc. Azithromycin premix formulation and product, methods of preparing same, and methods of using same
CN119034016B (en) * 2024-10-31 2025-01-21 明澈生物科技(苏州)有限公司 Drainage tube for treating glaucoma and preparation method thereof
CN120154622A (en) * 2025-04-23 2025-06-17 中山大学中山眼科中心 Application of prostaglandin D2 in the preparation of drugs for treating optic neuropathy
CN120754133B (en) * 2025-09-09 2025-11-18 中南大学湘雅医院 Ber-ApoEVs and their preparation and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090318512A1 (en) * 2004-04-07 2009-12-24 Advanced Medical Optics, Inc. Methods of maintaining ocular tissue cell membrane integrity using cetylpyridinium chloride
RU2576778C1 (en) * 2015-02-20 2016-03-10 Илья Александрович Марков Pharmaceutical composition in form of gel-like ophthalmic drops for treating glaucoma
US20190216857A1 (en) * 2016-09-09 2019-07-18 Cornell University Delivery of nucleic acids, proteins and small molecules in vitreous vesicular bodies

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02167233A (en) * 1988-11-10 1990-06-27 Kiyoshi Kita Adjuvant for intraocular operation
ES2079994B1 (en) * 1992-10-07 1996-08-01 Cusi Lab PHARMACEUTICAL FORMULATION BASED ON POLYMIXINE-TRIMETOPRIM AND AN ANTI-INFLAMMATORY AGENT FOR ITS TOPICAL OPHTHALMIC AND ETHICAL USE.
JPH08506081A (en) * 1993-02-12 1996-07-02 ファーモス コーポレイション Dry composition for the preparation of submicron emulsions
US6544193B2 (en) 1996-09-04 2003-04-08 Marcio Marc Abreu Noninvasive measurement of chemical substances
US6770675B2 (en) * 1997-03-17 2004-08-03 Novartis Ag Compositions and methods for reducing ocular hypertension
AR002194A1 (en) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany COMPUTERIZED INSTRUMENT FOR THE ANALYSIS OF MOVEMENT.
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US8329685B1 (en) * 2000-07-19 2012-12-11 North West University Enhancement of the action of anti-infective agents and of central and peripheral nervous system agents and transportation of nucleic acid substances
EP2302389B1 (en) 2002-05-09 2018-01-24 The University of Chicago Device and method for pressure-driven plug transport and reaction
ATE343789T1 (en) 2002-06-03 2006-11-15 Pamgene Bv BIOMOLECULAR KINETIC MEASUREMENT METHOD USING A FLOW MICROARRAY
US20080070324A1 (en) 2002-07-15 2008-03-20 Floyd Alton D Quantity control device for microscope slide staining assays
US20070009497A1 (en) 2004-03-10 2007-01-11 Steinman Ralph M Dendritic cell expanded T suppressor cells and methods of use thereof
US8021847B2 (en) 2004-06-02 2011-09-20 Proxy Life Science Holdings, Inc. Microvesicle-based compositions and methods
CN101437478A (en) * 2004-10-04 2009-05-20 Qlt美国有限公司 Ocular delivery of polymeric delivery formulations
CN101137369A (en) * 2005-02-09 2008-03-05 马库赛特公司 Preparations for eye treatment
EP1876965B1 (en) 2005-04-29 2018-09-12 Cook Biotech, Inc. Volumetric grafts for treatment of fistulae and related systems
US20080128341A1 (en) 2006-12-04 2008-06-05 Electronics And Telecommunications Research Institute Micro filtration device for separating blood plasma and fabrication method therefor
WO2008079980A1 (en) * 2006-12-22 2008-07-03 Alcon Research, Ltd. Inhibitors of protein kinase c-delta for the treatment of glaucoma
AU2014227534B2 (en) * 2007-08-16 2017-01-19 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
EP2245199B1 (en) 2008-02-01 2013-11-13 The General Hospital Corporation Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
US8193148B2 (en) 2008-02-08 2012-06-05 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
ES2563984T3 (en) 2008-10-22 2016-03-17 Quark Pharmaceuticals, Inc. Methods for the treatment of eye disorders
US8394588B2 (en) 2009-03-11 2013-03-12 The Rockefeller University Methods to fix and detect nucleic acids
TW201039824A (en) * 2009-04-21 2010-11-16 Bausch & Lomb Compositions and methods for treating ocular inflammation with lower risk of increased intraocular pressure
EP2440185B1 (en) * 2009-06-09 2015-04-08 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
PL2470191T3 (en) * 2009-08-24 2014-09-30 Stealth Peptides Int Inc Methods and compositions for preventing or treating an ophthalmic condition
WO2011044216A1 (en) 2009-10-08 2011-04-14 Neurotech Usa, Inc. Use of pedf in an encapsulated cell-based delivery system
IN2012DN06277A (en) 2009-12-28 2015-09-25 Dsm Ip Assets Bv
WO2011137210A2 (en) 2010-04-30 2011-11-03 The Regents Of The University Of California Modulating compliance of trabecular meshwork
WO2011143540A1 (en) 2010-05-14 2011-11-17 Mallinckrodt Llc UNIFORM, FUNCTIONALIZED, CROSS-LINKED NANOSTRUCTURES FOR MONITORING pH
US20110294730A1 (en) * 2010-05-31 2011-12-01 Shantha Totada R Method of treating glaucoma and intraocular hypertension
CA2843684A1 (en) 2010-08-13 2012-02-16 Tufts University Compositions, kits and methods for treatment of macular degeneration using soluble membrane-independent cd59 protein
US20130224110A1 (en) * 2010-09-16 2013-08-29 Cornell University Use of adenosine receptor signaling to modulate permeability of blood-brain barrier
WO2012064606A2 (en) 2010-11-10 2012-05-18 Wake Forest University Health Sciences Tissue-specific extracellular matrix with or without tissue protein components for cell culture
WO2012112689A1 (en) 2011-02-15 2012-08-23 The University Of North Carolina At Chapel Hill Nanoparticle, liposomes, polymers, agents and proteins modified with reversible linkers
WO2012170560A2 (en) 2011-06-06 2012-12-13 Cornell University Microfluidic device for extracting, isolating, and analyzing dna from cells
WO2013016712A2 (en) 2011-07-27 2013-01-31 The Rockefeller University Methods for fixing and detecting rna
US20140257075A1 (en) 2011-08-03 2014-09-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Measuring aqueous humor outflow
WO2013038195A2 (en) * 2011-09-13 2013-03-21 Altacor Limited Pharmaceutical nanoparticle compositions
EP2776587A4 (en) 2011-11-10 2015-07-15 Exosome Diagnostics Inc Cerebrospinal fluid assay
JP6293674B2 (en) 2012-01-13 2018-03-14 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Controlled delivery of TLR agonists in structured polymer devices
US9506907B2 (en) 2012-02-20 2016-11-29 The Research Foundation Of State University Of New York Bioengineered human trabecular meshwork for biological applications
US20150037422A1 (en) 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
KR20130140934A (en) 2012-05-09 2013-12-26 삼성전자주식회사 Methods for extracting directly microrna from microvesicle in cell line, cell culture or body fluid
TW201412325A (en) * 2012-06-20 2014-04-01 梅茲製藥有限兩合公司 Interval medical treatment for the treatment of human vision loss in patients with glaucoma and other degenerative eye diseases
US20150306236A1 (en) 2012-09-04 2015-10-29 Lauren Sciences Llc Bolaamphiphilic compounds, compositions and uses thereof
AU2013340414B2 (en) 2012-10-23 2019-05-02 Caris Science, Inc. Aptamers and uses thereof
US10220332B2 (en) 2013-02-15 2019-03-05 Douglas T. Gjerde Columns for isolation, detection and use of biological cells
US9730638B2 (en) * 2013-03-13 2017-08-15 Glaukos Corporation Intraocular physiological sensor
CN105209881B (en) 2013-03-13 2021-01-22 迈阿密大学 Methods of isolation and purification of microvesicles from cell culture supernatants and biological fluids
US12558316B2 (en) 2013-03-13 2026-02-24 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
EP2971137B1 (en) 2013-03-15 2018-05-09 The Broad Institute, Inc. Methods for the detection of dna-rna proximity in vivo
KR20140136805A (en) 2013-05-21 2014-12-01 건국대학교 산학협력단 A novel human exosomal proteins and use of the same
JP6652916B2 (en) 2013-06-20 2020-02-26 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Methods for diagnosing pancreatic cancer
JP2016527494A (en) * 2013-07-05 2016-09-08 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーション Methods, compositions and systems for microfluidic assays
US20160279055A1 (en) * 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
WO2015080758A1 (en) 2013-11-27 2015-06-04 Al-Qahtani Ahmed H Method and composition for the treatment of moderate to severe keratoconjunctivitis sicca
CA2934662C (en) * 2013-12-20 2024-02-20 President And Fellows Of Harvard College Low shear microfluidic devices and methods of use and manufacturing thereof
SG10201501925YA (en) * 2014-03-14 2015-10-29 Agency Science Tech & Res Microfluidic Devices And Methods For Controlling A Microfluidic Device
JP2017512818A (en) 2014-04-01 2017-05-25 モナシュ、ユニバーシティＭｏｎａｓｈ Ｕｎｉｖｅｒｓｉｔｙ Polymyxin derivatives as antibacterial compounds
WO2015166414A1 (en) 2014-04-28 2015-11-05 Association For The Advancement Of Tissue Engineering And Cell Based Technologies And Therapies - A4Tec Polimeric substrates with immobilized antibodies and method of production thereof
US10451628B2 (en) 2014-05-07 2019-10-22 University Of Utah Research Foundation Biomarkers and methods for diagnosis of early stage pancreatic ductal adenocarcinoma
US20160206780A1 (en) 2014-08-15 2016-07-21 Suzhou Cancercell Biotechnology Co. Ltd Matrix Scaffold for Three-Dimensional Cell Cultivation, Methods of Construction Thereof and Uses Thereof
US20170284975A1 (en) 2014-09-03 2017-10-05 The Regents Of The University Of California Methods to determine the distribution profiles of circulating micrornas
EP3210201B8 (en) 2014-10-24 2020-09-23 The Trustees Of The University Of Pennsylvania Methods and devices for modeling the eye
EP3754027A1 (en) 2014-12-01 2020-12-23 The Broad Institute, Inc. Methods for altering or modulating spatial proximity between nucleic acids inside of a cell
US20160245809A1 (en) 2015-02-20 2016-08-25 The Penn State Research Foundation Ligand Conjugated Quantum Dots for the Detection of Soluble Receptors and Exosomes in Biological Fluids
JP2016211925A (en) 2015-05-01 2016-12-15 地方独立行政法人東京都健康長寿医療センター Method of evaluating tolerance of cancer to docetaxel or paclitaxel, method of evaluating malignant alteration of cancer, and kits used for the same in cancer
WO2016201064A1 (en) 2015-06-09 2016-12-15 The Board Of Regents Of The University Of Texas System Diagnostic test for early stage cancer
US9808531B2 (en) * 2015-09-22 2017-11-07 Graybug Vision, Inc. Compounds and compositions for the treatment of ocular disorders
WO2017062901A2 (en) * 2015-10-07 2017-04-13 Tymora Analytical Operations Llc Methods to isolate extracellular vesicles in biofluids for biomarker discovery and disease diagnosis
WO2017087940A1 (en) 2015-11-20 2017-05-26 University Of Kansas Non-invasive monitoring cancer using integrated microfluidic profiling of circulating microvesicles
WO2017132233A1 (en) 2016-01-25 2017-08-03 The Research Foundation For The State University Of New York Use of vascular cells to create the conventional outflow tract
WO2017136430A1 (en) 2016-02-01 2017-08-10 The Board Of Trustees Of The Leland Stanford Junior University Exosome-total-isoloation-chip (exotic) device for isolation of exosome-based biomarkers
WO2017190142A1 (en) 2016-04-29 2017-11-02 Clearside Biomedical, Inc. Formulations and methods for reduction of intraocular pressure
CA3055767A1 (en) 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Methods for evaluating tumor cell spheroids using 3d microfluidic cell culture device
US11548002B2 (en) * 2017-05-19 2023-01-10 The General Hospital Corporation Engineered nano-interfaces for microfluidic isolation of extracellular vesicles
WO2019023584A1 (en) 2017-07-27 2019-01-31 Cornell University Fixation and retention of extracellular vesicles
WO2019109077A1 (en) 2017-12-01 2019-06-06 Cornell University Nanoparticles and distinct exosome subsets for detection and treatment of cancer
WO2019144056A1 (en) 2018-01-18 2019-07-25 Nanosomix, Inc. Dectection of exosomes and exosomal biomarkers for the diagnosis and prognosis of diseases and disorders
WO2019199499A1 (en) * 2018-04-13 2019-10-17 University Of Washington Methods and apparatus for single biological nanoparticle analysis
CN109999032A (en) * 2019-04-30 2019-07-12 南昌大学 Application of the rapamycin in the Local eye drop administration medicine of preparation drop intraocular pressure

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090318512A1 (en) * 2004-04-07 2009-12-24 Advanced Medical Optics, Inc. Methods of maintaining ocular tissue cell membrane integrity using cetylpyridinium chloride
RU2576778C1 (en) * 2015-02-20 2016-03-10 Илья Александрович Марков Pharmaceutical composition in form of gel-like ophthalmic drops for treating glaucoma
US20190216857A1 (en) * 2016-09-09 2019-07-18 Cornell University Delivery of nucleic acids, proteins and small molecules in vitreous vesicular bodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP4031244A4 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4125994A4 (en) * 2020-03-25 2024-06-12 Aufbau Medical Innovations Limited METHODS AND AGENTS AGAINST GLAUCOMA
WO2023159114A3 (en) * 2022-02-16 2023-09-28 The Cleveland Clinic Foundation Lymphatic delivery of nanoparticles to treat neurodegenerative, neurological, and eye conditions
WO2025120597A1 (en) * 2023-12-06 2025-06-12 Universidade De Aveiro Secretome-based biomaterial, method for its production and uses thereof

Also Published As

Publication number Publication date
CA3151625A1 (en) 2021-03-25
JP2025069138A (en) 2025-04-30
JP2022551404A (en) 2022-12-09
JP2024161349A (en) 2024-11-19
JP2022501438A (en) 2022-01-06
JP7617085B2 (en) 2025-01-17
CA3113528A1 (en) 2020-03-26
EP3852608A1 (en) 2021-07-28
US20240000849A1 (en) 2024-01-04
US20200121724A1 (en) 2020-04-23
WO2020061550A1 (en) 2020-03-26
AU2019343188A1 (en) 2021-05-20
US11752175B2 (en) 2023-09-12
CN114929340B (en) 2025-06-10
EP4031244A1 (en) 2022-07-27
AU2020348176A1 (en) 2022-04-21
JP7520851B2 (en) 2024-07-23
EP3852608A4 (en) 2022-09-28
CN113164043A (en) 2021-07-23
EP4031244A4 (en) 2023-10-18
CN114929340A (en) 2022-08-19
CN113164043B (en) 2024-10-22

Similar Documents

Publication Publication Date Title
US20240000849A1 (en) Microfluidic device for isolating components of bodily fluids
EP2389221B1 (en) Sustained released delivery of one or more agents
US20180338952A1 (en) Compositions and methods for treating and diagnosing ocular disorders
KR20150031340A (en) Ophthalmic drug delivery
US20220211800A1 (en) Processes and agents for glaucoma
US20210322457A1 (en) Treatment and diagnosis of ocular surface disorders
JP2022554277A (en) Treatment of eye disease using endothelin receptor antagonists
CA3118367A1 (en) Treatment and diagnosis of autoantibody-mediated eye diseases
CA2870353C (en) Compositions and methods for treating and diagnosing ocular disorders
Choonara et al. In vivo evaluation of a biodegradable donut-shaped minitablet for prolonged posterior segment drug delivery in the rabbit eye model
Bhujbal Topical Ocular Delivery of Tonabersat Using Transfersomes
Agarwal Application of Semifluorinated Alkanes in Dry Eye Therapy
Kaur et al. 25 Ocular Penetration Enhancers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20864492

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3151625

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022517878

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020348176

Country of ref document: AU

Date of ref document: 20200325

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2020864492

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2020864492

Country of ref document: EP

Effective date: 20220421

WWG Wipo information: grant in national office

Ref document number: 202080080832.2

Country of ref document: CN

WWW Wipo information: withdrawn in national office

Ref document number: 2020864492

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 786837

Country of ref document: NZ